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This	  thesis	  provides	  the	  first	  description	  of	  circulating	  anti-­‐‑Müllerian	  hormone	  
(AMH)	  in	  older	  men.	  AMH	  is	  a	  gonadal	  hormone,	  with	  overt	  function	  in	  the	  
generation	  of	  the	  male	  phenotype	  during	  development,	  and	  a	  biomarker	  for	  
ovarian	  reserve	  in	  women.	  AMH	  is	  one	  of	  four	  circulating	  hormones	  produced	  by	  
the	  adult	  testes,	  and	  assumed	  to	  have	  no	  functional	  significance	  in	  men.	  Therefore	  
there	  is	  an	  absence	  of	  information	  regarding	  basic	  physiology	  of	  AMH	  in	  the	  blood	  
of	  men.	  This	  thesis	  posits	  that	  AMH	  may	  have	  cryptic	  functions,	  with	  putative	  
interactions	  to	  the	  other	  testicular	  hormones.	  AMH	  also	  belong	  to	  the	  TGFβ	  
superfamily	  of	  cytokines	  with	  ubiquitous	  roles	  and	  convergent	  intracellular	  
signalling	  in	  a	  contexual	  manner.	  The	  role	  of	  AMH	  may	  become	  more	  evident	  in	  a	  
model	  of	  dysregulated	  homeostasis,	  such	  as	  that	  seen	  with	  ageing	  and	  frailty.	  	  
	  
This	  PhD	  examined	  a	  local	  cohort	  of	  223	  men	  from	  19	  years	  to	  90	  years	  old	  for	  
their	  circulating	  AMH	  levels.	  Three	  testicular	  hormones	  were	  concurrently	  
examined	  for	  interactions	  with	  AMH;	  Inhibin	  B	  (InhB),	  testosterone,	  and	  insulin-­‐‑
like	  peptide	  3	  (INSL3).	  The	  serum	  profiles	  of	  these	  four	  hormones	  were	  examined	  
throughout	  the	  day,	  and	  across	  the	  age	  spectrum	  with	  a	  focus	  on	  men	  aged	  70	  
years	  and	  older.	  A	  small	  group	  of	  older	  women	  were	  also	  examined	  for	  their	  
circulating	  AMH	  level	  to	  determine	  for	  sexual	  dimorphism	  with	  ageing.	  The	  extent	  
of	  cleavage	  of	  AMH	  precursor	  protein	  was	  also	  studied,	  and	  compared	  between	  
men	  and	  boys.	  A	  pilot	  study	  was	  concurrently	  set	  up	  to	  test	  for	  the	  feasibility	  of	  
correlating	  AMH	  and	  other	  hormones	  to	  functional	  traits	  associated	  with	  ageing.	  	  
	  
In	  healthy	  young	  men,	  circulating	  AMH	  and	  INSL3	  levels	  were	  both	  stable	  
throughout	  the	  day	  and	  independent	  to	  each	  other.	  This	  contrasted	  to	  the	  overt	  





Circulating	  AMH	  level	  varies	  significantly	  between	  men,	  with	  age-­‐‑related	  decline.	  
AMH	  level	  was	  partially	  correlated	  to	  the	  other	  Sertoli	  hormone	  InhB	  which	  
became	  divergent	  in	  older	  men.	  These	  findings	  were	  concordant	  with	  examination	  
of	  a	  distinct	  cohort	  of	  older	  men	  in	  the	  North	  Island	  of	  New	  Zealand.	  Both	  cohorts	  
however	  had	  average	  circulating	  AMH	  levels	  which	  were	  lower	  than	  a	  third	  age-­‐‑
matched	  cohort	  of	  age	  with	  healthy	  cardiovascular	  status.	  Circulating	  AMH	  was	  
largely	  sexually	  dimorphic	  with	  ageing,	  but	  not	  invariantly.	  A	  minority	  of	  older	  
men	  lacked	  AMH	  like	  all	  older	  women.	  	  
	  
All	  four	  circulating	  testicular	  hormones	  are	  independent	  in	  younger	  men.	  All	  four	  
testicular	  hormones	  exhibits	  age-­‐‑related	  decline,	  resulting	  in	  multiple	  
combinations	  of	  testicular	  hormonal	  deficiencies.	  A	  minority	  of	  older	  men	  was	  
deficient	  in	  all	  testicular	  hormones,	  similar	  to	  all	  postmenopausal	  women.	  	  
	  
The	  precursor	  hormone	  of	  AMH	  in	  blood	  was	  strongly	  linked	  to	  its	  total	  AMH	  level.	  
However	  the	  extent	  of	  its	  cleavage	  was	  distinct	  to	  the	  circulating	  AMH	  
concentration,	  and	  also	  to	  the	  other	  testicular	  hormones.	  AMH	  was	  cleaved	  more	  
in	  both	  younger	  and	  older	  men,	  when	  compared	  to	  boys,	  with	  no	  overlap	  in	  their	  
ranges.	  	  
	  
Amongst	  men	  over	  70	  years,	  circulating	  AMH	  showed	  a	  relationship	  to	  cognitive	  
function	  that	  was	  highly	  statistically	  significant.	  This	  was	  independent	  to	  the	  other	  
testicular	  hormones.	  The	  extent	  of	  its	  cleavage	  correlated	  to	  physical	  function	  and	  
weight.	  	  
	  
AMH	  is	  present	  in	  the	  circulation	  in	  men,	  including	  the	  oldest	  old.	  AMH	  may	  play	  a	  
role	  as	  a	  chronic	  reporter	  about	  the	  state	  of	  the	  testes	  that	  is	  independent	  to	  the	  
other	  three	  testicular	  hormones.	  This	  has	  relevance	  to	  the	  understanding	  of	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Anti-­‐‑Müllerian	  hormone	  (AMH)	  is	  a	  testicular	  hormone	  of	  importance	  in	  the	  
generation	  of	  the	  male	  phenotype	  during	  development.	  AMH	  continues	  to	  be	  
secreted	  by	  the	  testes	  throughout	  the	  life	  cycle;	  with	  many	  assuming	  that	  AMH	  
has	  no	  overt	  function	  in	  the	  adult	  male.	  AMH	  therefore	  has	  been	  poorly	  studied,	  
resulting	  in	  an	  absence	  of	  basic	  information	  pertaining	  to	  its	  physiology.	  This	  
thesis	  challenges	  the	  premise	  that	  AMH	  lacks	  function	  in	  man,	  and	  builds	  a	  case	  
for	  its	  putative	  role	  as	  a	  signalling	  testicular	  hormone	  in	  man.	  This	  thesis	  
therefore	  will	  commence	  with	  a	  description	  of	  the	  endocrine	  testicular	  function	  
in	  man,	  and	  review	  where	  AMH	  fits	  within	  this	  context.	  If	  AMH	  does	  have	  a	  
function,	  its	  mechanistic	  signalling	  pathway	  may	  be	  determined	  by	  considering	  
AMH	  as	  a	  member	  of	  the	  transforming	  growth	  factor	  beta	  (TGFβ)	  superfamily	  of	  
cytokines.	  This	  will	  be	  reviewed	  in	  the	  second	  part	  of	  this	  Chapter.	  	  
 
1.2  The  testes  contain  multiple  cell  types  
 
The	  testis	  is	  a	  complex	  organ	  comprising	  of	  multiple	  cell	  types,	  in	  different	  
compartments	  [Fig.	  1.1].	  Each	  cell	  type	  serves	  different	  functions,	  and	  interacts	  
with	  each	  other	  in	  a	  complex	  fashion.	  	  The	  simplified	  understanding	  of	  each	  cell	  
type	  is	  as	  follows.	  The	  germ	  cells	  undergo	  spermatogenesis,	  and	  supported	  by	  
the	  Sertoli	  cells	  lining	  the	  seminiferous	  tubules.	  The	  Leydig	  cells	  within	  the	  






Other	  intra-­‐‑testicular	  cells,	  such	  as	  the	  peritubular	  myoid	  cells,	  undergo	  
reciprocal	  interactions	  with	  Sertoli	  and	  Leydig	  cells,	  both	  in	  development	  and	  in	  
the	  adult	  (1a-­‐‑d).	  	  The	  interactions	  between	  these	  cell	  types	  appear	  to	  create	  
linkage	  and	  coordination	  between	  Sertoli	  and	  Leydig	  cell	  function.	  	  The	  evidence	  
for	  this	  comes	  from	  the	  study	  of	  sperm	  production	  and/or	  the	  development	  of	  
the	  testes.	  	  To	  date,	  there	  is	  no	  proof	  of	  linkage	  between	  the	  endocrine	  functions	  































Figure  1.1.  Schematic  representation  of  the  different  testicular  endocrine  
cells,  and  their  relationship  to  germ  cells  and  the  pituitary  gland.    




1.3  Function  of  the  testes  
 
1.3.1  Generation  of  the  male  phenotype  in  utero  
 
During	  development,	  the	  testes	  main	  function	  is	  to	  generate	  the	  male	  phenotype,	  
which	  involves	  both	  virilisation	  and	  defeminisation.	  This	  occurs	  at	  specific	  
stages.	  A	  characteristic	  feature	  of	  this	  developmental	  stage	  is	  the	  overt	  
phenotype	  that	  is	  generated,	  in	  a	  dichotomy	  fashion	  depending	  upon	  the	  
presence,	  or	  absence	  of	  testicular	  hormones.	  AMH	  induces	  the	  regression	  of	  the	  
paramesonephric	  ducts	  (Müllerian	  ducts).	  Loss	  of	  function	  mutation	  in	  the	  genes	  
of	  either	  AMH	  or	  its	  obligatory	  type-­‐‑2	  receptor	  AMHR2	  leads	  to	  the	  persistence	  
of	  the	  paramesonephric	  ducts	  (1).	  This	  process	  occurs	  independent	  of	  other	  
testicular	  hormones.	  Testosterone	  independently	  induces	  the	  development	  of	  
the	  mesonephric	  ducts	  into	  the	  male	  genitalia.	  Its	  absence	  or	  loss	  of	  function	  of	  
the	  androgen	  receptor	  results	  in	  the	  lack	  of	  virilisation	  of	  the	  genital	  (2,	  3).	  
	  
The	  testicular	  hormones	  AMH,	  testosterone	  and	  insulin-­‐‑like	  peptide	  3	  (INSL3)	  
also	  work	  in	  a	  concerted	  manner	  to	  facilitate	  the	  descent	  of	  the	  testes	  from	  
abdomen	  into	  the	  scrotum.	  The	  presence	  of	  each	  hormone	  during	  different	  
stages	  in	  the	  testicular	  descent	  is	  important,	  as	  the	  absence	  results	  in	  retention	  
of	  the	  testes	  within	  the	  abdomen	  (4-­‐‑6).	  	  
 
1.3.2  Generation  of  the  adult  male  phenotype  
 
The	  final	  adult	  male	  phenotype	  is	  generated	  from	  puberty,	  and	  maintained	  
during	  adulthood	  by	  testicular	  hormones.	  Aspects	  of	  this	  phenotype	  maybe	  overt	  
and	  result	  in	  sexual	  dimorphism.	  Clear	  examples	  include	  the	  deepening	  of	  the	  
voice,	  development	  of	  the	  penis,	  androgenic	  hair	  growth,	  changes	  to	  
anthropometric	  features	  such	  as	  increased	  muscle	  mass	  and	  the	  robustness	  of	  
bones.	  There	  is	  strong	  evidence	  that	  testosterone	  is	  the	  main	  mediator	  of	  these	  
overt	  functions,	  either	  directly	  via	  its	  steroid	  receptors	  (7),	  or	  indirectly	  in	  





Whilst	  adult	  human	  exhibit	  strong	  sexually	  dimorphic	  traits	  between	  genders,	  
various	  grades	  of	  phenotype	  exists	  within	  the	  same	  gender.	  Height	  and	  muscle	  
strength	  varies	  between	  men,	  with	  the	  variability	  not	  strongly	  explained	  by	  
differences	  in	  their	  testosterone	  level	  (9).	  The	  influence	  of	  other	  testicular	  
hormones	  on	  the	  variability	  is	  currently	  unexplored,	  and	  they	  may	  have	  
modulating	  roles	  in	  the	  maintenance	  of	  these	  traits.	  For	  instance,	  testosterone	  is	  
attributed	  to	  be	  important	  for	  maintenance	  of	  bone	  mass,	  and	  testosterone	  
deficiency	  results	  in	  osteoporosis	  for	  some,	  but	  not	  all	  men.	  Two	  other	  testicular	  
hormones,	  INSL3	  and	  inhibin	  B	  (InhB)	  are	  bone	  regulators,	  and	  the	  disruption	  in	  
their	  signalling	  leads	  to	  osteoporosis	  (10-­‐‑12).	  AMH	  therefore	  may	  have	  a	  
modulating	  role	  in	  the	  generation	  of	  male	  phenotype	  that	  explains	  the	  variability	  
between	  men,	  but	  not	  overtly	  seen.	  	  
	  
Two	  other	  testicular	  hormones,	  INSL3	  and	  inhibin	  B	  (InhB)	  are	  bone	  regulators	  
at	  an	  endocrine	  level.	  Adult	  male	  studies	  in	  men	  and	  mice	  have	  shown	  that	  
mutation	  in	  the	  sole	  INSL3	  receptor	  RXFP2	  leads	  to	  osteoporosis,	  backed	  by	  
mechanistic	  studies	  (12a).	  Similarly,	  serum	  inhibin	  level	  is	  better	  at	  predicting	  
osteoporosis	  than	  oestrogen	  in	  women,	  and	  supported	  by	  mechanistic	  studies	  
showing	  regulation	  of	  inhibins	  upon	  bone	  turnover	  (12b-­‐‑d).	  	  Since	  both	  
circulating	  INSL3	  and	  InhB	  are	  solely	  derived	  from	  the	  testes	  (30,	  165),	  the	  distal	  
effect	  on	  bone	  regulation	  strongly	  suggest	  their	  endocrine	  function	  in	  adult.	  	  
	  
 
1.3.3  Spermatogenesis  requires  complex  interaction  between  testicular  
hormones  
 
The	  study	  of	  spermatogenesis	  in	  relation	  to	  testicular	  hormones	  is	  outside	  of	  the	  
scope	  of	  this	  thesis.	  However	  a	  targeted	  review	  of	  testicular	  hormonal	  control	  of	  	  
spermatogenesis	  can	  illustrate	  the	  complexity	  of	  hormonal	  and	  cellular	  
interaction	  with	  the	  testes.	  	  
	  
Germ	  cells	  are	  isolated	  within	  the	  seminiferous	  tubules	  by	  the	  formation	  of	  tight	  
junctions	  (13).	  This	  isolation	  is	  crucial	  for	  spermatogenesis	  (14,	  15).	  Germ	  cells	  




Sertoli	  cell	  coincides	  with	  spermatogenesis,	  as	  the	  number	  of	  Sertoli	  cells	  
partially	  correlates	  with	  the	  number	  of	  germ	  cells	  (17).	  	  It	  has	  been	  proposed	  
that	  Sertoli	  hormones	  AMH	  and	  InhB	  may	  serve	  as	  surrogate	  markers	  for	  Sertoli	  
numbers	  (18-­‐‑20).	  If	  so,	  then	  either	  levels	  of	  AMH,	  or	  InhB,	  or	  both	  may	  reflect	  
Sertoli	  cell	  number.	  If	  both	  AMH	  and	  InhB	  are	  surrogate	  markers	  of	  Sertoli	  cell	  
numbers,	  they	  are	  expected	  to	  be	  highly	  linked,	  and	  therefore	  exhibit	  strong	  
correlation	  to	  each	  other	  in	  blood.	  	  
	  
The	  body	  is	  able	  to	  influence	  the	  process	  of	  spermatogenesis	  by	  follicle	  
stimulating	  hormone	  (FSH)	  and	  testosterone,	  via	  their	  Sertoli	  cell	  receptors	  (21).	  
However	  the	  interaction	  is	  redundant,	  as	  the	  loss	  of	  either	  testosterone	  or	  FSH	  
only	  leads	  to	  partial	  reduction	  in	  germ	  cells,	  with	  the	  complete	  disruption	  of	  
spermatogenesis	  only	  evident	  with	  abolishment	  of	  both	  hormonal	  receptors	  
(22).	  Sertoli	  cell	  is	  able	  to	  modify	  this	  interaction	  and	  provide	  feedback.	  InhB	  
negatively	  regulates	  FSH	  (23,	  24),	  and	  Sertoli	  cell	  also	  secretes	  androgen-­‐‑binding	  
protein	  that	  sequesters	  testosterone	  within	  the	  testes	  (25,	  26).	  This	  effect	  of	  
Sertoli	  protein	  production	  can	  be	  mediated	  directly	  by	  different	  state	  of	  
spermatogenesis	  (27).	  Hence	  the	  state	  of	  the	  Sertoli	  cell	  plays	  a	  pivotal	  role	  in	  
the	  cross-­‐‑talk	  between	  the	  body	  and	  spermatogenesis,	  and	  the	  level	  of	  AMH	  may	  
provide	  an	  indication	  about	  the	  state	  of	  the	  gametes.	  	  
 
1.4  Regulation  of  testicular  endocrine  cells  
 
1.4.1  Luteinizing  hormone  regulation  of  Leydig  cells  
 
The	  two	  endocrine	  cell	  types	  play	  major	  roles	  in	  the	  function	  of	  the	  testes.	  An	  
understanding	  of	  its	  regulation	  may	  shed	  light	  as	  to	  putative	  function	  for	  AMH.	  
Similar	  to	  the	  regulation	  of	  spermatogenesis,	  the	  regulation	  of	  both	  Leydig	  cells	  
and	  Sertoli	  cells	  are	  complex.	  Leydig	  cells	  produce	  two	  hormones	  in	  man;	  
testosterone	  and	  INSL3	  (28-­‐‑30).	  Both	  are	  controlled	  by	  the	  pituitary	  hormone	  
luteinizing	  hormone	  (LH)	  (29-­‐‑32),	  and	  reflects	  different	  effects	  of	  LH	  on	  the	  
Leydig	  cells.	  Both	  intrastesticular	  and	  systemic	  testosterone	  level	  fluctuates	  
episodically	  in	  reponse	  to	  the	  pulsatile	  pattern	  of	  LH.	  INSL3	  is	  invariant	  to	  acute	  




two	  Leydig	  hormones	  therefore	  report	  different	  states	  of	  the	  Leydig	  cell;	  
testosterone	  on	  the	  acute	  regulation	  of	  LH,	  whilst	  level	  of	  INSL3	  reflect	  the	  basal	  
state	  of	  Leydig	  cells	  (33).	  	  
 
1.4.2  Sertoli  regulation  of  Leydig  cells  
 
There	  are	  cross-­‐‑talk	  between	  the	  Leydig	  cells	  and	  Sertoli	  cells.	  Experimental	  
ablation	  of	  Sertoli	  cells	  in	  mice	  leads	  to	  a	  significant	  decrease	  in	  Leydig	  cell	  
number,	  suggesting	  that	  Sertoli	  cell	  maintains	  the	  Leydig	  cell	  (34,	  35).	  The	  
influence	  of	  Sertoli	  cells	  upon	  Leydig	  cells	  maybe	  due	  to	  Sertoli	  hormonal	  
function.	  InhB	  may	  indirectly	  affect	  Leydig	  cell	  growth	  via	  FSH	  (36)	  or	  directly	  
via	  its	  receptor	  on	  Leydig	  cells	  (37).	  
	  
AMH	  exerts	  several	  effects	  on	  Leydig	  cell	  development	  and	  function.	  It	  is	  
observed	  that	  mutant	  mice	  with	  loss	  of	  function	  AMH	  (38)	  or	  its	  receptor	  (39)	  
exhibit	  hyperplasia	  of	  Leydig	  cells	  but	  normal	  levels	  of	  testosterone	  (40).	  
Conversely,	  transgenic	  overexpression	  of	  AMH	  in	  mice	  leads	  to	  reduction	  of	  
Leydig	  cell	  numbers	  and	  testosterone	  level	  (40).	  However,	  interpretation	  of	  this	  
study	  is	  limited	  by	  the	  supraphysiological	  over-­‐‑expression	  of	  AMH	  at	  twice	  the	  
peak	  concentration	  of	  an	  infant	  male	  (41,	  42).	  The	  effect	  of	  AMH	  on	  Leydig	  cell	  is	  
said	  to	  be	  mediated	  via	  its	  receptor	  AMHR2	  expressed	  on	  Leydig	  cells	  (42-­‐‑45).	  
Again,	  interpretation	  of	  these	  studies	  are	  limited	  as	  data	  from	  in	  vivo	  studies	  is	  
lacking.	  The	  effect	  of	  AMH	  upon	  Leydig	  cell	  development	  or	  its	  function	  therefore	  
is	  unclear	  based	  on	  current	  literature.	  Putatively,	  AMH	  may	  exert	  a	  permissive	  
role	  in	  Leydig	  cell	  development	  (42)	  much	  like	  what	  has	  been	  demonstrated	  
with	  testicular	  hormones	  during	  development,	  and	  effect	  of	  LH	  on	  INSL3	  
[Chapter	  1.4.1].	  There	  is	  also	  a	  need	  to	  determine	  normal	  levels	  of	  circulating	  
AMH	  in	  men,	  to	  guide	  physiological	  replication	  of	  AMH	  levels	  in	  animal	  studies.	  
 
1.4.3  Regulation  of  Sertoli  cells  
 
The	  regulation	  of	  Sertoli	  cell	  is	  equally	  as	  complex	  as	  Leydig	  cell,	  and	  is	  lifestage	  
dependent,	  involving	  FSH,	  testosterone,	  thyroid	  hormones,	  activins,	  and	  other	  




proliferation	  during	  the	  pubertal	  transition,	  then	  terminally	  differentiate	  with	  
stable	  numbers	  in	  adulthood	  (45).	  Since	  Sertoli	  cells	  express	  androgen	  receptors	  
during	  puberty,	  it	  has	  been	  theorised	  that	  testosterone	  down-­‐‑regulate	  Sertoli	  
cells	  production	  of	  AMH	  during	  puberty,	  with	  this	  effect	  persisting	  into	  
adulthood	  (46).	  Consequently,	  circulating	  AMH	  level	  is	  thought	  to	  be	  suppressed	  
by	  peak	  adult	  testosterone	  level	  (47,	  48)	  and	  therefore	  not	  thought	  to	  have	  any	  
functional	  significance	  in	  adulthood.	  	  
	  
Testosterone	  appears	  to	  work	  in	  concert	  with	  FSH	  to	  regulate	  Sertoli	  cells,	  
similar	  to	  their	  effect	  on	  spermatogenesis.	  Mice	  that	  lacked	  FSH	  or	  FSH	  receptors	  
have	  reduced	  number	  of	  Sertoli	  cells	  during	  adulthood,	  even	  in	  the	  presence	  of	  
testosterone	  replacement	  (49).	  In	  a	  separate	  study,	  mice	  that	  lacked	  androgen	  
receptors	  specific	  to	  the	  Sertoli	  cells	  only	  have	  preserved	  number	  of	  Sertoli	  cells	  
(50),	  indicating	  that	  androgen	  effect	  is	  indirect.	  Additionally,	  mice	  that	  lacked	  
both	  FSH	  receptor	  and	  androgen	  receptor	  in	  their	  Sertoli	  cells	  have	  diminished	  
number	  of	  Sertoli	  cells	  (51).	  FSH	  effect	  on	  Sertoli	  cell	  appeared	  to	  stage	  specific,	  
as	  Sertoli	  cells	  become	  resistant	  to	  the	  effect	  of	  FSH	  following	  puberty	  (52).	  	  If	  
testosterone	  regulates	  the	  production	  of	  Sertoli	  cell	  hormones,	  then	  the	  levels	  of	  
testosterone	  and	  InhB	  and	  AMH	  should	  link	  during	  adulthood,	  or	  when	  
testosterone	  level	  changes.	  The	  first	  tests	  of	  whether	  AMH	  and	  testosterone	  
levels	  associate	  are	  described	  in	  this	  thesis	  [Chapters	  3,	  6	  and	  7].	  	  
	  
There	  is	  an	  absence	  of	  evidence	  of	  direct	  androgen	  regulation	  of	  Sertoli	  cells	  in	  
adult	  (48).	  This	  contrasts	  with	  the	  large	  and	  complex	  body	  of	  literature	  that	  
examines	  the	  interplay	  between	  Leydig	  cells	  and	  Sertoli	  cells	  during	  
development	  and	  puberty	  (21).	  Further	  in-­‐‑depth	  review	  of	  the	  interaction	  
between	  the	  two	  cell	  types	  have	  not	  been	  undertaken,	  as	  this	  does	  not	  translate	  









1.5  Circulating  levels  of  testicular  hormones  
 
1.5.1  Levels  of  testosterone,  INSL3  and  InhB  
 
The	  circulating	  levels	  of	  testicular	  hormones	  reflect	  their	  endocrine	  functions,	  
particularly	  of	  testosterone.	  In	  the	  first	  three	  months	  of	  life,	  testosterone,	  INSL3	  
and	  InhB	  all	  experience	  a	  surge	  in	  their	  circulating	  levels	  due	  to	  the	  elevation	  of	  
gonadotropins	  (53,	  54).	  This	  quickly	  subsides	  with	  the	  Leydig	  hormones	  during	  
childhood	  becoming	  queiscent	  (55).	  In	  contrast,	  InhB	  level	  is	  detected	  in	  blood	  of	  
boys,	  at	  approximately	  halved	  that	  of	  peak	  adult	  level	  (56-­‐‑58).	  In	  puberty,	  all	  
three	  hormones	  increase	  in	  their	  levels	  to	  reach	  their	  peak	  adult	  levels	  (56,	  58).	  
The	  prevailing	  theory	  is	  that	  boys’	  testes	  are	  non-­‐‑functional	  in	  childhood,	  due	  to	  
the	  their	  low	  levels	  of	  testicular	  hormones	  and	  a	  lack	  of	  overt	  sexual	  dimorphism	  
between	  boys	  and	  girls	  beyond	  what	  is	  established	  in	  utero,	  and	  not	  to	  the	  same	  
extent	  as	  in	  adulthoood.	  	  
 
1.5.2  Circulating  levels  of  AMH  in  males  and  females  
 
The	  level	  of	  circulating	  AMH	  in	  males	  are	  exclusively	  derived	  from	  the	  testes	  (41,	  
59-­‐‑61).	  At	  the	  commencement	  of	  this	  PhD	  levels	  of	  AMH	  is	  unknown	  beyond	  
puberty.	  In	  contrast	  to	  the	  other	  three	  hormones,	  circulating	  AMH	  level	  is	  
thought	  to	  peak	  in	  boys,	  with	  stable	  levels	  during	  childhood	  (41,	  62-­‐‑64).	  Females	  
also	  secrete	  AMH	  from	  their	  ovaries	  into	  blood,	  which	  exists	  in	  very	  low	  levels	  in	  
girls.	  It	  has	  been	  postulated	  that	  this	  distinction	  in	  serum	  AMH	  levels	  between	  
boys	  and	  girls	  may	  contribute	  to	  subtle	  sex	  bias	  (65).	  Evidence	  to	  support	  this	  
theory	  comes	  from	  the	  correlation	  between	  AMH	  and	  autism	  in	  boys	  (66),	  the	  
restraint	  on	  the	  speed	  of	  maturation	  in	  boys	  (62),	  and	  the	  preference	  of	  young	  
male	  mouse	  pups	  for	  novelty	  behaviour	  (67).	  If	  this	  is	  true,	  then	  AMH	  may	  have	  
similar	  role	  in	  maintaining	  the	  male	  phenotype	  in	  adulthood.	  	  
	  
Male	  circulating	  AMH	  levels	  decline	  during	  puberty	  down	  to	  an	  order	  of	  
magnitude	  from	  peak	  childhood	  level	  (41,	  68).	  It	  is	  therefore	  assumed	  that	  AMH	  
has	  no	  function	  in	  men	  due	  to	  the	  low	  levels.	  However,	  AMH	  at	  concentration	  




vitro	  (69),	  suggesting	  that	  it	  may	  be	  possible	  for	  AMH	  in	  men	  to	  elicit	  
intracellular	  signalling.	  This	  will	  be	  discussed	  in	  greater	  detail	  in	  the	  
TGFβ superfamily	  section	  of	  this	  Chapter.	  
	  
Female	  circulating	  AMH	  level	  peak	  during	  young	  adulthood,	  and	  is	  derived	  from	  
the	  granulosa	  cells	  surrounding	  the	  germ	  cells	  (70,	  71).	  Circulating	  levels	  of	  AMH	  
in	  women	  decline	  in	  parallel	  with	  the	  decline	  of	  their	  ovarian	  reserve	  of	  follicles	  
(72,	  73),	  with	  an	  universal	  cessation	  of	  AMH	  level	  near	  menopause	  (74,	  75).	  
Circulating	  AMH	  level	  informs	  about	  the	  state	  of	  the	  germ	  cells	  in	  women,	  with	  
this	  being	  utilised	  clinically	  as	  a	  biomarker	  for	  fertility	  (76,	  77).	  This	  sets	  the	  
possibility	  that	  AMH	  level	  in	  men	  may	  play	  similar	  role	  as	  a	  biomarker	  for	  the	  
state	  of	  the	  germ	  cells.	  
  
1.5.3	  Implications	  of	  circulating	  testicular	  hormonal	  levels	  to	  late	  onset	  
hypogonadism	  
	  
Numerous	  population	  studies	  have	  shown	  that	  circulating	  testosterone	  level	  
decline	  in	  men	  as	  they	  age.	  The	  proportion	  of	  older	  men	  having	  testosterone	  
levels	  in	  the	  hypogonadal	  range	  of	  younger	  men	  increased	  to	  nearly	  50%	  of	  men	  
in	  their	  9th	  decade	  of	  life.	  	  (77a-­‐‑c,	  172).	  The	  low	  androgen	  state	  of	  these	  older	  
men	  do	  not	  consistently	  correlate	  with	  classical	  symptoms	  of	  pathological	  low	  
androgen	  status	  commonly	  seen	  in	  younger	  men	  (172).	  This	  has	  led	  to	  the	  
emergence	  of	  late	  onset	  hypogonadism	  as	  a	  clinical	  concept	  to	  describe	  
pathological	  low	  testosterone	  level	  in	  the	  older	  person	  (77d),	  with	  diagnostic	  
criteria	  being	  low	  levels	  of	  circulating	  testosterone	  level	  and	  concurrent	  specific	  
sexual	  dysfunction	  symptoms,	  resulting	  in	  an	  estimated	  prevalence	  of	  only	  2%	  in	  
older	  men	  (77e).	  The	  lack	  of	  utility	  of	  LH	  in	  this	  diagnostic	  criteria	  reflects	  the	  
heterogeneity	  of	  LH	  levels	  amongst	  older	  men	  with	  low	  testosterone	  levels,	  with	  
some	  being	  elevated,	  some	  normal,	  and	  others	  being	  low	  (77f-­‐‑g).	  	  
	  
Circulating	  INSL3	  levels	  in	  older	  men	  have	  only	  been	  profiled	  in	  one	  cross-­‐‑




indicates	  that	  the	  two	  Leydig	  hormones	  exhibit	  distinct	  profiles	  in	  ageing,	  and	  
are	  not	  regulated	  together	  at	  the	  Leydig	  cell	  level	  or	  at	  the	  pituitary	  level	  by	  LH.	  	  
	  
The	  profile	  of	  circulating	  InhB	  level	  in	  older	  men	  is	  similarly	  variable	  to	  ageing	  
and	  to	  the	  FSH	  level	  (176-­‐‑178),	  whilst	  circulating	  AMH	  level	  in	  older	  men	  was	  
unknown	  at	  the	  commencement	  of	  this	  PhD.	  The	  description	  of	  late	  onset	  
hypogonadism	  is	  therefore	  incomplete	  when	  only	  analysing	  either	  Leydig	  cell	  
hormones	  or	  Sertoli	  cell	  hormones,	  with	  the	  study	  of	  all	  four	  hormones	  required	  
to	  better	  understood	  the	  biological	  changes	  associated	  with	  the	  ageing	  endocrine	  
testes.	  	  
	  
1.6  AMH  as  a  TGFβ  superfamily  member    
 
AMH	  has	  one	  overt	  function	  in	  the	  male,	  which	  is	  to	  induce	  the	  regression	  of	  the	  
paramesonephric	  ducts	  (Müllerian	  ducts),	  by	  activating	  the	  AMH-­‐‑specific	  
receptor,	  AMHR2	  (1).	  	  For	  this	  function,	  AMH	  behaves	  like	  a	  classical	  hormone,	  
producing	  an	  effect	  that	  is	  overt	  and	  independent	  of	  the	  presence	  or	  absence	  of	  
other	  regulators.	  	  This	  model	  of	  AMH	  action	  does	  not	  assist	  the	  search	  for	  the	  
functions	  of	  AMH	  in	  the	  adult	  male,	  as	  men	  with	  a	  null	  mutation	  of	  AMH	  do	  not	  
exhibit	  any	  overt	  symptoms,	  beyond	  cryptorchidism	  due	  to	  the	  retention	  of	  the	  
paramesonephric	  ducts	  (1,	  78).	  
	  
This	  thesis	  proposes	  that	  AMH	  should	  be	  considered	  in	  the	  context	  of	  being	  a	  
member	  of	  the	  TGFβ	  superfamily	  of	  cytokines.	  This	  family	  of	  35	  cytokines,	  
including	  AMH	  and	  InhB,	  converge	  onto	  a	  limited	  number	  of	  receptors	  to	  activate	  
its	  canonical	  signalling	  pathway	  (79,	  80).	  Despite	  the	  limited	  number	  of	  
combinations,	  members	  of	  this	  family	  is	  ubiquitous	  in	  their	  function	  spanning	  
from	  development,	  to	  homeostasis	  and	  pathology	  (81,	  82).	  Diversity	  and	  
pleiotropism	  is	  achieved	  through	  complex	  interactions	  between	  the	  ligands,	  
receptors	  and	  associated	  binding	  proteins	  (83).	  The	  expression	  of	  each	  ligand	  
varies	  between	  different	  cell	  types,	  and	  between	  different	  stages	  of	  life	  from	  
development	  through	  to	  homeostasis,	  to	  ageing	  and	  pathology.	  The	  influence	  of	  




fully	  independent.	  Consequently,	  null	  mutations	  of	  the	  TGFβ	  superfamily	  
members	  often	  results	  in	  mild	  deviation	  from	  the	  normal	  phenotype	  (84-­‐‑87),	  
with	  this	  being	  evidence	  of	  the	  independent	  functions	  of	  the	  ligand.	  If	  AMH	  
operates	  in	  a	  similar	  manner,	  then	  it	  may	  have	  broad	  functions	  in	  inducing	  and	  
maintaining	  the	  male	  phenotype,	  in	  concert	  with	  bone	  morphogenetic	  proteins	  
(BMP)	  ligands	  (65).	  Hence,	  AMH	  maybe	  misconstrued	  as	  not	  having	  any	  
functional	  significance	  in	  adults,	  if	  it	  is	  exclusively	  seen	  as	  signalling	  independent	  
to	  the	  other	  ligands.	  
 
1.6.1  Cleavage  of  the  prohormone  
 
Protein	  hormones	  and	  cytokines	  are	  synthesised	  as	  precursor	  proteins	  that	  
undergo	  processing	  prior	  to	  binding	  to	  its	  target	  receptors.	  The	  classic	  model	  is	  
an	  initial	  production	  of	  protein	  called	  preproprotein,	  which	  is	  thought	  to	  
undergo	  cleavage	  of	  its	  signal	  peptide	  intracellularly	  to	  generate	  a	  proprotein.	  
This	  proprotein	  is	  then	  cleaved,	  to	  yield	  its	  N-­‐‑terminal	  and	  C-­‐‑terminal	  
components,	  with	  the	  cleavage	  occurring	  either	  intracellularly	  during	  protein	  
synthesis	  or	  at	  multiple	  extracellular	  sites.	  	  In	  the	  case	  of	  the	  TGFβ	  superfamily	  
members,	  it	  is	  the	  C-­‐‑terminal	  component	  that	  binds	  to	  the	  target	  receptors.	  	  The	  
N-­‐‑terminal	  also	  has	  diverse	  functions,	  and	  therefore	  remain	  non-­‐‑covalently	  
associated	  with	  the	  C-­‐‑terminal	  for	  some	  TGFβ	  superfamily	  members.	  This	  
includes	  the	  susceptibility	  of	  the	  proform	  to	  cleavage	  (88),	  and	  after	  cleavage	  the	  
regulation	  of	  the	  stability	  (88)	  and	  transport	  and	  the	  complex	  (80).	  	  	  AMH	  is	  
typical	  of	  this	  scenario,	  where	  the	  proAMH	  is	  cleaved	  to	  its	  C-­‐‑terminal	  receptor	  
binding	  form	  with	  the	  N-­‐‑terminal	  non-­‐‑covalently	  bonded	  as	  AMHN,C	  (89).	  
Consistent	  with	  known	  N-­‐‑terminal	  function,	  free	  C-­‐‑terminal	  AMH	  do	  not	  exist	  in	  
biological	  fluid	  including	  blood	  (90),	  and	  it	  is	  thought	  that	  the	  AMHN,C	  dissociate	  
with	  influence	  by	  the	  target	  receptor	  (91).	  
	  
There	  is	  an	  emerging	  awareness	  of	  the	  possible	  significance	  of	  pre-­‐‑protein	  in	  
biology,	  beyond	  its	  role	  intracellularly.	  The	  signal	  peptide	  cleaved	  from	  some	  
preproproteins	  can	  be	  detected	  in	  the	  circulation	  (92,	  93),	  with	  some	  correlation	  
to	  pathology	  (94).	  The	  most	  topical	  in	  the	  New	  Zealand	  setting	  are	  studies	  of	  the	  




pathophysiology	  of	  cardiovascular	  diseases	  (95,	  96).	  The	  natriuretic	  signal	  
peptides	  have	  been	  shown	  to	  be	  correlative	  to	  certain	  cardiovascular	  traits,	  and	  
research	  is	  ongoing	  into	  its	  potential	  role	  as	  a	  cardiovascular	  biomarker	  (92,	  94,	  
97).	  It	  is	  currently	  unknown	  if	  preproAMH	  exists	  in	  circulation.	  	  
	  
Similarly,	  the	  proprotein	  were	  initially	  thought	  to	  have	  no	  functional	  purpose	  
beyond	  being	  a	  substrate	  for	  the	  generation	  of	  the	  C-­‐‑terminal.	  However,	  this	  may	  
not	  be	  universally	  correct,	  with	  the	  strongest	  evidence	  for	  function	  of	  proprotein	  
coming	  from	  the	  study	  of	  proneutrophins	  (proNGF	  and	  proBDNF).	  The	  
proneutrophins	  are	  able	  to	  activate	  receptors	  independent	  from	  their	  C-­‐‑terminal	  
site	  (98,	  99).	  This	  generates	  a	  mechanism	  where	  the	  ability	  of	  the	  target	  cell	  to	  
cleave	  the	  proneurotrophin	  dictates	  the	  final	  phenotype.	  	  
	  
In	  other	  instances,	  the	  role	  of	  the	  intact	  proprotein	  prior	  to	  cleavage	  is	  unknown	  
but	  thought	  to	  have	  biological	  significance.	  Some	  proproteins	  are	  concurrently	  
detected	  in	  circulation	  as	  well	  as	  the	  cleaved	  active	  peptide.	  Consequently,	  there	  
is	  emerging	  interest	  in	  the	  exploration	  of	  the	  extent	  of	  the	  cleavage	  of	  the	  
proprotein	  as	  potential	  biomarkers.	  For	  instance,	  both	  proinsulin	  and	  the	  
activated	  insulin	  are	  detected	  in	  blood	  of	  people	  with	  normal	  glucose	  
metabolism	  and	  those	  with	  diabetes	  mellitus	  (100,	  101).	  The	  relative	  ratio	  of	  
proinsulin	  to	  insulin	  in	  blood	  have	  been	  shown	  be	  different	  with	  ageing	  and	  with	  
a	  glucose	  challenge	  (100).	  Subsequently	  the	  ratio	  of	  the	  two	  hormones	  have	  been	  
suggested	  as	  potential	  biomarker	  for	  prediction	  of	  development	  of	  diabetes	  
mellitus	  due	  to	  pancreatic	  beta	  cell	  dysfunction	  (100,	  102).	  
	  
Differential	  cleavage	  of	  the	  proprotein	  may	  yield	  different	  active	  cytokines	  that	  
have	  distinct	  functions,	  in	  a	  context	  specific	  manner.	  For	  example,	  pro-­‐‑
opiomelanocortin	  is	  a	  prohormone	  synthesised	  in	  the	  anterior	  pituitary	  gland,	  
and	  cleaved	  by	  several	  prohormone	  convertase	  enzymes.	  The	  cleavage	  is	  tissue	  
specific,	  and	  yields	  several	  distinct	  cytokines	  and	  hormones,	  including	  
adrenocorticotropic	  hormone	  in	  the	  pituitary	  gland,	  and	  melanin	  in	  the	  skin	  
(103).	  The	  prohormone	  chromogranin	  A	  is	  another	  example.	  Chromogranin	  A	  is	  




functions	  (104).	  Chromogranin	  A	  itself	  is	  found	  in	  blood	  and	  is	  utilised	  as	  a	  
biomarker	  for	  diagnosis	  of	  neuroendocrine	  tumours	  such	  as	  carcinoid	  tumours	  
and	  pheochromocytoma	  (105,	  106).	  The	  regulation	  of	  the	  cleavage	  activity	  of	  a	  
propeptide	  therefore	  may	  influence	  different	  bodily	  function	  to	  the	  active	  
peptide	  itself.	  
	  
There	  is	  scarce	  knowledge	  about	  the	  processing	  of	  precursors	  of	  AMH,	  and	  an	  
absent	  of	  information	  pertaining	  to	  its	  cleavage	  in	  men.	  Intact	  proAMH	  is	  known	  
to	  exist,	  with	  its	  presence	  in	  blood	  only	  being	  documented	  since	  the	  
commencement	  of	  this	  PhD	  (90).	  ProAMH	  is	  putatively	  cleaved	  by	  several	  
prohormone	  convertase	  enzymes	  that	  has	  wide	  ranging	  functions,	  such	  as	  furin	  
[Chapter	  6.1].	  The	  role	  of	  proAMH	  has	  not	  been	  elucidated.	  Given	  the	  possibility	  
of	  functional	  significance	  of	  prohormones,	  as	  well	  as	  the	  cleavage	  extent	  being	  a	  
biomarker	  for	  other	  prohormones,	  this	  provides	  the	  basis	  to	  studying	  proAMH	  
and	  the	  extent	  of	  its	  cleavage	  in	  circulation	  to	  the	  cleaved	  form	  AMHN,C.	  The	  
regulation	  and	  influence	  of	  proAMH	  and	  its	  cleavage	  extent	  may	  be	  distinct	  to	  
the	  ability	  of	  AMH	  to	  interact	  with	  its	  receptor	  and	  downstream	  intracellular	  
signalling.	  	  
	  




1.6.2  Canonical  receptor  activation  
 
The	  canonical	  receptor	  activation	  for	  all	  TGFβ	  superfamily	  members	  involves	  
shared	  signalling	  components:	  35	  ligands	  converge	  onto	  5	  type-­‐‑2	  receptors	  
which	  associates	  and	  activate	  7	  type-­‐‑1	  receptors	  [Fig.	  1.2]	  (79,	  107).	  Each	  
receptor	  type	  only	  interacts	  with	  certain	  members	  of	  this	  superfamily.	  
Consequently	  the	  specificity	  of	  the	  ligands	  to	  the	  different	  type-­‐‑2	  receptors	  is	  
used	  to	  subdivide	  this	  superfamily	  into	  the	  following	  groups:	  the	  TGFβ	  
(TGFβR2),	  the	  activins	  (ACVR2A),	  the	  BMP	  (BMPR2,	  ACVR2B)	  and	  AMH	  
(AMHR2).	  	  The	  largest	  subgroup	  is	  the	  BMP,	  which	  also	  includes	  the	  growth	  and	  
differentiating	  factors.	  Each	  of	  the	  type-­‐‑2	  receptors	  can	  associate	  with	  a	  subset	  of	  
the	  type-­‐‑1	  receptors,	  resulting	  in	  certain	  type-­‐‑1	  receptors	  being	  able	  to	  bind	  to	  
multiple	  type-­‐‑2	  receptors	  [Fig.	  1.2].	  The	  type-­‐‑1	  receptor	  defines	  downstream	  
intracellular	  signalling	  by	  phosphorylating	  specific	  intracellular	  proteins	  called	  
receptor-­‐‑SMADs,	  which	  can	  be	  broadly	  divided	  into	  two	  groups:	  those	  that	  are	  
activated	  by	  the	  BMPs	  and	  a	  minority	  of	  TGFβ	  subfamily	  signalling	  
(SMAD1/5/8),	  and	  members	  that	  belong	  to	  the	  TGFβ/activin/inhibin	  group	  
(SMAD2/3).	  The	  canonical	  receptor	  signalling	  therefore	  results	  in	  35	  ligands	  
interacting	  with	  distinct	  type-­‐‑2	  receptors	  which	  converges	  to	  2	  groups	  at	  an	  
intracellular	  level,	  due	  to	  shared	  type-­‐‑1	  receptors.	  This	  may	  be	  central	  to	  the	  
understanding	  of	  AMH	  signalling,	  as	  the	  type-­‐‑1	  receptors	  and	  receptor-­‐‑SMADs	  
activated	  by	  AMH	  are	  common	  to	  the	  BMP	  group	  (79,	  108).	  AMH	  therefore	  may	  
signal	  as	  a	  BMP	  ligand,	  with	  phenotypic	  features	  common	  to	  the	  BMPs	  (65).	  	  	  
	  








Figure  1.2.  Canonical  signalling  pathway  of  TGFβ  superfamily  ligands  
and  their  receptors.    
The	  type-­‐‑1	  receptor	  (red	  box)	  used	  by	  AMH	  signalling	  is	  shared	  by	  the	  BMP	  and	  
GDF	  ligands,	  despite	  their	  differences	  in	  type-­‐‑2	  receptors	  (blue	  box).	  AMH,	  BMPs	  
and	  GDFs	  all	  activate	  the	  common	  receptor	  SMADs	  1/5/8.	  	  Figures	  are	  adapted	  




InhB	  acts	  as	  an	  antagonist	  to	  the	  activins,	  by	  competitively	  binding	  to	  the	  same	  
type-­‐‑2	  receptors	  as	  activins,	  but	  not	  recruiting	  the	  type-­‐‑1	  receptors	  and	  hence	  
not	  inducing	  any	  intracellular	  signalling	  of	  the	  activin	  group	  (109,	  110).	  	  Both	  
InhB	  and	  AMH	  are	  products	  of	  the	  Sertoli	  cells,	  but	  their	  effect	  on	  the	  
intracellular	  pathways	  are	  divergent.	  This	  suggests	  that	  the	  Sertoli	  cell	  hormones	  
may	  have	  independent	  functions.	  	  
	  
AMH	  has	  been	  thought	  to	  lack	  function	  in	  men,	  as	  the	  circulating	  level	  of	  AMH	  in	  
the	  post-­‐‑pubertal	  male	  is	  much	  lower	  than	  that	  of	  boys	  [Chapter	  1.5.2].	  When	  
viewed	  in	  the	  context	  as	  a	  member	  of	  the	  TGFβ	  superfamily,	  there	  maybe	  a	  
possibility	  that	  AMH	  may	  have	  function	  at	  adult	  concentration.	  A	  defining	  feature	  
of	  this	  superfamily	  is	  the	  ability	  to	  induce	  cell	  signalling	  by	  ligands	  across	  a	  wide	  
range	  of	  concentrations	  by	  orders	  of	  magnitude	  (111).	  This	  is	  achieved	  with	  the	  
use	  of	  binding	  proteins	  that	  potentiate	  the	  binding	  of	  the	  ligand	  to	  the	  receptor.	  
For	  instance,	  betaglycans	  acts	  as	  a	  co-­‐‑receptor	  for	  InhB	  on	  ACVR2	  receptor	  in	  
certain	  tissues	  to	  result	  in	  antagonism	  of	  activin,	  whereas	  the	  absence	  of	  
betaglycans	  result	  in	  a	  lack	  of	  binding	  by	  InhB	  (112).	  Again,	  this	  illustrates	  the	  
contextual	  nature	  of	  signalling	  in	  this	  superfamily.	  The	  existence	  of	  a	  binding	  
protein	  for	  AMH	  is	  currently	  unknown,.	  The	  activin	  binding	  protein	  Follistatin	  
may	  be	  a	  putative	  candidate,	  and	  forms	  the	  basis	  of	  a	  colleague’s	  PhD	  thesis	  
submission.	  	  
	  
Variations	  in	  AMHR2,	  the	  specific	  type-­‐‑2	  receptor	  for	  AMH	  is	  known	  (113),	  and	  
influence	  the	  ability	  for	  AMH	  to	  signal	  (114).	  Consequently,	  there	  is	  increasing	  
interest	  in	  the	  exploration	  of	  the	  AMHR2	  polymorphism	  and	  gonadal	  function	  in	  
the	  female	  (115-­‐‑119).	  
	  
The	  signalling	  pathway	  for	  AMH	  is	  known	  for	  induction	  of	  paramesonephric	  duct	  
regression.	  This	  involves	  the	  binding	  of	  AMH	  onto	  AMHR2,	  and	  recruiting	  two	  of	  
the	  BMP	  type-­‐‑1	  receptors,	  resulting	  in	  the	  activation	  of	  intracellular	  signalling	  
common	  to	  the	  BMP	  subgroup	  (120,	  121).	  The	  type-­‐‑1	  receptors	  have	  been	  
shown	  to	  be	  redundant	  in	  the	  generation	  of	  the	  overt	  phenotype	  persistent	  




other	  type-­‐‑2	  receptors	  beyond	  AMHR2,	  but	  the	  possibilities	  have	  been	  set	  up	  in	  
the	  above	  sections.	  AMHR2	  is	  expressed	  by	  tissues	  beyond	  the	  testes	  (124,	  125),	  
particularly	  in	  the	  nervous	  system	  (69,	  126,	  127).	  This	  sets	  up	  a	  direction	  to	  
explore	  for	  putative	  association	  of	  AMH	  in	  the	  central	  nervous	  system.	  
Alternatively	  or	  concurrently,	  AMH	  may	  function	  like	  a	  BMP	  ligand.	  As	  stated	  
above,	  its	  function	  may	  not	  be	  obvious,	  unless	  there	  is	  significant	  disruption	  to	  
other	  ligands	  that	  share	  similar	  downstream	  signalling.	  A	  potential	  model	  to	  
examine	  for	  putative	  AMH	  function	  may	  be	  found	  in	  the	  older	  person	  with	  
naturally	  occurring	  states	  of	  impaired	  homeostasis,	  particularly	  when	  associated	  
with	  frailty	  [Chapter	  7].  
  




1.7  Objectives  of  the  thesis  
 
This	  thesis	  aims	  to	  examine	  a	  circulating	  hormone	  in	  men,	  for	  which	  there	  is	  no	  
known	  function.	  The	  receptor	  for	  AMH	  is	  present	  in	  multiple	  tissues,	  but	  this	  
does	  not	  prove	  its	  function	  [Section	  1.6.2].	  AMH	  is	  found	  in	  circulation	  in	  young	  
men	  and	  women,	  but	  scarce	  information	  is	  known	  regarding	  its	  physiology	  
following	  puberty	  [Section	  1.5.2].	  Null	  mutants	  for	  AMH	  are	  extremely	  rare	  in	  
humans,	  which	  means	  that	  the	  study	  for	  putative	  AMH	  action	  has	  to	  begin	  with	  
association	  studies,	  to	  correlate	  phenotypic	  traits,	  including	  diseases,	  and	  
circulating	  AMH	  levels.	  All	  postmenopausal	  women	  lack	  AMH,	  whilst	  the	  profile	  
of	  circulating	  AMH	  in	  older	  men	  is	  unknown	  [Section	  1.5.2,	  Chapter	  4.1].	  If	  AMH	  
exhibits	  sexual	  dimorphism	  with	  ageing,	  then	  the	  lack	  of	  AMH	  in	  older	  women	  
may	  hold	  clues	  as	  to	  putative	  functions	  of	  AMH.	  Ageing	  changes	  such	  as	  
cardiovascular	  disease	  profiles	  and	  osteoporosis	  differ	  between	  men	  and	  
women,	  with	  these	  changes	  historically	  attributable	  to	  differences	  in	  sex	  steroid	  
levels	  (127a-­‐‑b).	  	  
	  
Evidence	  from	  mice	  have	  shown	  that	  AMH	  is	  regulator	  of	  neurons,	  which	  is	  not	  
easily	  studied	  in	  younger	  people	  due	  to	  multiple	  redundant	  biological	  systems	  
[Section	  1.6.2].	  If	  AMH	  has	  a	  functional	  significance,	  perturbations	  in	  its	  levels	  
would	  be	  more	  likely	  to	  be	  observed	  in	  older	  men	  compared	  to	  younger	  men,	  as	  
older	  people	  exhibit	  more	  dysregulation	  in	  their	  homeostasis	  with	  ageing.	  This	  is	  
profiled	  in	  the	  context	  of	  AMH	  as	  a	  Sertoli	  hormone	  [Chapter	  4]	  and	  also	  in	  the	  
context	  of	  AMH	  as	  a	  testicular	  hormone	  in	  relation	  to	  the	  Leydig	  hormones	  
[Chapter	  5].	  The	  profiling	  of	  proAMH	  and	  the	  extent	  of	  its	  cleavage	  in	  men	  is	  
described	  in	  Chapter	  6.	  There	  is	  no	  a	  priori	  hypothesis	  as	  to	  the	  function	  of	  AMH	  
in	  men.	  However,	  if	  AMH	  does	  have	  broad	  function,	  then	  its	  perturbation	  is	  more	  
likely	  to	  be	  observed	  in	  men	  that	  lacks	  physiological	  reserve	  to	  maintain	  
homeostasis.	  This	  is	  more	  frequently	  seen	  in	  the	  older	  person,	  particularly	  those	  
with	  frailty.	  Chapter	  7	  will	  describe	  the	  first	  putative	  association	  study	  of	  
circulating	  AMH,	  in	  the	  context	  of	  its	  cleavage	  and	  other	  testicular	  hormones,	  in	  a	  




clinician	  in	  both	  endocrinology	  and	  geriatric	  medicine,	  and	  consolidates	  both	  
clinical	  acumen	  and	  laboratory	  skills	  learnt	  during	  the	  PhD	  study.	  	  
Before	  any	  correlative	  studies	  can	  be	  performed,	  the	  stability	  of	  circulating	  AMH	  
throughout	  the	  day	  has	  to	  be	  determined,	  and	  whether	  it	  is	  subjected	  to	  any	  
sporadic	  influence	  or	  exhibit	  moment-­‐‑moment	  relationship	  with	  the	  other	  
testicular	  hormones	  [Chapter	  3].	  	  
	  
This	  thesis	  is	  an	  exploration	  into	  an	  uncharted	  territory	  in	  biological	  and	  medical	  
science.	  This	  requires	  observational	  studies,	  which	  forms	  the	  basis	  of	  this	  PhD	  
thesis.	  Where	  levels	  of	  circulating	  AMH	  is	  varying,	  this	  may	  hold	  clues	  as	  to	  its	  









Common	  methodological	  techniques	  employed	  throughout	  the	  thesis	  are	  
described	  in	  this	  Chapter.	  Specific	  methodologies	  are	  discussed	  in	  individual	  
Chapters	  that	  are	  pertinent	  to	  that	  Chapter.	  
  
2.1  Serum  Hormonal  Analyses  
  
2.1.1  Processing  of  Sera  
  
Venous	  bloods	  were	  collected	  into	  6	  mL	  BD	  Vacutainer	  red	  top	  test	  tubes	  from	  
the	  antecubital	  vein	  by	  venepuncture	  using	  a	  20G	  hypodermic	  needle	  encased	  in	  
a	  plastic	  container.	  Blood	  samples	  were	  left	  to	  clot	  at	  room	  temperature	  in	  
upright	  position	  for	  60	  minutes.	  Sera	  were	  obtained	  by	  centrifugation	  at	  2,000	  g	  
for	  five	  minutes,	  immediately	  snapped	  frozen	  with	  liquid	  nitrogen	  and	  stored	  at	  
minus	  800C	  freezer	  in	  multiple	  aliquots.	  	  Samples	  were	  thawed	  only	  once	  in	  40C	  
fridge	  for	  at	  least	  an	  hour	  prior	  to	  enzyme	  linked	  immunosorbent	  assay	  (ELISA)	  
assay.	  	  
  
2.1.2  ELISA  description  
  
Circulating	  hormones	  were	  mostly	  assayed	  by	  ELISA,	  either	  of	  the	  sandwich	  or	  
competitive	  type	  [Table	  2.1].	  ELISA	  assays	  allows	  relative	  quantification	  of	  
specific	  proteins	  within	  a	  sample,	  in	  relation	  to	  a	  set	  of	  protein	  standards	  with	  
known	  concentrations	  values.	  The	  general	  techniques	  are	  described	  below.	  To	  
reduce	  interassay	  variability,	  all	  blood	  samples	  were	  assayed	  in	  a	  single	  batch	  for	  




Table  2.1  Commercial  ELISA  kits  employed  in  PhD    
	  
Hormone	   Company	   Name	  
(Catalogue)	  
Sensitivity	  	   Intra	  and	  
Inter	  assay	  
values	  
AMH	   Beckman	  Coulter	   Gen	  II	  ELISA	  
(A73818)	  
1.1	  pM	  	   5.4%	  /	  
5.6%	  
InhB	   Beckman	  Coulter	   Gen	  II	  ELISA	  
(A81303)	  
1	  pg/mL	   5.6%	  /	  
6.2%	  








19.6	  pg/mL	   10%	  /	  15%	  




0.3	  nM	   7.6%	  
/12.5%	  




0.2	  IU/L	   4.5%	  /	  
5.1%	  





1	  IU/L	   5.8%	  /	  
7.7%	  











The	  primary	  antibody	  to	  a	  particular	  epitope	  of	  the	  protein	  is	  either	  added	  to	  the	  
ELISA	  wells	  (testosterone	  assay)	  or	  is	  already	  pre-­‐‑coated	  by	  the	  manufacturer.	  
Sera	  and	  standard	  solutions	  in	  measured	  amounts	  are	  incubated	  in	  the	  
individual	  ELISA	  wells	  for	  set	  timed	  intervals	  at	  room	  temperature,	  which	  
facilitates	  binding	  of	  the	  antigen	  to	  the	  primary	  antibody.	  In	  the	  context	  of	  a	  
competitive	  ELISA	  such	  as	  cortisol	  assay,	  a	  fixed	  amount	  of	  horseradish	  
peroxidase	  (HRP)	  labelled	  cortisol	  is	  concomitantly	  added	  to	  the	  wells	  to	  
compete	  with	  the	  endogenous	  cortisol	  for	  the	  primary	  antibody.	  The	  greater	  the	  
amount	  of	  endogenous	  cortisol,	  the	  fewer	  binding	  sites	  are	  available	  for	  the	  HRP	  
labelled	  cortisol.	  The	  wells	  are	  subsequently	  washed	  with	  a	  biological	  detergent,	  
leaving	  only	  the	  primary	  antibody-­‐‑antigen	  attached	  to	  the	  wall	  of	  the	  ELISA	  
wells.	  In	  the	  case	  of	  a	  sandwich	  ELISA,	  a	  second	  antibody	  labelled	  with	  biotin	  is	  
then	  added,	  specific	  to	  another	  epitopic	  site	  of	  the	  protein,	  thereby	  
“sandwiching”	  the	  protein	  of	  interest	  between	  two	  antibodies.	  HRP	  is	  
consequently	  added	  that	  attach	  to	  the	  biotin	  labelled	  detection	  antibody.	  In	  both	  
ELISA	  types,	  a	  substrate,	  usually	  tetramethylbenzadine	  is	  added	  and	  incubated	  
for	  a	  fixed	  time	  period,	  allowing	  the	  HRP	  to	  catalyse	  a	  colourimetric	  reaction,	  
which	  is	  stopped	  by	  the	  addition	  of	  sulphuric	  acid.	  The	  degree	  of	  HRP	  mediated	  
enzymatic	  reaction	  is	  quantified	  by	  measuring	  the	  light	  absorbance	  VICTORTM	  
X3	  Multilabel	  Plate	  Reader	  (PerkinElmer)	  at	  450	  nm	  wavelength,	  corrected	  for	  
the	  background	  570	  nm	  wavelength.	  The	  values	  are	  plotted	  against	  a	  standard	  
curve	  obtained	  from	  the	  standards	  generated	  using	  the	  best-­‐‑fit	  equation	  (usually	  
quadratic	  curve,	  or	  5-­‐‑point	  parametric	  curve).	  In	  the	  context	  of	  the	  sandwich	  
ELISA,	  the	  value	  of	  the	  light	  absorbance	  is	  proportional	  to	  the	  amount	  of	  
protein/antigen	  tested.	  For	  the	  competitive	  ELISA,	  there	  is	  an	  inverse	  
relationship	  between	  the	  absorbance	  and	  the	  amount	  of	  protein	  due	  to	  the	  
competition	  with	  HRP	  labeled	  protein.	  All	  ELISAs	  were	  performed	  manually,	  and	  
each	  sample	  was	  assayed	  in	  duplicate,	  with	  the	  final	  results	  obtained	  by	  taking	  
the	  average	  of	  the	  two	  samples.	  The	  AMH	  assay	  CV	  was	  tested	  by	  my	  laboratory,	  
with	  inter	  and	  intra-­‐‑assay	  reported	  in	  Table	  2.1.	  	  
	  
Testosterone	  was	  initially	  assayed	  with	  the	  R&D	  Testosterone	  ELISA	  kit	  




samples	  preclude	  further	  utility	  of	  the	  data	  for	  analyses.	  The	  decision	  was	  made	  
to	  engage	  the	  clinical	  laboratory	  for	  Christchurch	  Hospital	  (Endolab,	  
Christchurch),	  using	  a	  competitive	  ELISA	  developed	  in-­‐‑house	  (128).	  
  
2.1.3  ProAMH  ELISA  
  
The	  Beckman	  Coulter	  AMH	  Gen	  II	  AMH	  ELISA	  reports	  total	  AMH,	  which	  is	  an	  
aggregate	  measure	  of	  proAMH	  and	  AMHN,C	  found	  in	  blood	  (Chapter	  6.1)(90).	  A	  
laboratory	  grade	  ELISA	  was	  developed	  to	  quantify	  the	  amount	  of	  proAMH	  in	  
serum	  (129),	  by	  modifying	  the	  procedure	  utilised	  in	  the	  AMH	  Gen	  II	  assay	  kit.	  
The	  capture	  antibody	  in	  the	  Gen	  II	  assay	  binds	  to	  AMHC,	  and	  the	  detection	  
antibody	  binds	  to	  AMHN.	  The	  ProAMH	  ELISA	  dissociates	  AMHN,C	  with	  
deoxycholate,	  which	  removes	  AMHN	  and	  prevents	  its	  binding	  to	  the	  detection	  
antibody.	  ProAMH	  is	  unaffected	  by	  the	  treatment	  as	  the	  protein	  is	  uncleaved,	  and	  
therefore	  the	  AMHN	  and	  AMHC	  species	  do	  not	  dissociate.	  Two	  15-­‐‑minute,	  150-­‐‑μL	  
wash	  steps	  of	  0.2	  %w/v	  sodium	  deoxycholate	  were	  inserted	  into	  the	  AMH	  Gen	  II	  
protocol	  after	  the	  sample-­‐‑binding	  step.	  
	  
Intra	  and	  inter-­‐‑assay	  variations	  were	  reported	  to	  be	  8%	  and	  13%	  respectively.	  	  
The	  limit	  of	  detection	  for	  total	  AMH	  and	  proAMH	  were	  measured	  by	  my	  
laboratory,	  and	  were	  1.1	  and	  0.9	  pM	  respectively	  (129).	  
The	  AMH	  prohormone	  index	  (API)	  was	  calculated	  as	  the	  relative	  proportion	  of	  
proAMH,	  expressed	  as	  a	  percentage	  of	  total	  AMH	  (API	  =	  [proAMH]/[total	  
AMH]	  ×	  100).	  The	  level	  of	  AMHN,C	  was	  estimated	  as	  [total	  AMH]	  −	  [proAMH].	  
  




2.1.4  INSL3  assay  description  
  
The	  INSL3	  enzyme	  immunoassay	  (EIA)	  [Table	  2.1]	  is	  a	  fluorescent	  immunoassay	  
that	  uses	  the	  competitive	  ELISA	  principle.	  The	  EIA	  wells	  are	  pre-­‐‑coated	  with	  a	  
secondary	  antibody,	  which	  captures	  the	  detection	  antibody.	  Diluted	  samples	  and	  
standards	  are	  added	  to	  the	  wells,	  and	  compete	  for	  primary	  antibody	  binding	  in	  
the	  presence	  of	  biotinylated-­‐‑INSL3	  peptide.	  Only	  the	  biotinylated-­‐‑peptide	  will	  
bind	  the	  HRP,	  which	  in	  turn	  catalyses	  the	  substrate	  reaction.	  The	  relative	  
immunofluorescence	  level	  is	  quantified	  by	  the	  fluorescence	  microplate	  reader	  
with	  excitation	  and	  emission	  wavelengths	  of	  320	  nm	  and	  405	  nm	  respectively	  
set	  for	  detection.	  The	  relative	  degree	  of	  fluorescence	  is	  inversely	  proportional	  to	  
the	  amount	  of	  amount	  of	  INSL3	  in	  a	  sample,	  and	  solved	  by	  standard	  curves	  using	  
5-­‐‑point	  parameters	  equations.	  	  
  




2.1.5  Limitations  of  ELISAs  
  
2.1.5A.  AMH  field  notice  
  
AMH	  was	  measured	  using	  Beckman	  Coulter	  AMH	  Gen	  II	  ELISA	  commercial	  kit.	  In	  
June	  2013,	  Beckman	  Coulter	  issued	  a	  field	  notice	  alerting	  to	  underestimation	  of	  
AMH	  due	  to	  interference	  within	  samples,	  and	  advised	  pre-­‐‑diluting	  the	  samples	  
for	  one	  hour	  at	  room	  temperature	  with	  assay	  buffer	  prior	  to	  assay	  to	  nullify	  the	  
effect	  of	  the	  interference.	  Most	  of	  the	  AMH	  data	  within	  this	  thesis	  had	  to	  be	  re-­‐‑
assayed,	  with	  the	  exception	  of	  sera	  from	  the	  Vascular	  and	  the	  LiLACS	  NZ	  cohorts,	  
due	  to	  sample	  availability.	  	  
	  
	  
On	  average,	  AMH	  values	  post	  field	  notice	  were	  1.6	  times	  greater	  than	  pre-­‐‑
dilution	  (standard	  deviation	  =0.58,	  n=316),	  with	  this	  difference	  being	  highly	  
significant	  (p<0.0001,	  two	  tailed	  paired	  Student’s	  t-­‐‑test).	  The	  correlation	  
between	  the	  old	  and	  newer	  data	  sets	  was	  high	  (Pearson’s	  linear	  regression	  
R2=0.87,	  p<0.0001).	  These	  findings	  are	  consistent	  with	  published	  literature	  on	  
AMH	  values	  in	  women	  (130-­‐‑133),	  and	  the	  first	  to	  be	  described	  in	  men.	  The	  
absolute	  values	  of	  AMH	  vary	  between	  pre-­‐‑	  and	  post-­‐‑Field	  notice	  data,	  but	  the	  
relative	  values	  are	  still	  preserved.	  Therefore,	  conclusions	  drawn	  from	  studies	  












2.1.5B  Comparisons  of  results  between  studies  
	  
ELISA	  kits	  allow	  the	  quantification	  of	  proteins	  by	  comparing	  the	  measured	  value	  
against	  a	  reference	  curve	  generated	  from	  standards	  measured	  within	  the	  same	  
kit.	  Currently	  there	  is	  no	  agreed	  international	  standard	  for	  AMH	  and	  INSL3,	  
which	  precludes	  the	  ability	  to	  compare	  the	  absolute	  hormonal	  values	  derived	  
from	  different	  studies	  that	  utilise	  different	  ELISA	  kits.	  Additionally,	  different	  
laboratory	  environmental	  conditions	  can	  also	  affect	  the	  results	  of	  the	  ELISA	  
output,	  hence	  necessitating	  the	  practice	  of	  local	  laboratory	  reference	  ranges	  for	  
comparisons.	  	  
	  
The	  distribution	  of	  hormonal	  values	  however	  can	  be	  meaningfully	  compared,	  as	  
the	  ranked	  distribution	  between	  individuals	  should	  remain	  invariant	  between	  
different	  studies.	  The	  profiling	  of	  circulating	  male	  INSL3	  is	  a	  recent	  phenomenon,	  
with	  differences	  in	  absolute	  mean	  values	  of	  INSL3	  observed	  between	  different	  
cross-­‐‑sectional	  studies	  (30,	  134).	  However,	  when	  the	  individual	  values	  are	  
normalised	  against	  other	  studies,	  the	  distribution	  of	  INSL3	  from	  this	  PhD	  study	  










Figure  2.1.  Circulating  INSL3  levels  between  the  Otago  cohort  and  two  
other  cohorts.    
Each	  symbol	  represents	  an	  individual’s	  INSL3	  level.	  A.	  The	  distributions	  of	  INSL3	  
in	  the	  study	  by	  Bay	  et	  al	  (30)	  is	  similar	  to	  the	  distribution	  in	  the	  Otago	  cohort,	  
when	  the	  Otago	  values	  are	  normalised	  to	  achieve	  the	  same	  mean	  as	  that	  in	  Bay	  et	  
al.	  	  
B.	  The	  distribution	  of	  INSL3	  in	  the	  Australian	  cohort	  of	  men	  was	  positively	  
skewed	  (134),	  with	  similar	  proportions	  of	  men	  with	  high	  INSL3	  values	  as	  the	  
Otago	  cohort.    




2.1.5C  Comparisons  with  alternative  immunoassays  or  assay  platforms  
	  
The	  perceived	  gold	  standard	  for	  the	  assay	  of	  testosterone	  in	  the	  laboratory	  
setting	  has	  been	  mass	  spectrometry,	  with	  better	  sensitivity	  for	  measurement	  of	  
very	  low	  levels	  of	  testosterone.	  However,	  a	  large	  observational	  study	  comparing	  
measurement	  of	  circulating	  testosterone	  by	  both	  mass	  spectrometry	  and	  
immunoassay	  have	  found	  high	  correlation	  of	  results	  between	  the	  two	  platforms,	  
with	  no	  advantage	  of	  using	  mass	  spectrometry	  (30a).	  The	  utility	  of	  mass	  
spectrometry	  for	  measurement	  of	  testosterone	  in	  this	  PhD	  study	  was	  explored,	  
but	  not	  pursued	  further.	  	  
	  
Immunoassays	  for	  both	  AMH	  and	  INSL3	  are	  currently	  still	  at	  a	  research	  stage,	  
although	  the	  Beckman	  Coulter	  Gen	  II	  AMH	  ELISA	  is	  used	  clinically	  within	  in-­‐‑vitro	  
fertilisation	  programmes.	  	  This	  has	  led	  to	  extensive	  off-­‐‑label	  use	  of	  this	  ELISA	  in	  
clinical	  research	  relating	  to	  obstetrics	  and	  gynaecology.	  	  The	  Beckman	  Coulter	  
Gen	  II	  AMH	  ELISA	  was	  the	  dominant	  AMH	  assay	  throughout	  the	  period	  of	  the	  
thesis	  research.	  	  The	  results	  from	  the	  various	  competing	  AMH	  assays	  correlate	  
with	  a	  high	  correlation	  coefficient,	  indicating	  that	  they	  accurately	  rank	  samples	  
by	  level	  of	  AMH.	  	  The	  absolute	  values	  from	  AMH	  ELISA	  are	  less	  concordant,	  as	  
there	  is	  no	  international	  standard	  for	  the	  AMH	  ELISA.	  	  The	  INSL3	  ELISAs	  are	  less	  
developed	  than	  AMH	  ELISA,	  with	  all	  INSL3	  ELISA	  being	  in-­‐‑house	  or	  sold	  by	  small	  
companies.	  	  The	  INSL3	  ELISAs	  use	  competitive	  binding	  and	  are	  therefore	  more	  
prone	  to	  error	  than	  the	  sandwich	  technology	  used	  in	  the	  AMH	  and	  InhB	  ELISAs.	  	  
As	  with	  the	  AMH	  ELISA,	  absolute	  values	  can	  not	  be	  compared	  between	  studies.	  
	  
Recently,	  our	  research	  group	  have	  identified	  two	  species	  of	  AMH	  in	  blood,	  
proAMH	  and	  AMHN,C.	  However,	  all	  commercial	  immunoassays	  for	  AMH	  only	  
report	  the	  aggregate	  or	  total	  amount.	  	  The	  significance	  of	  this	  can	  not	  currently	  
be	  assessed,	  as	  the	  bioactivity	  of	  circulating	  proAMH	  and	  AMHN,C	  are	  unclear.	  
Another	  factor	  that	  may	  impact	  on	  ELISA	  output	  is	  the	  degree	  of	  glycosylation	  of	  






2.2  Calculations  and  statistical  analyses    
  
The	  levels	  of	  circulating	  hormones	  and	  clinical	  attributes	  are	  reported	  as	  mean	  
with	  standard	  deviation,	  and/or	  as	  median	  with	  range.	  Distributions	  of	  the	  
hormonal	  values	  were	  examined	  for	  skewness,	  with	  statistical	  significance	  tested	  
using	  SKTEST	  (Skewness	  and	  Kurtosis	  Test	  for	  Normality).	  A	  minority	  of	  men	  
examined	  in	  Chapter	  4	  and	  5	  had	  undetectable	  levels	  of	  circulating	  testicular	  
hormones,	  whilst	  some	  men	  had	  low	  but	  detectable	  levels.	  These	  men	  were	  
included	  in	  all	  statistical	  analyses,	  thereby	  avoiding	  left	  censoring.	  	  
	  
Associations	  between	  two	  variables	  were	  tested	  in	  univariate	  analyses	  using	  
linear	  regression	  with	  Pearson	  correlation.	  Multiple	  variables	  were	  examined	  for	  
their	  impact	  on	  the	  relationship	  using	  partial	  correlation.	  Differences	  between	  
two	  groups	  of	  the	  same	  variable	  were	  tested	  using	  Student’s	  t-­‐‑test,	  whilst	  
variations	  between	  subgroups	  were	  examined	  by	  one-­‐‑way	  ANOVA,	  and	  post-­‐‑hoc	  
analyses	  with	  Scheffe’s	  test	  to	  investigate	  for	  differences	  between	  subgroups.	  	  P	  
values	  less	  than	  0.05	  are	  considered	  statistically	  significant.	  	  
	  
The	  levels	  of	  hormones	  vary	  between	  individuals.	  If	  the	  relationship	  between	  
hormones	  (e.g.	  AMH	  and	  InhB)	  were	  described	  as	  a	  simple	  ratio,	  the	  resulting	  
distribution	  would	  not	  be	  symmetrical.	  Individuals	  with	  high	  AMH	  would	  be	  
represented	  by	  a	  range	  of	  1	  to	  infinity,	  whilst	  those	  with	  high	  InhB	  would	  range	  
from	  0	  to	  1.	  To	  achieve	  parity	  between	  the	  numerator	  and	  the	  denominator,	  the	  
hormonal	  values	  are	  first	  standardised	  by	  taking	  their	  natural	  logarithmic	  
values,	  then	  examined	  by	  taking	  the	  differences	  between	  the	  two	  logged	  values.	  
When	  this	  ratio	  is	  standardised	  using	  the	  mean	  levels	  of	  the	  hormones	  in	  the	  
young	  men,	  then	  the	  distribution	  centers	  around	  zero.	  Any	  variation	  from	  a	  
normal	  distribution	  indicates	  biological	  skewing,	  with	  the	  width	  of	  the	  bell	  curve	  
being	  a	  measure	  of	  the	  variation	  in	  the	  population:	  as	  per	  the	  normal	  distribution	  





The	  approaches	  used	  in	  the	  thesis	  were	  based	  on	  advice	  provided	  by	  Prof.	  
Herbison,	  one	  of	  the	  University	  statistical	  advisers.	  	  Prof.	  Herbison	  has	  retired,	  
and	  further	  advice	  has	  been	  obtained	  from	  Mr	  Andrew	  Gray,	  the	  statistical	  
adviser	  for	  the	  Department	  of	  Anatomy.	  	  Based	  on	  this	  advice,	  I	  believe	  the	  
statistical	  methods	  used	  in	  the	  thesis	  are	  robust.	  	  Much	  of	  the	  data	  from	  the	  
thesis	  has	  been	  published,	  adding	  support	  to	  this	  view.	  
	  
With	  correlative	  analyses,	  the	  unexplained	  variance	  must	  be	  normal,	  when	  
Pearson’s	  method	  is	  used.	  	  There	  is	  no	  requirement	  for	  the	  initial	  distributions	  of	  
the	  variables	  to	  be	  normal.	  	  The	  purpose	  of	  a	  Box-­‐‑Cox	  transformation	  is	  to	  
normalise	  the	  initial	  distributions,	  prior	  to	  correlation.	  	  The	  initial	  distributions	  
of	  some	  of	  the	  hormones	  examined	  in	  the	  thesis	  were	  not	  normal,	  but	  the	  
distributions	  of	  residuals	  for	  the	  correlative	  analysis	  were	  normal,	  or	  near-­‐‑
normal.	  	  For	  this	  reason,	  Prof.	  Herbison	  recommended	  the	  use	  of	  Pearson’s	  
method,	  although	  all	  results	  were	  also	  verified	  by	  non-­‐‑parametric	  analyses,	  in	  
line	  with	  best	  practice.	  	  Box-­‐‑Cox	  transformations	  produce	  arbitrary	  alteration	  to	  
data,	  which	  arguably	  should	  only	  be	  undertaken	  when	  no	  alternative	  approach	  
exist.	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3.1.1  Circadian  pattern  of  endocrine  systems  
  
Many	  hormones	  exhibit	  oscillating	  rhythms.	  These	  rhythms	  respond	  to	  changes	  
in	  the	  environment,	  and	  regulate	  homeostasis.	  The	  pancreas	  secrete	  insulin	  into	  
the	  portal	  vein	  in	  a	  pulsatile	  fashion	  every	  four	  minutes	  (also	  known	  as	  an	  
ultradian	  rhythm),	  and	  is	  modulated	  by	  the	  presence	  or	  anticipation	  of	  food	  
intake	  (135).	  The	  amplitude	  and	  the	  frequency	  of	  insulin	  secretion	  regulates	  the	  
metabolism	  of	  glucose	  by	  the	  liver	  (136).	  Other	  rhythms	  exhibit	  a	  daily	  recurring	  
pattern,	  which	  is	  known	  as	  a	  circadian	  rhythm.	  Cortisol	  levels	  peak	  in	  the	  
morning	  (diurnal	  pattern)	  in	  anticipation	  of	  physical	  stress	  during	  waking	  (137),	  
whilst	  melatonin	  level	  has	  a	  secretory	  burst	  at	  night	  to	  facilitate	  sleep	  (nocturnal	  
rhythm)	  (138).	  	  
  
3.1.2  Regulation  and  influences  of  circadian  patterns  
  
The	  regulation	  of	  these	  circadian	  and	  other	  rhythms	  are	  controlled	  at	  multiple	  
levels.	  Most	  rhythms	  are	  centrally	  mediated	  by	  the	  suprachiasmatic	  nucleus	  in	  
the	  hypothalamus	  (137),	  and	  peripherally	  within	  target	  organs	  putatively	  by	  
autonomous	  pacemaker	  genes,	  such	  as	  CLOCK	  and	  PER	  genes	  (139).	  The	  
interactions	  between	  the	  hypothalamic-­‐‑pituitary	  centres	  and	  target	  organs	  are	  






Other	  endogenous	  and	  environmental	  factors,	  such	  as	  ageing,	  pathology	  and	  the	  
presence	  of	  light	  can	  modify	  these	  effects	  further.	  Melatonin	  secretion,	  for	  
example,	  exhibit	  an	  age-­‐‑related	  decline,	  and	  during	  exposure	  to	  nocturnal	  
lighting;	  with	  both	  factors	  resulting	  in	  changes	  to	  sleep	  architecture	  (140).	  
Similarly,	  people	  with	  Type	  II	  diabetes	  mellitus	  experience	  attenuation	  of	  their	  
insulin	  amplitude	  and	  pulses	  into	  the	  portal	  vein	  that	  consequently	  affect	  hepatic	  
glucose	  metabolism	  and	  hyperglycaemia	  (136).	  	  
  
3.1.3  Diurnal  rhythm  of  testicular  hormones  
  
Amongst	  the	  four	  testicular	  hormones,	  the	  daily	  profiles	  for	  AMH	  and	  INSL3	  are	  
unknown.	  In	  contrast,	  daily	  patterns	  of	  testosterone	  and	  InhB	  have	  been	  well	  
described,	  with	  both	  hormones	  exhibiting	  diurnal	  profiles	  with	  morning	  peak	  
levels	  (141-­‐‑149).	  In	  clinical	  practice,	  there	  is	  a	  tacit	  assumption	  that	  testicular	  
hormonal	  output	  is	  regulated	  at	  a	  pan-­‐‑testicular	  level,	  with	  physiological	  and	  
pathological	  correlation	  done	  to	  morning	  blood	  samples	  of	  testicular	  hormones.	  	  
An	  alternative	  theory	  is	  that	  regulation	  might	  occur	  at	  a	  cell	  type	  level	  generating	  
common	  variation	  between	  the	  Sertoli	  hormones	  and	  Leydig	  hormones	  [Chapter	  
1.4].	  A	  third	  model	  posits	  that	  each	  hormone	  is	  independently	  regulated,	  
supported	  by	  some	  evidence	  of	  partial	  covariation	  between	  diurnal	  testicular	  
hormones	  [Chapter	  1.4].	  	  
  
3.1.4  Sporadic  influences  on  testicular  hormones  
  
Another	  layer	  of	  complexity	  are	  sporadic	  factors	  that	  can	  influence	  hormonal	  
levels,	  particularly	  testosterone.	  An	  acute	  rise	  in	  testosterone	  level	  can	  be	  
induced	  by	  the	  onset	  of	  REM	  sleep	  (150,	  151),	  physical	  exercise	  (152-­‐‑154),	  
interaction	  with	  an	  unfamiliar	  woman	  (155),	  and	  sexual	  activities	  (156),	  whilst	  
levels	  are	  lower	  with	  fatherhood	  status	  (157),	  marital	  status	  (158),	  feeding	  







3.1.5  Objectives  of  study  
  
The	  daily	  profiles	  for	  AMH	  and	  INSL3	  are	  unknown.	  Consequently,	  there	  is	  a	  lack	  
of	  understanding	  of	  how	  the	  endocrine	  testicular	  hormones	  are	  regulated	  as	  a	  
whole,	  and	  whether	  sporadic	  influences	  exert	  common	  or	  specific	  effects	  on	  each	  
testicular	  hormone.	  This	  Chapter	  aims	  to	  profile	  the	  daily	  profile	  for	  each	  
testicular	  hormone	  in	  healthy	  young	  men,	  and	  examine	  for	  any	  covariation	  and	  
sporadic	  influences	  between	  hormones.	  






3.2.1  Study  participants  
  
The	  study	  was	  of	  community-­‐‑based	  young	  men,	  with	  no	  known	  health	  issues.	  	  
Men	  were	  recruited	  from	  the	  University	  of	  Otago	  and	  from	  the	  staff	  of	  the	  
Dunedin	  Public	  Hospital	  by	  advertisement.	  	  The	  median	  age	  of	  the	  men	  was	  26.7	  
years,	  with	  a	  range	  of	  19.3	  to	  57.3	  years	  [Table	  3.1].	  	  Only	  one	  of	  the	  men	  was	  
older	  than	  40	  years	  of	  age.	  	  The	  men	  were	  not	  taking	  any	  regular	  medications,	  
non-­‐‑smokers,	  had	  no	  known	  testicular	  or	  pituitary	  disorders,	  not	  obese	  and	  not	  
involved	  in	  shift	  work.	  	  	  	  
  
3.2.2  Study  design  
  
Study	  1:	  blood	  sampling	  
Thirteen	  men	  had	  a	  peripheral	  intravenous	  catheter	  inserted	  into	  their	  
antecubital	  fossa	  vein	  at	  20:00	  for	  acclimatisation.	  They	  were	  housed	  either	  in	  
their	  own	  dwelling	  (n=6)	  or	  slept	  in	  a	  communal	  university	  hostel	  (n=7).	  	  The	  
sleep	  location	  had	  no	  effect	  on	  the	  hormone	  levels,	  and	  the	  data	  for	  the	  two	  
groups	  were	  combined.	  	  Participants	  were	  encouraged	  to	  maintain	  their	  regular	  
routine	  and	  sleeping	  pattern.	  	  A	  series	  of	  6	  mL	  blood	  samples	  were	  aspirated	  at	  
the	  following	  times:	  00:00,	  06:00,	  09:00,	  12:00,	  14:00,	  17:00	  and	  19:00	  by	  the	  
author.	  The	  06:00	  sampling	  was	  fasting	  and	  pre-­‐‑dawn,	  the	  12:00	  and	  17:00	  
bloods	  were	  pre-­‐‑meal,	  with	  the	  corresponding	  post-­‐‑prandial	  bloods	  2	  hours	  
later.	  Sunrise	  was	  approximately	  06:30	  and	  sunset	  was	  approximately	  20:50	  
during	  the	  sampling	  period.	  	  The	  catheter	  was	  flushed	  with	  isotonic	  saline	  
periodically	  to	  maintain	  patency.	  
	  	  
Study	  2:	  blood	  sampling	  
A	  second	  study	  was	  conducted	  to	  increase	  the	  statistical	  power	  and	  validate	  
observations	  from	  Study	  1.	  	  This	  group	  consisted	  of	  20	  men,	  19	  new	  participants	  




above,	  blood	  samples	  were	  drawn	  at	  19:00	  on	  day	  1	  and	  at	  06:00	  on	  day	  2,	  with	  
sunset	  at	  19:00	  and	  sunrise	  at	  07:00	  during	  the	  second	  study.	  
  
3.2.3  Calculations  and  statistical  analyses  
  
The	  hormone	  values	  for	  each	  participant	  were	  normalised	  to	  their	  24-­‐‑hour	  
mean.	  	  This	  ensures	  that	  each	  participant’s	  value	  is	  of	  equal	  weight	  in	  the	  
statistical	  tests,	  by	  removing	  the	  influence	  of	  inter-­‐‑person	  variation	  in	  the	  
absolute	  level	  of	  the	  hormones	  [Chapter	  2.2].	  	  
	  
The	  number	  of	  possible	  diurnal	  patterns	  is	  large,	  which	  limits	  direct	  comparison	  
between	  time	  points,	  unless	  there	  is	  an	  a	  priori	  hypothesis	  about	  the	  pattern.	  	  
Study	  1	  was	  therefore	  tested	  using	  repeated	  measures	  ANOVA,	  with	  pairwise	  
comparison	  as	  the	  post-­‐‑hoc	  test.	  	  Study	  1	  detects	  overt	  diurnal	  variation,	  as	  
occurs	  with	  cortisol	  and	  testosterone,	  but	  lacks	  the	  power	  to	  detect	  subtle	  
variation.	  	  Hence,	  the	  second	  study	  was	  designed	  to	  test	  a	  specific	  diurnal	  
pattern,	  with	  the	  06:00	  and	  19:00	  samples	  being	  compared	  using	  a	  paired	  
Student	  t-­‐‑test.	  	  	  
	  
Covariance	  between	  the	  testicular	  hormones	  were	  tested	  using	  mixed	  model	  
analyses	  with	  the	  hormones	  as	  independent	  continuous	  variables,	  and	  time	  
points	  as	  categorical	  variables	  (161).	  






3.3.1  Baseline  characteristics    
  
The	  baseline	  characteristics	  of	  participants	  in	  both	  studies	  are	  presented	  in	  
Table	  3.1.	  The	  09:00	  values	  for	  testosterone,	  InhB,	  and	  gonadotropins	  were	  
within	  the	  normal	  range	  of	  the	  local	  clinical	  laboratory	  for	  morning	  sample.	  Only	  
one	  individual	  had	  a	  testosterone	  level	  that	  was	  marginally	  low	  at	  8.7	  nM	  (9-­‐‑38	  
nM).	  This	  man	  was	  not	  obese,	  and	  had	  proven	  fertility.	  Physiological	  ranges	  for	  
AMH	  and	  INSL3	  have	  not	  been	  established	  in	  men.	  The	  AMH	  values	  of	  all	  men	  in	  
this	  study	  were	  within	  a	  reference	  biochemical	  range	  of	  local	  men	  with	  defined	  
health	  status	  [Chapter	  4.3].	  
	  
All	  men	  in	  Study	  1	  exhibited	  a	  normal	  daily	  pattern	  of	  cortisol	  [Fig	  3.1D],	  
establishing	  that	  their	  circadian	  rhythms	  were	  intact.	  LH	  had	  a	  significant	  
diurnal	  variation	  with	  higher	  values	  in	  the	  nocturnal	  and	  early	  morning	  periods,	  
and	  subsequently	  trending	  towards	  an	  evening	  nadir	  [Fig.	  3.1C,	  p=0.032	  
ANOVA].	  FSH,	  in	  contrast,	  did	  not	  vary	  significantly	  between	  time	  points	  [Fig.	  
3.1C,	  p=0.36	  ANOVA].	  Similar	  results	  were	  obtained	  for	  LH	  and	  FSH	  in	  Study	  2	  
comparing	  06:00	  and	  19:00	  values	  in	  20	  men	  (LH	  6:00	  4.7	  ±	  0.5	  IU	  vs.	  19:00	  3.7	  
±	  0.3	  IU,	  p=0.032	  paired	  Student’s	  t-­‐‑test;	  FSH	  6am	  4.1	  ±	  0.5	  IU	  vs.	  7	  pm	  4.0	  ±	  0.4	  
IU,	  not	  significantly	  different).	  These	  findings	  were	  consistent	  with	  reported	  
gonadotropins	  daily	  profiles	  (162,	  163).	  




Table  3.1:  Characteristics  of  participants  in  both  diurnal  studies    
  
	  	   Study	  1	   Study	  2	   Lab	  ref	  range	  
Sample	  size	   13	   20	   	  	  
Age	  (years)	   28.7	  +	  9.5	   25.8	  +	  3.2	   	  	  
AMH	  (pM)	   48.2	  +	  22.4	   57.6	  +	  23.5	   N/A	  
INSL3	  (ng/mL)	   1.7	  +	  1.5	   2.4	  +	  0.9	   N/A	  
T	  (nM)	   17.3	  +	  6.2	   20.2	  +	  9.2	   9	  –	  38	  
InhB	  (pg/mL)	   178.9	  +	  51.9	   187.3	  +	  68.0	   30	  -­‐‑	  320	  
FSH	  (IU)	   5.2	  +	  1.8	   4.7	  +	  2.0	   2	  -­‐‑	  12	  
LH	  (IU)	   2.9	  +	  1.9	   3.7	  +	  1.4	   2	  –	  9	  
Cortisol	  (nM)	   377.7	  +	  119.4	   	  	   250	  –	  800	  
	  
The	  data	  are	  the	  mean	  +	  standard	  deviation	  of	  the	  0900	  time	  of	  day	  values	  for	  
study	  1	  and	  the	  0600	  value	  for	  Study	  2.	  	  
  




3.3.2  Sertoli  cell  hormones  
  
There	  was	  no	  statistical	  variation	  in	  AMH	  across	  the	  day	  in	  study	  1	  (p=0.48	  
ANOVA),	  indicating	  the	  absence	  of	  a	  consistent	  and	  overt	  diurnal	  profile.	  
However,	  AMH	  levels	  were	  moderately	  lower	  in	  the	  nocturnal	  phase,	  with	  a	  
nadir	  at	  06:00,	  and	  a	  subsequent	  rise	  in	  the	  hours	  after	  waking	  [Fig.	  3.1A	  and	  
3.2A].	  The	  veracity	  of	  this	  subtle	  variation	  was	  tested	  in	  Study	  2,	  which	  
confirmed	  that	  the	  06:00	  levels	  were	  slightly	  lower	  on	  average	  (4.9%,	  p=0.004,	  
paired	  Student’s	  t-­‐‑test),	  with	  the	  inter-­‐‑person	  variation	  encompassing	  a	  range	  
between	  -­‐‑7.9%	  and	  18.1%	  [Fig.	  3.3].	  	  
In	  contrast,	  InhB	  exhibited	  an	  overt	  diurnal	  pattern	  with	  significant	  variation	  
throughout	  the	  day	  [Fig.	  3.1A,	  p<0.0001].	  The	  InhB	  values	  peaked	  at	  09:00	  and	  
then	  diminished	  to	  a	  19:00	  nadir,	  with	  an	  average	  total	  decrease	  of	  26%	  during	  
this	  period.	  This	  diurnal	  pattern	  was	  observed	  in	  11	  of	  the	  13	  participants,	  with	  
the	  levels	  of	  InhB	  in	  the	  other	  two	  men	  being	  relatively	  stable	  throughout	  the	  
day	  [Fig.	  3.2B].	  	  












Figure  3.1.    Study  1:  diurnal  pattern  of  hormonal  expression.      
Each	  individual’s	  hormone	  levels	  were	  normalised	  to	  that	  individual’s	  mean	  
across	  the	  entire	  sample	  period.	  	  (A)	  Sertoli	  cell	  hormones:	  InhB	  (blue	  circles)	  
and	  AMH	  (green	  triangles);	  (B)	  Leydig	  cell	  hormones:	  testosterone	  (red	  circles)	  
and	  INSL3	  (orange	  diamonds);	  (C)	  Gonadotropins:	  LH	  (brown	  diamonds)	  and	  
FSH	  (pink	  circle)	  and	  (D)	  Circadian	  marker:	  	  Cortisol.	  	  The	  single	  0:00	  data	  point	  
is	  plotted	  at	  both	  0:00	  and	  24:00	  with	  the	  dashed	  line	  used	  to	  indicate	  this	  
extrapolation.	  The	  data	  are	  the	  mean	  +	  the	  standard	  error	  of	  13	  men.	  









Figure  3.2.    Study  1:  Daily  trend  of  serum  testicular  hormones  from  13  
healthy  men  plotted  individually.      
(A)	  AMH,	  (B)	  InhB,	  (C)	  INSL3	  and	  (D)	  testosterone.	  	  The	  00:00	  data	  points	  are	  
plotted	  at	  both	  0:00	  and	  24:00,	  with	  the	  dashed	  line	  used	  to	  indicate	  this	  
extrapolation.	  






Figure  3.3.  Changes  in  serum  testicular  hormonal  concentration  
between  19:00  and  06:00  (Study  2).      
(A)	  AMH,	  (B)	  INSL	  and	  (C)	  InhB	  and	  (D)	  testosterone	  levels	  were	  analysed	  in	  20	  
men.	  	  AMH,	  on	  average	  declined	  by	  4.9%,	  (p=0.004,	  paired	  Student	  t-­‐‑test),	  
whereas	  the	  levels	  of	  InhB	  and	  testosterone	  increased	  on	  average	  by	  30%	  
(p=0.000)	  and	  38%	  (p=0.011)	  respectively.	  	  There	  was	  no	  significant	  change	  in	  
the	  levels	  of	  INSL3,	  on	  average	  (p=0.78).	  




3.3.3  Leydig  cell  hormones  
  
INSL3	  was	  the	  least	  variable	  testicular	  hormone	  with	  no	  significant	  variation	  
observed	  across	  the	  study	  population	  [Fig.	  3.1B,	  p=0.13	  ANOVA].	  The	  moderate	  
spike	  in	  INSL3	  observed	  at	  06:00	  was	  predominantly	  caused	  by	  variable	  levels	  in	  
3	  individuals	  with	  no	  consistent	  circadian	  pattern	  [Fig.	  3.2C].	  When	  each	  man’s	  
values	  were	  normalised	  to	  his	  average	  value	  for	  the	  day,	  the	  standard	  deviation	  
for	  all	  the	  data	  points	  was	  26%.	  There	  was	  also	  no	  significant	  difference	  on	  
average	  in	  INSL3	  levels	  in	  Study	  2	  (p=0.78	  paired	  Student’s	  t-­‐‑test),	  although	  4	  of	  
the	  20	  men	  had	  non-­‐‑concordant	  values	  at	  06:00	  and	  19:00,	  but	  without	  
consistent	  direction;	  two	  had	  higher	  values	  at	  06:00	  and	  two	  had	  lower	  [Fig.	  
3.3B].	  	  
Serum	  testosterone	  levels	  in	  Study	  1	  were	  consistent	  with	  the	  established	  
diurnal	  profile	  (148),	  with	  a	  peak	  morning	  value	  and	  a	  nadir	  concentration	  in	  the	  
evening	  [Fig.	  3.1B,	  p=0.04	  ANOVA].	  There	  was	  an	  average	  decrease	  of	  47%	  
between	  the	  06:00	  and	  the	  19:00	  nadir	  samples.	  This	  circadian	  pattern	  was	  
replicated	  in	  Study	  2	  with	  an	  average	  38%	  increase	  between	  19:00	  and	  06:00	  the	  
following	  day	  [Fig.	  3.3C,	  p=0.011,	  paired	  Student’s	  t-­‐‑test].	  The	  average	  amplitude	  
for	  the	  testosterone	  diurnal	  variation	  was	  larger	  than	  that	  of	  InhB	  (47%	  vs.	  26%,	  
respectively),	  but	  with	  less	  statistical	  confidence	  because	  the	  testosterone	  
rhythms	  were	  highly	  variable	  between	  individuals.	  




3.3.4  Hormonal  covariation  
  
AMH,	  INSL3	  and	  testosterone	  did	  not	  covary	  to	  each	  other	  when	  comparing	  the	  
entire	  groups	  and	  each	  individual.	  For	  example,	  the	  individuals	  with	  the	  most	  
overt	  changes	  in	  AMH	  levels	  did	  not	  have	  the	  largest	  changes	  in	  testosterone.	  
Similarly,	  the	  individuals	  with	  some	  variation	  in	  their	  levels	  of	  INSL3	  had	  
unremarkable	  diurnal	  variations	  in	  testosterone	  and	  InhB,	  relative	  to	  other	  men.	  
The	  time-­‐‑point-­‐‑to-­‐‑time-­‐‑point	  variation	  in	  InhB	  partially	  correlated	  to	  
testosterone	  only	  (p=0.001,	  mixed	  model	  covariation)	  and	  not	  to	  either	  AMH	  or	  
INSL3	  [Table	  3.2].	  




Table  3.2:  Covariation  of  the  diurnal  patterns  of  the  hormones  
  
	   InhB	   AMH	   Testosterone	  
InhB	   -­‐‑	   0.06	  (p=0.48)	   1.26	  (p=0.001)*	  
AMH	   0.06	  (p=0.48)	   -­‐‑	   -­‐‑0.30	  (p=0.65)	  
Testosterone	   1.26	  (p=0.001)*	   -­‐‑0.30	  (p=0.65)	   -­‐‑	  
INSL3	   0.09	  (p=0.049)*	   0.03	  (p=0.43)	   0.07	  (p=0.68)	  
	  
The	  covariation	  between	  time	  points	  for	  each	  of	  the	  testicular	  hormones	  were	  
calculated	  for	  20	  men	  using	  mixed	  model	  analysis,	  and	  expressed	  as	  the	  
covariation	  coefficient	  (p	  value).	  Note	  that	  the	  data	  is	  normalised	  to	  the	  daily	  
mean,	  and	  is	  therefore	  independent	  of	  the	  absolute	  levels	  of	  the	  men’s	  hormones.	  
*	  indicates	  statistical	  significance.	  	  







3.4.1  Diurnal  pattern  of  testes  is  regulated  at  level  of  the  hormone    
	  
AMH	  has	  a	  subtle	  nocturnal	  variation	  with	  an	  evening	  peak	  whereas	  INSL3	  
exhibits	  no	  overt	  circadian	  pattern.	  Hence,	  the	  Sertoli	  and	  Leydig	  cells	  each	  
secrete	  one	  hormone	  with	  minimal	  variation	  during	  the	  day	  (AMH	  and	  INSL3)	  
and	  another	  hormone	  with	  an	  overt	  diurnal	  pattern	  (InhB	  and	  testosterone),	  
indicating	  that	  the	  diurnal	  variation	  operates	  at	  the	  level	  of	  the	  hormone	  and	  is	  
not	  a	  universal	  property	  of	  the	  endocrine	  cell	  type.	  
The	  circulating	  level	  of	  a	  hormone	  is	  a	  product	  of	  its	  synthesis,	  secretion	  and	  
clearance.	  Testosterone	  and	  InhB,	  which	  had	  the	  most	  covariance,	  have	  similarly	  
short	  half-­‐‑lives	  in	  blood,	  ranging	  from	  23	  minutes	  to	  45	  minutes	  (164-­‐‑166).	  
AMH,	  in	  contrast,	  has	  a	  long	  half-­‐‑life	  that	  is	  not	  fully	  characterised	  in	  men.	  In	  
women	  and	  bulls	  the	  half-­‐‑life	  of	  AMH	  exceeds	  one	  day	  (59,	  167).	  Consequently,	  
the	  presence	  of	  a	  subtle	  change	  in	  the	  levels	  of	  AMH	  between	  06:00	  and	  19:00	  
[Fig.	  3.3]	  may	  represent	  a	  larger	  diurnal	  variation	  in	  either	  the	  production	  or	  the	  
secretion	  from	  the	  testes,	  with	  the	  magnitude	  of	  the	  change	  in	  serum	  levels	  being	  
dampened	  by	  its	  slow	  clearance.	  
The	  synthesis	  of	  AMH	  is	  putatively	  decreased	  by	  testosterone	  [Chapter	  1.4.3].	  
The	  diurnal	  decrease	  in	  AMH	  coincided	  with	  a	  diurnal	  rise	  in	  testosterone,	  
raising	  the	  possibility	  that	  the	  variation	  in	  AMH	  is	  secondary	  to	  the	  larger	  
diurnal	  variation	  in	  testosterone.	  However,	  both	  AMH	  and	  testosterone	  cycles	  
vary	  in	  magnitude	  and	  direction	  between	  men.	  Consequently,	  if	  the	  daily	  pattern	  
of	  AMH	  levels	  is	  driven	  by	  testosterone	  then	  the	  person-­‐‑to-­‐‑person	  variation	  in	  
the	  two	  hormones	  should	  associate,	  which	  was	  not	  the	  case.	  This	  suggests	  that	  
testosterone	  is	  not	  a	  main	  driver	  of	  the	  daily	  variation	  in	  AMH	  levels.	  
The	  diurnal	  rhythm	  of	  InhB	  and	  testosterone	  partially	  covaried,	  despite	  being	  
derived	  from	  different	  testicular	  cells,	  and	  has	  been	  reported	  in	  some	  studies	  




circadian	  rhythm	  of	  the	  testes.	  One	  putative	  candidate	  is	  gonadotrophin	  
releasing	  hormone,	  by	  driving	  the	  gonadotropins	  FSH	  and	  LH.	  The	  basal	  
secretion	  of	  InhB	  is	  mediated	  by	  FSH,	  and	  testosterone	  similarly	  is	  influenced	  by	  
LH.	  LH	  is	  related	  to	  testosterone	  levels	  but	  only	  during	  the	  early	  hours	  of	  the	  
morning	  whilst	  asleep	  (146,	  168),	  with	  the	  total	  daily	  relationship	  between	  
gonadotropins	  and	  testicular	  hormones	  being	  independent	  of	  each	  other	  (142).	  
Human	  chorionic	  gonadotropin	  (HCG)	  mimics	  the	  effect	  of	  LH	  as	  a	  stimulant	  to	  
Leydig	  cells	  in	  secreting	  testosterone.	  Men	  who	  have	  low	  levels	  of	  testosterone	  
secondary	  to	  low	  gonadotropins	  can	  reestablish	  their	  diurnal	  pattern	  of	  
testosterone	  from	  a	  single	  injection	  of	  HCG	  (169).	  Taken	  together,	  gonadotropins	  
may	  play	  a	  role	  in	  the	  generation	  of	  testicular	  diurnal	  rhythm,	  particularly	  with	  
testosterone,	  but	  not	  in	  a	  direct	  temporal	  relationship.	  
Intra-­‐‑testicular	  elements	  have	  not	  been	  shown	  to	  regulate	  the	  circadian	  pattern	  
of	  testicular	  hormones.	  Testicular	  autonomous	  pacemaker	  genes,	  such	  as	  PER	  
and	  CLOCK	  genes	  similarly	  do	  not	  generate	  circadian	  patterns	  of	  expression,	  
unlike	  other	  peripheral	  organs	  such	  as	  the	  kidneys	  and	  liver	  (139,	  170)	  and	  
therefore	  unlikely	  to	  regulate	  diurnal	  rhythms	  of	  the	  testes.	  
	  
3.4.2  INSL3  as  a  biomarker  for  Leydig  cell  function  
	  
Testicular	  hormones	  are	  often	  used	  as	  surrogate	  biomarkers	  of	  their	  respective	  
testicular	  cell	  types.	  InhB	  exhibit	  a	  more	  marked	  diurnal	  pattern	  than	  AMH,	  
making	  it	  a	  less	  reliable	  biomarker	  for	  Sertoli	  cells.	  In	  a	  similar	  context,	  INSL3	  is	  
an	  emerging	  biomarker	  for	  hypogonadism,	  with	  the	  greater	  day-­‐‑to-­‐‑day	  
consistency	  of	  INSL3	  over	  testosterone	  being	  advantageous	  in	  this	  context	  (10,	  
33).	  The	  absence	  of	  diurnal	  variation	  in	  INSL3	  further	  supports	  the	  use	  of	  INSL3	  
as	  a	  biomarker	  for	  Leydig	  cell	  function.	  The	  overall	  intrapersonal	  variation	  in	  
INSL3	  levels	  between	  points	  was	  26%,	  which	  is	  similar	  to	  the	  21%	  day-­‐‑to-­‐‑day	  
variation	  reported	  by	  Ivell	  et	  al	  (33).	  These	  values	  include	  variation	  from	  the	  





Testosterone	  is	  known	  to	  exhibit	  sporadic	  variation	  due	  to	  multiple	  
environmental	  determinants.	  INSL3	  levels	  within	  a	  male	  is	  shown	  to	  be	  
relatively	  invariant	  for	  the	  majority	  of	  the	  men	  studied,	  suggesting	  that	  these	  
sporadic	  influences	  have	  no	  influence	  on	  INSL3	  levels.	  
A	  minority	  of	  men	  in	  Study	  1	  had	  very	  high	  concentrations	  of	  serum	  INSL3,	  
which	  was	  also	  observed	  in	  Study	  2.	  The	  combined	  data	  from	  the	  two	  studies	  
showed	  a	  right	  skewed	  distribution	  [Fig.	  2.1]	  that	  was	  significantly	  different	  
from	  normality	  (SK	  test	  skewness	  1.01,	  p=0.03)	  with	  a	  range	  that	  encompassed	  
an	  order	  of	  magnitude.	  This	  is	  the	  first	  longitudinal	  study	  examining	  INSL3	  in	  
young	  men,	  and	  the	  current	  body	  of	  literature	  on	  INSL3	  is	  small.	  However,	  two	  
large	  cross-­‐‑sectional	  studies	  on	  INSL3	  in	  men	  also	  found	  similarly	  right	  skewed	  
distributions	  in	  a	  pattern	  not	  different	  to	  the	  current	  study	  [Fig.	  2.1],	  with	  similar	  
ranges	  (30,	  171).	  One	  possible	  interpretation	  for	  the	  phenomenon	  common	  to	  all	  
three	  studies	  is	  that	  INSL3	  is	  released	  in	  a	  pulsatile	  manner	  similar	  to	  LH	  
(ultradian	  rhythm),	  or	  affected	  by	  sporadic	  influences	  like	  testosterone.	  The	  
clearance	  of	  INSL3	  is	  unknown.	  
  
3.4.3  Technical  issues  
  
This	  study	  had	  no	  a	  priori	  assumptions	  of	  daily	  pattern	  of	  AMH	  and	  INSL3,	  and	  
hence	  took	  into	  account	  several	  factors	  for	  study	  design.	  Firstly,	  all	  the	  men	  in	  
the	  first	  study	  were	  sampled	  in	  the	  same	  season	  to	  remove	  any	  potential	  effect	  of	  
seasonality.	  Similarly,	  the	  timing	  for	  blood	  tests	  coincided	  with	  various	  social	  
and	  physiological	  processes	  that	  are	  known	  to	  affect	  testosterone,	  such	  as	  pre-­‐‑
dawn	  sleeping	  fasting	  blood	  test	  (0600),	  post	  prandial	  bloods	  (0900,	  1400,	  
1900),	  and	  midnight	  sleeping	  (0000).	  No	  restrictions	  were	  placed	  on	  each	  
participant’s	  daily	  habits,	  including	  being	  in	  their	  place	  of	  abode	  to	  mimic	  usual	  
rhythm	  for	  the	  participants.	  Testosterone	  level	  can	  be	  confounded	  by	  sporadic	  
influences	  such	  as	  the	  presence	  of	  a	  female	  and	  sexual	  activities,	  and	  it	  is	  
unknown	  if	  this	  phenomenon	  also	  affects	  the	  other	  testicular	  hormones.	  The	  
study	  therefore	  required	  blood	  sampling	  to	  be	  performed	  by	  the	  male	  author,	  




during	  the	  sampling	  period.	  
	  
The	  first	  study	  observed	  a	  small	  nocturnal	  rise,	  with	  invariance	  in	  INSL3	  levels	  
overnight.	  The	  second	  study	  was	  therefore	  conducted	  to	  confirm	  this	  finding	  in	  
another	  cohort	  of	  men	  between	  evening	  and	  the	  following	  early	  morning,	  which	  
validated	  the	  initial	  results	  with	  statistical	  significance.	  
	  
Both	  studies	  were	  designed	  to	  examine	  for	  circadian	  rhythms,	  and	  therefore	  any	  
additional	  ultradian	  patterns	  particularly	  for	  AMH	  and	  INSL3	  were	  unable	  to	  be	  
profiled,	  due	  to	  frequency	  of	  sampling	  that	  would	  be	  required.	  Gonadotropins	  
secretions	  are	  pulsatile,	  and	  levels	  within	  an	  individual	  would	  vary	  considerably	  
with	  a	  frequency	  that	  is	  shorter	  than	  the	  time	  intervals	  for	  the	  testicular	  
hormones.	  This	  therefore	  precludes	  any	  covariant	  analysis	  between	  the	  pituitary	  
and	  testicular	  hormones.	  	  
	  
The	  study	  also	  did	  not	  examine	  for	  the	  effect	  of	  ethnicity,	  seasonality,	  diet,	  sexual	  
activities	  and	  other	  environmental	  influences.	  The	  number	  of	  participants	  
recruited	  in	  both	  studies	  was	  of	  similar	  magnitude	  to	  other	  circadian	  
observational	  studies	  of	  this	  nature	  (141-­‐‑149).	  	  
	  
One	  participant,	  out	  of	  the	  total	  sample	  size	  of	  28	  (3%)	  had	  peak	  morning	  
testosterone	  level	  that	  was	  marginally	  below	  the	  local	  laboratory	  reference	  
range.	  Reference	  ranges	  are	  usually	  defined	  by	  the	  levels	  found	  in	  the	  middle	  
95%	  of	  a	  normal	  reference	  population.	  The	  remaining	  5%	  of	  these	  normal	  people	  
will	  therefore	  have	  values	  that	  fall	  outside	  of	  this	  range.	  This	  is	  likely	  to	  be	  the	  
case	  with	  our	  participant,	  who	  did	  not	  have	  any	  features	  of	  androgen	  deficiency	  
(149,	  172),	  and	  consequently	  was	  included	  in	  the	  data	  analyses.	  






AMH	  and	  the	  other	  three	  testicular	  hormones	  exhibit	  distinct	  daily	  profiles	  in	  the	  
blood	  of	  young	  men,	  indicating	  that	  the	  regulation	  of	  circadian	  cycles	  are	  at	  a	  
hormonal	  level,	  rather	  than	  cell	  type	  or	  pan-­‐‑testicular	  level.	  Individual	  variations	  
exist	  for	  all	  hormones,	  which	  infers	  sporadic	  influences	  that	  are	  yet	  to	  be	  
determined.	  The	  physiological	  significance	  of	  this	  finding	  is	  unclear	  due	  to	  the	  
paucity	  of	  information	  relating	  to	  the	  non-­‐‑reproductive	  role	  of	  protein	  testicular	  
hormones.	  This	  study	  however	  guides	  blood	  sampling	  to	  be	  ideally	  performed	  in	  
the	  morning	  for	  testosterone	  and	  InhB,	  with	  AMH	  and	  INSL3	  levels	  being	  stable	  
throughout	  the	  day	  enabling	  sampling	  to	  be	  done	  at	  any	  time.	  









Chapter  4:    
Circulating  AMH  levels  in  older  





This	  thesis	  aims	  to	  explore	  the	  role	  of	  circulating	  AMH	  level	  in	  men,	  an	  area	  that	  
currently	  lacks	  any	  data.	  At	  the	  commencement	  of	  this	  thesis,	  AMH	  research	  in	  
males	  had	  predominantly	  focussed	  on	  development	  and	  childhood.	  
Consequently,	  AMH	  levels	  were	  not	  known	  beyond	  early	  adulthood	  [Chapter	  
1.5.2].	  	  
	  
AMH	  levels	  vary	  between	  boys	  (41).	  Most	  males	  exhibit	  a	  decline	  in	  their	  AMH	  
levels	  during	  the	  pubertal	  transition,	  resulting	  in	  post-­‐‑pubertal	  AMH	  on	  average	  
being	  an	  order	  of	  magnitude	  lower	  than	  boyhood	  levels	  [Chapter	  1.5.2].	  A	  recent	  
study	  has	  found	  that	  post-­‐‑pubertal	  AMH	  is	  predominantly	  genetically	  
determined	  (173).	  Information	  regarding	  any	  variability	  in	  men	  that	  is	  currently	  
unknown	  will	  therefore	  form	  the	  basis	  for	  examination	  of	  interaction	  between	  
AMH	  with	  other	  testicular	  hormones	  [Chapter	  5],	  as	  well	  as	  association	  between	  
AMH	  and	  specific	  traits	  [Chapter	  7].	  	  
	  
This	  Chapter	  will	  also	  examine	  AMH	  levels	  in	  older	  men.	  Many	  hormones	  
undergo	  age-­‐‑related	  decline,	  with	  the	  classical	  example	  being	  growth	  hormone	  
(174,	  175).	  InhB	  levels	  however	  are	  thought	  to	  be	  stable	  throughout	  the	  adult	  
male	  lifespan	  (176-­‐‑178).	  Both	  InhB	  and	  AMH	  have	  been	  utilised	  separately	  as	  




regulated	  with	  respect	  to	  their	  daily	  levels	  [Chapter	  3.3.2],	  and	  this	  Chapter	  will	  
examine	  if	  both	  hormones	  remain	  independent	  across	  the	  lifespan,	  or	  if	  both	  
hormones	  are	  linked	  due	  to	  changes	  in	  Sertoli	  cell	  number	  or	  function.	  	  
	  
AMH	  levels	  remain	  largely	  unchanged	  over	  the	  course	  of	  24	  hours,	  as	  shown	  in	  
Chapter	  3.3.2.	  This	  allows	  the	  measurement	  of	  AMH	  in	  a	  cross-­‐‑sectional	  study	  
design,	  to	  provide	  population	  level	  data	  as	  a	  basis	  for	  comparison	  of	  AMH	  levels	  
in	  different	  population	  groups.	  To	  enrich	  the	  dataset,	  sera	  from	  three	  cohorts	  
independently	  recruited	  were	  assayed	  for	  their	  Sertoli	  hormone	  level	  to	  profile	  
AMH	  across	  lifespan.	  The	  focus	  of	  this	  thesis	  is	  on	  the	  older	  male;	  hence	  the	  
design	  of	  this	  study	  has	  a	  bias	  towards	  recruitment	  of	  older	  males.	  	  
	  
In	  contrast	  to	  men,	  AMH	  levels	  has	  been	  profiled	  extensively	  in	  women,	  which	  
decline	  in	  parallel	  to	  age-­‐‑related	  diminishment	  of	  their	  ovarian	  reserve	  [Chapter	  
.5.2].	  The	  normal	  curves	  for	  AMH	  in	  women	  however	  do	  not	  extend	  significantly	  
beyond	  the	  age	  of	  menopause,	  with	  older	  women	  presumed	  to	  have	  no	  
circulating	  AMH	  [Chapter	  1.5.2].	  	  	  However,	  in	  some	  primates,	  AMH-­‐‑producing	  
granulosa	  cell	  clusters	  are	  a	  normal	  feature	  of	  the	  aged	  ovary,	  with	  the	  clusters	  
increasing	  in	  size	  after	  reproductive	  senescence	  (179).	  	  A	  small	  group	  of	  older	  
women	  were	  therefore	  examined	  as	  part	  of	  this	  thesis,	  to	  determine	  whether	  
circulating	  AMH	  in	  the	  elderly	  is	  a	  male-­‐‑specific	  hormone,	  and	  reported	  in	  the	  
second	  part	  of	  this	  Chapter.	  










Serum	  samples	  were	  collected	  from	  657	  men	  aged	  from	  19	  to	  93	  years,	  with	  a	  
focus	  on	  elderly	  men	  (n=522).	  The	  participants	  were	  drawn	  from	  three	  distinct	  
cohorts,	  with	  the	  Otago	  cohort	  recruited	  by	  the	  author,	  and	  the	  Vascular	  and	  
LiLACS	  (Life	  and	  Living	  in	  Advanced	  Age:	  A	  Cohort	  Study	  in	  New	  Zealand;	  Te	  
Puawaitanga	  o	  Nga	  Tapuwae	  Kia	  Ora	  Tonu)	  NZ	  cohorts	  recruited	  by	  other	  
research	  groups.	  A	  non-­‐‑fasting	  5	  mL	  venous	  blood	  sample	  was	  obtained	  in	  the	  
antecubital	  vein	  between	  7	  am	  and	  3	  pm.	  	  
	  
The	  Lower	  South	  Regional	  Ethics	  Committee	  (NZ)	  approved	  the	  studies	  on	  the	  
Vascular	  cohort	  and	  the	  older	  men	  subgroup	  from	  the	  Otago	  cohort,	  whilst	  the	  
younger	  men	  from	  the	  Otago	  cohort	  was	  approved	  by	  the	  University	  of	  Otago	  
Human	  Ethics	  Committee.	  The	  LiLACS	  NZ	  cohort	  was	  approved	  by	  the	  Northern	  
X	  Regional	  Ethics	  Committee	  (NZ).	  The	  ethical	  approvals	  permitted	  the	  assay	  of	  
sera	  in	  collaborative	  studies	  collected	  from	  the	  Vascular	  and	  LiLACS	  NZ	  cohorts.	  
  
4A.2.1A  Otago  cohort  
  
The	  Otago	  cohort	  was	  a	  cross-­‐‑sectional	  study	  of	  99	  community	  dwelling	  men	  
aged	  70	  or	  older,	  with	  124	  younger	  men	  as	  a	  comparison.	  The	  men	  were	  
predominantly	  Caucasian	  and	  resided	  in	  Dunedin,	  a	  small	  university	  city	  in	  New	  
Zealand.	  Men	  were	  excluded	  from	  the	  study	  if	  they	  had	  a	  history	  of	  testicular	  
tumour	  or	  trauma,	  orchiectomy,	  undescended	  testes,	  self-­‐‑reported	  infertility,	  
chemotherapy	  or	  abdominal	  or	  pelvic	  radiation	  therapy.	  None	  of	  the	  men	  were	  
on	  anti-­‐‑androgen	  medication	  or	  steroid	  medications.	  
	  
All	  the	  men	  in	  this	  cohort	  were	  recruited	  from	  the	  community	  via	  advertising	  




from	  community	  groups	  and	  social	  clubs,	  including	  Age	  Concerns	  meetings,	  
Probus	  Club,	  local	  bowling	  clubs,	  University	  of	  the	  Third	  Age	  (University	  of	  
Otago),	  local	  church	  congregations,	  and	  the	  Dunedin	  Phoenix	  club.	  Some	  older	  
men	  joined	  the	  study	  from	  viewing	  advertisements	  placed	  in	  the	  University,	  the	  
local	  hospital	  foyer,	  and	  a	  local	  community	  newspaper.	  A	  small	  subgroup	  of	  older	  
men	  was	  recruited	  from	  the	  hospital’s	  Older	  Person’s	  Health	  community	  
outpatient	  rehabilitation	  classes.	  These	  men	  were	  living	  in	  their	  own	  homes,	  able	  
to	  walk	  without	  assistance	  from	  another	  person,	  but	  had	  a	  range	  of	  physical,	  
psychiatric	  or	  cognitive	  limitations	  requiring	  rehabilitation.	  All	  men	  recruited	  
were	  able	  to	  provide	  informed	  consent	  to	  participate	  in	  the	  study.	  	  
	  
The	  younger	  men	  aged	  from	  19	  years	  to	  69	  years	  were	  recruited	  from	  various	  
facilities	  and	  work	  places	  in	  the	  Dunedin	  metropolitan	  area.	  These	  included	  
students	  and	  staff	  from	  the	  University	  of	  Otago	  and	  local	  hospital,	  civil	  service	  
employees,	  office	  based	  private	  sector	  employees,	  workers	  from	  light	  and	  heavy	  
industries,	  and	  a	  local	  karate	  club.	  None	  of	  these	  men	  were	  shift	  workers,	  and	  all	  
had	  no	  known	  history	  of	  medical	  issues	  or	  medications	  that	  would	  affect	  the	  
pituitary-­‐‑gonadal	  axis.	  	  
	  
4A.2.1B  Vascular  cohort  
  
The	  vascular	  cohort	  was	  a	  separate	  Dunedin	  cohort	  comprised	  of	  153	  
community	  dwelling	  men	  aged	  54–93	  years,	  with	  no	  history	  of	  cardiovascular	  
disease.	  These	  men	  were	  recruited	  from	  community	  advertisements	  and	  
excluded	  if	  they	  have	  features	  of	  peripheral	  arterial	  disease	  and	  carotid	  stenosis.	  
This	  was	  defined	  as	  having	  a	  carotid	  stenosis	  of	  50%	  or	  greater	  on	  Doppler	  
ultrasound	  scan,	  and/or	  an	  arterial	  pressure	  ratio	  at	  the	  ankle	  compared	  to	  the	  
brachial	  artery	  of	  less	  than	  0.9,	  or	  greater	  than	  1.3.	  These	  men	  were	  recruited	  
and	  blood	  sampled	  by	  the	  Vascular	  Research	  Group	  from	  the	  University	  of	  Otago.	  
Permission	  was	  granted	  to	  access	  their	  biobank	  for	  the	  men’s	  sera.	  None	  of	  the	  
participants	  from	  the	  Otago	  cohort	  were	  duplicated	  in	  the	  Vascular	  cohort.	  	  
  




4A.2.1C  LiLACS  NZ  Cohort  
  
Sera	  from	  257	  elderly	  men	  were	  analysed	  from	  the	  LiLACS	  NZ	  Research	  Group.	  
This	  is	  an	  ongoing	  epidemiological	  study	  examining	  factors	  that	  lead	  to	  
successful	  aging	  in	  older	  New	  Zealanders.	  A	  cohort	  of	  937	  community-­‐‑dwelling	  
men	  and	  women	  were	  recruited	  in	  the	  East	  Coast	  (Bay	  of	  Plenty	  and	  Rotorua)	  of	  
the	  North	  Island,	  from	  the	  electoral	  roll	  registry,	  with	  methodology	  described	  
elsewhere	  (180).	  The	  inclusion	  criteria	  were	  primarily	  based	  on	  age	  and	  
ethnicity:	  Māori	  aged	  between	  80–90	  years	  old,	  and	  non-­‐‑	  Māori	  aged	  85	  years	  
old	  were	  recruited,	  with	  a	  response	  rate	  of	  65%	  from	  the	  male	  cohort.	  Study	  
participants	  had	  varying	  health	  and	  physical	  performance	  status	  measured,	  with	  
the	  257	  men	  examined	  being	  those	  that	  had	  consented	  for	  their	  sera	  to	  be	  used	  
for	  collaborative	  research.	  None	  of	  the	  participants	  reported	  a	  history	  of	  
orchiectomy.	  
  
4A.2.2  Hormonal  analysis  
  
Sera	  were	  assayed	  for	  their	  AMH	  and	  InhB	  levels	  as	  described	  in	  Chapter	  2.	  The	  
AMH	  reported	  and	  calculated	  here	  are	  based	  on	  the	  values	  obtained	  prior	  to	  the	  
field	  notice	  from	  Beckman	  Coulter	  [Chapter	  2.1.5]	  for	  consistency	  in	  comparing	  
between	  the	  three	  distinct	  cohorts.	  	  










The	  levels	  of	  AMH	  were	  highly	  variable	  between	  men,	  with	  a	  distribution	  that	  
was	  positively	  skewed	  both	  in	  men	  younger	  than	  50	  years	  [Fig.	  4.1A,	  SK	  Test	  1.4,	  
p<0.0001,	  n=111],	  and	  in	  those	  older	  than	  50	  [Fig.	  4.1B,	  SK	  Test	  2.1,	  p<0.0001,	  
n=112].	  All	  younger	  men	  under	  50	  years	  had	  AMH	  levels	  greater	  than	  6.6	  pM.	  
There	  was	  no	  correlation	  between	  AMH	  level	  and	  age	  in	  these	  younger	  men	  
(R2=0.03,	  p=0.10,	  n=111),	  after	  which	  there	  was	  a	  change	  in	  the	  profile	  of	  AMH	  
levels	  [Fig.	  4.2A	  and	  B].	  In	  men	  over	  50	  years	  of	  age,	  there	  was	  a	  progressive	  and	  
significant	  decline	  in	  the	  geometric	  mean	  [Fig.	  4.2B,	  p<0.0005	  ANOVA],	  and	  the	  
median	  AMH	  in	  older	  men	  was	  nearly	  half	  that	  of	  younger	  men	  [Table	  4.1].	  A	  
quarter	  of	  older	  men	  had	  AMH	  levels	  below	  the	  cohort’s	  reference	  range	  
generated	  from	  younger	  men’s	  values	  [Table	  4.1].	  There	  was	  a	  concurrent	  
increase	  in	  the	  variability	  of	  AMH	  levels	  between	  older	  men:	  5	  men	  had	  levels	  
below	  the	  limit	  of	  detection,	  but	  none	  of	  the	  older	  men	  had	  AMH	  levels	  above	  the	  
upper	  reference	  range.	  Consequently,	  the	  coefficient	  of	  variation	  increased	  with	  
age,	  from	  50%	  in	  those	  younger	  than	  30	  years	  old	  (n=33),	  to	  105%	  in	  men	  over	  




The	  profile	  of	  InhB	  across	  the	  lifespan	  was	  similar	  to	  that	  of	  AMH.	  InhB	  was	  less	  
variable	  between	  individuals	  than	  AMH	  [cf.	  Fig.	  4.2A,	  4.2C],	  and	  was	  normally	  
distributed	  in	  both	  younger	  and	  older	  men	  subgroups	  [Fig.	  4.1C,D].	  An	  age-­‐‑
related	  change	  in	  InhB	  was	  only	  observed	  in	  older	  men.	  As	  with	  AMH,	  this	  
involved	  a	  diminishing	  geometric	  mean	  with	  age,	  with	  a	  concurrent	  increase	  in	  
the	  coefficient	  of	  variation	  [Fig.	  4.2D].	  21%	  of	  the	  older	  men	  had	  levels	  of	  InhB	  





Table  4.1  Description  of  the  Otago  cohort  
  
	   <	  50	  years	   >	  50	  years	   Entire	  cohort	  
Numbers	   111	   112	   223	  
Mean	  age	  
years	  
36.4	   75.8	   56.3	  	  
(range	  19.3	  –	  89.7)	  
















Ref	  range	  AMH	  
pM	  
8.2	  –	  85.6	  
	  
%	  below	  ref	  range	   1.8%	   25%	   13.5%	  
















Ref	  range	  InhB	  
pg/mL	  
61.4-­‐‑311.2	  











Figure  4.1:  Distribution  of  Sertoli  hormone  levels  in  men.  	  
A:	  the	  distribution	  of	  serum	  AMH	  in	  the	  young	  subset	  of	  community	  dwelling	  
men	  in	  Otago	  (n	  =	  111,	  19–50	  years),	  B:	  distribution	  of	  AMH	  in	  the	  older	  subset	  
in	  Otago	  (n	  =	  112,	  50–90	  years).	  Both	  distributions	  for	  AMH	  were	  positively	  
skewed	  (skewness	  1.4	  for	  younger	  and	  2.1	  for	  older	  subgroups).	  C:	  distribution	  
of	  serum	  InhB	  in	  the	  young	  subset	  of	  community	  dwelling	  men	  in	  Otago	  (n	  =	  110,	  
19–50	  years),	  D:	  distribution	  of	  InhB	  in	  the	  older	  subset	  in	  Otago	  (n	  =	  112,	  50–90	  
years).	  Both	  distributions	  for	  InhB	  were	  normally	  distributed	  (skewness	  0.2	  for	  















Figure  4.2:  The  levels  of  serum  Sertoli  hormones  in  223  community  
dwelling  men  (Otago  cohort)  are  illustrated.    
A:	  each	  circle	  represented	  an	  individual’s	  AMH	  value.	  B:	  the	  geometric	  mean	  and	  
95%	  confidence	  interval	  for	  AMH	  is	  indicated	  for	  various	  age	  groups.	  The	  levels	  
of	  AMH	  in	  the	  older	  men	  (80–85	  years)	  were	  significantly	  less	  than	  those	  in	  the	  
younger	  men	  (19–30	  years)	  (p	  =	  0.001).	  C:	  each	  triangle	  represented	  an	  
individual’s	  InhB	  value.	  D:	  the	  geometric	  mean	  and	  95%	  confidence	  interval	  for	  
InhB	  is	  indicated	  for	  various	  age	  groups.	  The	  young	  men	  were	  grouped	  by	  
decade	  (20-­‐‑29.9;	  30-­‐‑39.9;40-­‐‑49.9)	  whereas	  the	  elderly	  men	  were	  group	  by	  hemi-­‐‑
decade	  (70-­‐‑74.9;75-­‐‑79.9;	  80-­‐‑84.9;	  85-­‐‑89.9).	  	  Only	  limited	  data	  was	  collected	  
from	  men	  of	  intermediate	  age,	  precluding	  further	  subdivision	  of	  the	  50-­‐‑69.9	  
year-­‐‑old	  group.	  
	  




4A.3.1.C  Sertoli  hormonal  balance  
  
The	  relative	  levels	  of	  AMH	  and	  InhB	  varied	  between	  individuals	  across	  the	  
cohort,	  with	  a	  minority	  of	  older	  men	  having	  more	  InhB	  than	  AMH	  [Fig.	  4.3A].	  All	  
men	  (n=5)	  with	  undetectable	  levels	  of	  one	  hormone	  simultaneously	  had	  
undetectable	  levels	  of	  the	  other	  [Fig.	  4.3C],	  with	  all	  of	  these	  men	  being	  over	  75	  
years	  old.	  Approximately	  half	  of	  the	  men	  with	  AMH	  levels	  below	  the	  reference	  
range	  also	  had	  InhB	  levels	  below	  its	  reference	  range,	  with	  this	  observation	  
replicated	  when	  examining	  low	  levels	  of	  InhB.	  Consequently,	  the	  levels	  of	  the	  
two	  hormones	  were	  not	  completely	  independent	  as	  a	  Pearson’s	  linear	  regression	  
between	  them	  was	  R2=0.22	  [Fig.	  4.3C].	  
  








Figure  4.3:  The  relative  ratio  of  Sertoli  hormones  for  the  Otago  cohort.  
Each	  cyan	  circle	  represents	  an	  individual,	  across	  age	  in	  A.	  B:	  The	  relationship	  





4A.3.2  Comparison  of  AMH  with  other  cohorts  
  
The	  Otago	  cohort	  was	  then	  compared	  with	  two	  other	  independently	  recruited	  
cohorts,	  to	  determine	  generalisability	  of	  the	  findings.	  	  
	  
The	  first	  comparison	  was	  between	  the	  Otago	  cohort	  described	  above,	  and	  a	  
second	  cohort	  recruited	  from	  the	  same	  geographical	  region,	  but	  selected	  for	  the	  
absence	  of	  cardiovascular	  disease	  (Vascular	  cohort).	  The	  average	  level	  of	  AMH	  in	  
the	  Vascular	  cohort	  (n=153)	  was	  higher	  than	  the	  age-­‐‑matched	  participants	  from	  
the	  Otago	  cohort	  [Fig.	  4.4,	  mean	  difference	  AMH	  9.5	  pM,	  p<0.0001,	  Student’s	  t-­‐‑
test],	  but	  were	  no	  different	  to	  the	  younger	  portion	  from	  the	  Otago	  cohort	  [Fig.	  
4.4A,	  p=0.06].	  	  Two	  participants	  from	  the	  Vascular	  cohort	  had	  AMH	  levels	  above	  
the	  upper	  reference	  range	  in	  contrast	  to	  none	  of	  the	  aged-­‐‑matched	  Otago	  cohort.	  
Consequently,	  only	  8.5%	  of	  the	  men	  from	  the	  Vascular	  cohort	  had	  AMH	  levels	  
below	  the	  reference	  range.	  A	  minority	  of	  these	  men	  had	  undetectable	  levels	  of	  
AMH,	  in	  similar	  prevalence	  to	  the	  older	  Otago	  cohort	  [Table	  4.2].	  	  In	  contrast,	  the	  
difference	  in	  InhB	  values	  was	  less	  pronounced	  between	  the	  Vascular	  cohort	  and	  
the	  aged	  matched	  Otago	  cohort	  (mean	  InhB	  difference	  16	  pg/mL,	  p=0.054,	  
Student’s	  t-­‐‑test),	  with	  35.9%	  of	  the	  Vascular	  cohort	  having	  InhB	  values	  below	  the	  
reference	  range.	  	  
	  
The	  older	  portion	  of	  the	  Otago	  cohort	  was	  then	  compared	  to	  the	  LiLACS	  cohort	  
(n=270),	  a	  geographically	  distinct	  group	  of	  men	  in	  the	  East	  coast	  of	  North	  Island	  
with	  a	  significant	  component	  of	  Māori	  ethnicity.	  The	  age-­‐‑matched	  AMH	  values	  
between	  the	  two	  cohorts	  were	  similar	  [Fig.	  4.4B,	  p=0.14].	  The	  coefficient	  of	  
variation	  in	  the	  LiLACS	  cohort	  was	  similar	  to	  the	  older	  Otago	  subgroup	  (102%	  
vs.	  96%),	  despite	  17%	  of	  men	  in	  the	  LiLACS	  group	  having	  undetectable	  AMH	  
levels,	  in	  comparison	  to	  8%	  of	  the	  Otago	  cohort	  [Fig.	  4.4B].	  One	  LiLACS	  
participant	  had	  atypically	  high	  AMH	  level	  above	  the	  upper	  reference	  range.	  InhB	  
values	  were	  similar	  between	  the	  two	  cohorts	  (p=0.51).	  34%	  of	  the	  LiLACS	  cohort	  
contain	  Māori	  men,	  and	  by	  design	  were	  older	  (mean	  age	  difference	  2.3	  years,	  
p<0.0001).	  AMH	  values	  between	  Maori	  and	  non-­‐‑	  Māori	  men	  were	  similar	  




p=0.0041).	  One	  Māori	  man	  and	  8	  non-­‐‑	  Māori	  men	  had	  InhB	  levels	  above	  the	  
upper	  reference	  range	  [Fig.	  4.4D].	  	  
	  
When	  the	  three	  cohorts	  were	  combined,	  older	  men	  displayed	  a	  larger	  divergence	  
in	  the	  ratio	  of	  AMH	  and	  InhB,	  in	  both	  the	  positive	  and	  negative	  directions.	  The	  
vascular	  group	  had	  a	  prominent	  AMH	  bias,	  whereas	  the	  LiLACS	  group	  had	  an	  
InhB	  bias	  [Fig.	  4.5].	  There	  was	  no	  racial	  difference	  in	  the	  Sertoli	  hormonal	  




Table  4.2  Comparisons  of  AMH  values  between  3  different  cohorts    
	  
	   Otago	   Vascular	   LiLACS	  NZ	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%	  below	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range	  
11.7%	   35.9%	   26.7%	  



















Figure  4.4:  A  comparison  of  Sertoli  hormone  levels  between  Otago  
cohort  and  2  other  New  Zealand  cohorts.  
The	  Otago	  cohort	  (223	  community	  dwelling	  men	  in	  Dunedin)	  is	  illustrated	  with	  
cyan	  circles;	  the	  Vascular	  cohort	  (153	  men	  in	  Dunedin	  selected	  for	  their	  absence	  
of	  cardiovascular	  disease)	  with	  red	  squares	  and	  the	  LiLACS	  NZ	  cohort	  (270	  men	  
from	  a	  distinct	  geographical	  area	  to	  Otago)	  with	  orange	  triangles.	  Each	  symbol	  
represents	  an	  individual.	  A:	  The	  Vascular	  cohort	  had	  a	  higher	  mean	  AMH	  value	  
than	  the	  aged	  matched	  portion	  of	  Otago	  cohort	  (p<0.0001),	  but	  were	  not	  
different	  to	  the	  younger	  subset	  (19–50	  years),	  p	  =	  0.06.	  B:	  The	  LiLACS	  NZ	  cohort	  
showed	  similar	  aged	  related	  decline	  in	  AMH	  (p	  =	  0.14)	  when	  compared	  to	  the	  
aged	  matched	  subset	  of	  the	  Otago	  cohort,	  whilst	  being	  different	  to	  the	  younger	  
subset	  p<0.0001	  (19–50	  years).C:	  	  The	  vascular	  cohort	  had	  similar	  InhB	  levels	  to	  
the	  aged	  matched	  subset	  of	  the	  Otago	  cohort	  (p	  =	  0.13),	  but	  lower	  than	  levels	  
than	  the	  younger	  Otago	  subset	  (p,0.001).	  D:	  The	  LiLACS	  NZ	  cohort	  showed	  
similar	  aged	  related	  decline	  in	  InhB	  (p	  =	  0.76)	  when	  compared	  to	  the	  aged	  
matched	  subset	  of	  the	  Otago	  cohort,	  whilst	  being	  different	  to	  the	  younger	  subset	  
p=0.001	  (19–50	  years).	  	  






Figure  4.5:  The  ratio  of  AMH  and  InhB  in  the  cohorts  of  community  
dwelling  men.    
The	  Otago	  cohort	  is	  represented	  by	  cyan	  open	  circles	  (n	  =	  223),	  the	  vascular	  
cohort	  by	  red	  open	  squares	  (n	  =	  153)	  and	  the	  LiLACS	  NZ	  cohort	  by	  orange	  open	  
triangles	  (n	  =	  270).	  Each	  open	  symbol	  represents	  an	  individual.	  An	  increasing	  







4A.4.1  Levels  of  AMH  in  adult  males  across  lifespan  
  
At	  the	  commencement	  of	  this	  PhD,	  young	  men	  were	  known	  to	  have	  circulating	  
AMH	  levels.	  This	  Chapter	  extends	  the	  observation	  to	  show	  that	  circulating	  AMH	  
persists	  into	  the	  very	  old.	  The	  range	  of	  AMH	  values	  in	  this	  Chapter	  are	  broadly	  
consistent	  with	  subsequently	  published	  data	  of	  AMH	  levels	  in	  an	  unselected	  
cohort	  of	  younger	  men	  (41).	  	  
	  
All	  men	  from	  the	  three	  cohorts	  studied	  had	  AMH	  levels	  at	  least	  an	  order	  of	  
magnitude	  lower	  than	  boyhood	  levels,	  with	  the	  highest	  values	  measured	  (118	  
pM)	  being	  less	  than	  half	  of	  the	  lowest	  range	  in	  boys	  (41,	  62).	  Most	  (41),	  but	  not	  
all	  males	  (68)	  exhibited	  a	  decline	  in	  AMH	  levels	  during	  the	  pubertal	  transition.	  
Seminal	  fluids	  in	  men	  contain	  AMH	  (181),	  at	  concentrations	  higher	  than	  serum	  
level	  (182),	  although	  not	  consistently.	  One	  possibility	  to	  explain	  this	  discrepancy	  
is	  that	  for	  some	  men,	  AMH	  becomes	  preferentially	  secreted	  into	  the	  seminiferous	  
tubular	  lumen	  by	  Sertoli	  cells	  rather	  than	  into	  blood,	  when	  compared	  to	  boys.	  It	  
is	  also	  possible	  that	  men	  have	  lower	  circulating	  levels	  of	  AMH	  due	  to	  a	  reduction	  
of	  AMH	  production	  by	  mature	  Sertoli	  cells	  in	  men,	  compared	  to	  immature	  forms	  
in	  boys	  (183).	  The	  persistence	  of	  adult	  levels	  of	  AMH	  in	  men	  in	  the	  studied	  
cohorts,	  even	  from	  the	  youngest	  participant	  (19	  years)	  suggest	  that	  none	  of	  the	  
men	  had	  testes	  that	  were	  similar	  to	  pre-­‐‑pubescent	  boys.	  	  
  
A	  minority	  of	  men	  (4%)	  in	  the	  Otago	  cohort	  had	  AMH	  levels	  above	  the	  upper	  
limit	  of	  reference	  range.	  It	  had	  been	  postulated	  that	  older	  testes	  undergo	  de-­‐‑
differentiation	  of	  their	  Sertoli	  cells	  in	  some	  of	  the	  seminiferous	  tubules,	  leading	  
to	  elevations	  of	  plasma	  AMH	  levels	  (47,	  48),	  such	  as	  that	  found	  in	  boys.	  A	  priori,	  
the	  InhB	  levels	  should	  be	  low,	  which	  was	  not	  observed	  in	  any	  of	  these	  men,	  
thereby	  indicating	  that	  immature	  Sertoli	  cells	  is	  not	  a	  prominent	  mechanism	  to	  






4A.4.2  AMH  profiles  are  different  between  younger  and  older  men  
	  
AMH	  levels	  in	  younger	  men	  had	  characteristics	  that	  were	  on	  average	  different	  to	  
older	  men.	  AMH	  levels	  were	  not	  significantly	  different	  between	  different	  age	  
groups	  under	  50	  years	  [Fig.	  4.2B],	  a	  finding	  that	  was	  consistent	  with	  other	  cross-­‐‑
sectional	  studies	  (41,	  64).	  The	  levels	  of	  InhB	  likewise	  were	  stable	  for	  men	  under	  
the	  age	  of	  50	  years,	  with	  a	  range	  that	  is	  similar	  to	  a	  clinically	  defined	  normal	  
range	  obtained	  from	  a	  clinical	  laboratory	  in	  another	  centre	  in	  New	  Zealand	  
(Canterbury	  Health	  Laboratories,	  Christchurch).	  This	  suggests	  that	  Sertoli	  cell	  
function	  and	  number	  is	  maintained	  in	  men	  younger	  than	  50	  years	  (176-­‐‑178,	  
184).	  	  	  
	  
Men	  over	  the	  age	  of	  70	  years	  had	  AMH	  and	  InhB	  levels	  that	  were	  more	  variable	  
than	  younger	  men,	  with	  average	  values	  being	  less	  than	  half	  that	  of	  younger	  men.	  
One	  possible	  explanation	  for	  this	  observation	  is	  an	  age-­‐‑related	  attrition	  of	  Sertoli	  
cells,	  which	  is	  supported	  by	  histological	  studies	  (185,	  186).	  Consistent	  with	  this,	  
a	  minority	  of	  older	  men	  in	  both	  Otago	  and	  Vascular	  cohort	  (3%	  and	  2%	  
respectively)	  had	  undetectable	  levels	  of	  both	  AMH	  and	  InhB,	  indicating	  that	  
these	  older	  men	  have	  complete	  cessation	  of	  Sertoli	  output	  (187),	  analogous	  to	  all	  
postmenopausal	  women	  with	  regression	  of	  their	  ovarian	  follicular	  cells.	  The	  loss	  
of	  one	  Sertoli	  hormone	  in	  older	  men	  was	  strongly	  associated	  with	  loss	  of	  the	  
second	  Sertoli	  hormone	  suggesting	  that	  diminishment	  of	  Sertoli	  hormones	  is	  
occurring	  at	  a	  cellular	  level.	  The	  relationship	  between	  loss	  of	  Sertoli	  cells	  and	  
Leydig	  cell	  hormones	  is	  examined	  in	  Chapter	  5.	  	  
	  
This	  variability	  of	  AMH	  is	  unlikely	  to	  be	  attributable	  to	  the	  presence	  of	  diurnal	  
fluctuations,	  or	  sporadic	  influences	  like	  testosterone,	  as	  demonstrated	  in	  the	  
preceding	  Chapter.	  	  
  
4A.4.3  Relationship  between  the  Sertoli  hormones  
  
AMH	  level	  is	  dissociated	  with	  InhB	  level	  (R2=0.22	  Pearson	  linear	  regression),	  




both	  Sertoli	  hormones	  are	  possibly	  independently	  regulated,	  or	  have	  different	  
functions.	  Both	  hormones	  have	  been	  individually	  used	  in	  literature	  as	  markers	  of	  
Sertoli	  number	  or	  function	  (188-­‐‑191),	  and	  this	  finding	  suggests	  that	  studies	  of	  
Sertoli	  function	  requires	  the	  examination	  of	  both	  AMH	  and	  InhB.	  
	  
AMH	  however	  is	  not	  totally	  independent	  to	  InhB	  due	  to	  its	  partial	  correlation,	  
which	  is	  statistically	  significant,	  with	  this	  linkage	  possibly	  due	  to	  both	  hormones	  
being	  derived	  from	  Sertoli	  cells.	  The	  linkage	  is	  strongest	  in	  some	  older	  men,	  
particularly	  at	  low	  levels	  of	  both	  hormones,	  putatively	  due	  to	  Sertoli	  cell	  loss.	  If	  
either	  hormones	  have	  functional	  significance	  in	  older	  age,	  their	  levels	  should	  be	  
maintained	  by	  remaining	  Sertoli	  cells	  through	  increased	  hormonal	  output	  (176),	  
which	  was	  not	  evident	  in	  these	  older	  men.	  This	  suggests	  that	  the	  loss	  of	  Sertoli	  
cells	  in	  these	  men	  significantly	  overwhelm	  any	  homeostatic	  mechanisms	  to	  
maintain	  AMH	  and	  InhB	  levels.	  	  
	  
A	  greater	  proportion	  of	  men	  in	  the	  LiLACS	  group	  (12%)	  had	  undetectable	  levels	  
of	  AMH	  than	  both	  Otago	  and	  Vascular	  cohorts.	  These	  men	  in	  the	  LiLACS	  group	  
were	  older	  than	  the	  other	  two	  cohorts	  [Table	  4.2,	  Fig.	  4.4],	  and	  majority	  had	  
concurrent	  low	  InhB	  levels,	  raising	  the	  possibility	  that	  the	  degree	  of	  Sertoli	  cell	  
attrition	  maybe	  related	  to	  advancing	  age.	  Interestingly	  the	  remaining	  two	  men	  
with	  undetectable	  AMH	  level	  had	  low	  normal	  levels	  of	  InhB,	  raising	  the	  
possibility	  of	  dysregulation	  in	  Sertoli	  cellular	  function.	  The	  LiLACS	  group	  had	  a	  
significantly	  higher	  proportion	  of	  Māori	  men	  compared	  to	  the	  other	  two	  cohorts,	  
but	  the	  ratio	  of	  LiLACS	  participants	  with	  low	  AMH	  levels	  were	  similar	  between	  
Māori	  and	  non-­‐‑Māori	  suggesting	  that	  Māori	  ethnicity	  was	  not	  a	  major	  
determinant	  of	  AMH	  levels	  in	  older	  men.	  	  	  
	  
The	  Vascular	  cohort,	  which	  was	  free	  from	  cardiovascular	  disease,	  had	  higher	  
levels	  of	  AMH	  and	  tended	  to	  have	  a	  higher	  AMH	  to	  InhB	  ratio.	  The	  most	  obvious	  
difference	  between	  the	  cohorts	  is	  the	  proven	  absence	  of	  cardiovascular	  disease	  
in	  the	  Vascular	  cohort.	  The	  importance	  of	  this	  is	  unknown,	  although	  it	  is	  
consistent	  with	  recent	  observations	  linking	  AMH	  to	  atherosclerosis	  in	  rhesus	  





InhB	  levels	  were	  similar	  between	  the	  older	  men	  in	  the	  three	  cohorts	  despite	  the	  
cardiovascular	  differences	  between	  the	  Vascular	  cohort	  and	  the	  other	  two	  
groups.	  	  
There	  was	  a	  difference	  in	  ethnicity,	  as	  Māori	  men	  on	  average	  had	  statistically	  
significant	  lower	  levels	  of	  InhB	  but	  not	  AMH	  than	  non-­‐‑Māori	  men,	  with	  the	  
biological	  relevance	  of	  this	  currently	  unknown.	  	  
  
4A.4.4  Strengths  and  Limitations  of  study  
  
The	  comparison	  of	  two	  additional	  cohorts	  to	  the	  Otago	  cohort,	  allows	  the	  first	  
exploration	  of	  the	  Sertoli	  cell	  hormonal	  profiles	  in	  the	  context	  of	  biology	  or	  
pathology.	  Each	  cohort	  therefore	  provides	  different	  contextual	  information.	  The	  
Otago	  cohort	  is	  an	  unselected	  cohort,	  and	  examines	  the	  profiles	  of	  Sertoli	  cell	  
hormones	  across	  the	  adult	  male	  lifespan.	  This	  is	  the	  most	  representative	  of	  
community	  men.	  The	  Vascular	  cohort	  at	  the	  other	  end	  of	  the	  spectrum	  is	  a	  highly	  
selected	  subset	  of	  men	  in	  the	  same	  population	  that	  is	  devoid	  of	  any	  
cardiovascular	  disease	  and	  atypically	  healthy.	  Comparison	  between	  the	  two	  
cohorts	  in	  the	  Otago	  region	  provides	  insight	  that	  allows	  generation	  of	  hypothesis	  
to	  elucidate	  function	  of	  AMH	  in	  men.	  Similarly,	  the	  inclusion	  of	  the	  LiLACS	  cohort	  
with	  ethnic	  and	  geographical	  disparity	  to	  the	  two	  Otago	  cohort	  enriches	  the	  
study	  and	  allows	  generation	  of	  further	  hypotheses	  to	  guide	  further	  specific	  
studies	  on	  AMH.	  	  
  
The	  cross-­‐‑sectional	  nature	  of	  this	  study	  means	  that	  secular	  changes	  such	  as	  
intergenerational	  differences	  of	  AMH	  levels	  cannot	  be	  excluded,	  and	  better	  
answered	  in	  a	  longitudinal	  study	  that	  is	  outside	  of	  the	  scope	  of	  this	  thesis.	  	  
	  
Whilst	  AMH	  has	  moment-­‐‑to-­‐‑moment	  stability	  in	  blood,	  the	  stability	  across	  days,	  
weeks	  or	  months	  have	  not	  been	  determined	  for	  AMH	  or	  InhB.	  This	  includes	  more	  
chronic	  sporadic	  influences	  such	  as	  the	  effect	  of	  seasonality	  on	  the	  variability	  
between	  men.	  The	  three	  cohorts	  were	  individually	  recruited	  and	  sampled	  for	  




different	  between	  the	  Otago	  and	  the	  LiLACS	  cohort,	  suggesting	  that	  these	  
sporadic	  variabilities	  such	  as	  seasonality	  are	  not	  a	  major	  determinant	  in	  the	  
circulating	  level	  of	  AMH.	  This	  is	  in	  keeping	  with	  a	  limited	  study	  in	  InhB	  in	  young	  
men	  that	  showed	  InhB	  to	  be	  invariant	  to	  the	  effect	  of	  seasonality	  (194).	  To	  
definitively	  assess	  for	  seasonality,	  a	  longitudinal	  study	  assessing	  AMH	  levels	  
taken	  at	  several	  times	  during	  the	  year	  would	  be	  informative.	  	  
  
The	  age-­‐‑related	  changes	  for	  AMH	  are	  unknown	  and	  presumed	  to	  be	  a	  continuous	  
variable.	  The	  correlation	  of	  age-­‐‑related	  changes	  to	  traits	  would	  require	  a	  study	  of	  
much	  larger	  sample	  size.	  This	  is	  beyond	  the	  scope	  of	  this	  exploratory	  study	  that	  
was	  set	  out	  to	  compare	  changes	  between	  the	  young	  and	  the	  older	  males.	  The	  age	  
cut-­‐‑off	  of	  50	  years	  is	  arbitrary,	  in	  order	  to	  facilitate	  statistical	  analysis	  between	  
the	  two	  age	  groups.	  	  	  
Another	  limitation	  of	  the	  study	  is	  the	  sampling	  of	  blood	  at	  different	  times	  of	  day,	  
which	  may	  limit	  the	  implication	  of	  the	  findings	  in	  a	  clinical	  context,	  where	  blood	  
is	  commonly	  sampled	  in	  the	  morning.	  AMH	  levels,	  however,	  have	  been	  shown	  to	  
invariant	  to	  the	  time	  of	  the	  day	  [Chapter	  3].	  	  
  






AMH	  persists	  across	  the	  male	  lifespan	  and	  into	  the	  very	  elderly,	  with	  variability	  
between	  men.	  This	  variability	  increases	  with	  age.	  AMH	  exhibits	  partial	  
independence	  to	  InhB,	  suggesting	  that	  the	  regulation	  of	  these	  two	  Sertoli	  
hormones	  is	  largely	  independent	  from	  each	  other.	  This	  mirrors	  the	  distinct	  daily	  
profiles	  of	  these	  hormones	  as	  demonstrated	  in	  Chapter	  3.	  The	  relationship	  
between	  AMH	  and	  InhB	  however	  have	  some	  partial	  linkage,	  with	  the	  strength	  of	  
this	  coupling	  increasing	  at	  lower	  levels	  of	  both	  hormones,	  indicating	  loss	  of	  
Sertoli	  function	  and/or	  number	  for	  some	  older	  men.	  The	  following	  Chapter	  will	  
examine	  whether	  this	  loss	  of	  Sertoli	  function	  influences	  the	  level	  of	  Leydig	  cell	  
output,	  and	  vice	  versa.	  The	  role	  of	  AMH	  is	  unknown,	  with	  putative	  roles	  in	  the	  
cardiovascular	  system,	  but	  is	  outside	  the	  scope	  of	  this	  thesis.	  








21	  women	  aged	  65	  years	  and	  older	  were	  recruited	  from	  the	  community	  in	  
Dunedin.	  Flyers	  were	  advertised	  around	  the	  local	  hospital	  and	  University.	  The	  
majority	  of	  the	  women	  were	  Caucasian.	  Participants	  were	  excluded	  from	  the	  
study	  if	  they	  had	  a	  history	  of	  oophorectomy,	  ovarian	  malignancy,	  on	  oestrogen	  
hormone	  replacement	  therapy,	  radiation	  therapy	  to	  pelvis,	  or	  chemotherapy.	  	  
	  
A	  comparison	  group	  consisting	  of	  9	  healthy	  young	  women	  with	  regular	  
menstrual	  cycles	  was	  recruited	  via	  flyers	  advertised	  in	  similar	  venues	  to	  the	  
postmenopausal	  women.	  Women	  were	  excluded	  from	  the	  study	  if	  they	  had	  a	  
history	  of	  polycystic	  ovarian	  syndrome,	  on	  hormonal	  treatment	  including	  
hormonal	  contraception,	  and	  chronic	  medical	  illnesses.	  	  
	  
A	  single	  non-­‐‑fasting	  venous	  sample	  of	  4mL	  was	  collected	  from	  the	  antecubital	  
fossa	  vein	  from	  each	  participant,	  and	  assayed	  for	  the	  AMH	  value.	  	  
	  
This	  study	  was	  approved	  by	  the	  University	  of	  Otago	  Human	  Ethics	  committee.	  	  
	  







Postmenopausal	  women,	  with	  mean	  age	  of	  76.9	  years	  (range	  65-­‐‑108	  years)	  have	  
either	  undetectable	  (18	  out	  of	  21	  women)	  serum	  AMH	  levels,	  or	  their	  levels	  just	  
above	  the	  limit	  of	  detection	  [Fig.	  4.6,	  1.13-­‐‑2.76	  pM].	  There	  were	  no	  
discriminating	  features	  between	  the	  subgroup	  with	  detectable	  AMH	  and	  those	  
without,	  in	  relation	  to	  age	  at	  sampling,	  age	  at	  menopause,	  or	  ovarian	  pathology.	  9	  
healthy	  ovulating	  young	  women’s	  serum	  AMH	  levels	  were	  measured	  in	  the	  same	  
assay	  as	  the	  postmenopausal	  women	  to	  ensure	  that	  the	  ELISA	  kit	  utilised	  were	  
able	  to	  detect	  normal	  age-­‐‑based	  values	  of	  AMH.	  The	  mean	  age	  for	  the	  younger	  
women	  was	  22.4	  years,	  and	  their	  mean	  AMH	  level	  was	  36.4	  pM	  (range	  3-­‐‑82	  pM),	  
consistent	  with	  normal	  values	  for	  younger	  women	  (72).	  
  








Figure  4.6:  Serum  AMH  levels  in  women.    
Each	  dark	  blue	  circle	  represents	  an	  older	  postmenopausal	  women	  and	  showed	  
undetectable	  AMH	  levels,	  in	  contrast	  to	  the	  younger	  healthy	  women	  represented	  
by	  light	  blue	  squares.	  	  






This	  data	  demonstrates	  that	  the	  loss	  of	  AMH	  in	  women	  prior	  to	  menopause	  
persists	  into	  senescence,	  in	  contrast	  to	  squirrel	  monkeys	  (179).	  Therefore,	  
subsequent	  Chapters	  in	  this	  thesis	  have	  not	  studied	  women,	  as	  this	  falls	  outside	  
the	  scope	  of	  the	  thesis,	  which	  has	  a	  focus	  on	  ageing,	  and	  AMH.	  However,	  this	  data	  
may	  be	  informative	  regarding	  the	  role	  of	  AMH	  in	  older	  males,	  with	  this	  Chapter	  
showing	  the	  sexual	  dimorphism	  of	  AMH	  with	  ageing.	  Some	  older	  men	  have	  
undetectable	  AMH	  levels	  like	  all	  postmenopausal	  women,	  and	  these	  older	  men	  
may	  putatively	  have	  ageing	  traits	  more	  commonly	  seen	  in	  older	  women.	  	  
	  
This	  information	  may	  also	  be	  useful	  for	  the	  detection	  of	  granulosa	  cell	  tumours,	  a	  
form	  of	  ovarian	  malignancy	  typically	  first	  presenting	  in	  the	  peri-­‐‑menopausal	  
period.	  Long-­‐‑term	  follow-­‐‑up	  is	  recommended	  after	  treatment,	  as	  the	  tumours	  
frequently	  reoccur,	  up	  to	  37	  years	  after	  resection	  (195,	  196).	  Granulosa	  cell	  
tumours	  can	  be	  associated	  with	  elevation	  of	  oestradiol	  and	  inhibin,	  which	  are	  
used	  as	  biomarkers	  for	  recurrence.	  However,	  oestradiol	  is	  falsely	  normal	  in	  up	  to	  
30%	  of	  granulosa	  cell	  tumours	  (197).	  Similarly,	  inhibin	  lacks	  specificity,	  as	  it	  can	  
also	  be	  elevated	  in	  epithelial	  ovarian	  tumours	  (198,	  199).	  The	  absence	  of	  AMH	  in	  
postmenopausal	  women	  makes	  this	  hormone	  an	  ideal	  biomarker	  for	  detection	  of	  
granulosa	  cell	  tumours	  following	  resection	  amongst	  women	  in	  this	  age	  group.	  	  
	  
The	  average	  level	  of	  serum	  AMH	  in	  elderly	  women	  was	  not	  significantly	  different	  
from	  the	  lowest	  detection	  limit	  of	  the	  ELISA.	  However,	  a	  minority	  of	  women	  had	  
values	  marginally	  higher	  than	  the	  detection	  limit.	  This	  may	  be	  explained	  by	  
statistical	  variation	  around	  the	  zero	  value	  of	  the	  ELISA	  or	  alternatively	  maybe	  
secondary	  to	  a	  low	  level	  of	  AMH	  production	  in	  a	  minority	  of	  elderly	  women.	  In	  
support	  of	  the	  latter	  argument,	  trace	  level	  of	  AMH	  can	  be	  immunoprecipitated	  
from	  the	  serum	  of	  some	  elderly	  women	  (M.	  Pankhurst,	  personal	  
communication).	  This	  suggests	  that	  a	  minority	  of	  elderly	  women	  have	  small	  
numbers	  of	  residual	  granulosa	  cells	  in	  their	  ovaries,	  which	  may	  modify	  their	  
background	  risk	  of	  developing	  late-­‐‑onset	  granulosa	  cell	  tumours.	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The	  circulating	  levels	  of	  AMH	  and	  InhB	  differ	  between	  men,	  with	  age-­‐‑related	  
decline	  [Chapter	  4].	  The	  regulation	  of	  Sertoli	  cell	  is	  complex,	  and	  involves	  the	  
expression	  of	  androgen	  receptors	  during	  puberty	  [Chapter	  1.4.3].	  Testosterone	  
is	  postulated	  to	  mediate	  the	  decrease	  of	  AMH	  level	  during	  puberty	  [Chapter	  
1.4.3].	  The	  influence	  of	  testosterone	  on	  Sertoli	  hormonal	  output	  is	  unknown,	  but	  
if	  the	  effect	  of	  testosterone	  persists	  during	  adulthood,	  then	  linkage	  should	  occur	  
between	  the	  Sertoli	  and	  Leydig	  hormones.	  Conversely,	  non-­‐‑physiological	  studies	  
have	  shown	  that	  AMH	  can	  impact	  on	  the	  production	  of	  testosterone	  in	  Leydig	  
cells	  [Chapter	  1.4.2].	  The	  relationship	  between	  INSL3	  and	  Sertoli	  hormones	  are	  
currently	  unknown.	  This	  Chapter	  will	  examine	  the	  relationship	  between	  
testicular	  hormones	  in	  blood	  of	  a	  cohort	  of	  men,	  in	  a	  normal	  physiological	  model	  
(young	  men).	  This	  will	  be	  compared	  to	  a	  cohort	  of	  older	  men	  to	  examine	  if	  the	  
age-­‐‑related	  decline	  seen	  in	  Sertoli	  hormones	  is	  associated	  with	  any	  changes	  in	  








5.1.1  Profiles  of  Leydig  hormones  across  lifespan  
  
Circulating	  testosterone	  level	  in	  man	  has	  been	  extensively	  studied	  across	  the	  
lifespan.	  Similar	  to	  the	  observation	  for	  Sertoli	  hormones,	  there	  is	  an	  age-­‐‑related	  
decline,	  although	  occurring	  earlier	  than	  the	  Sertoli	  hormones	  (200-­‐‑204).	  
Consequently,	  up	  to	  50%	  of	  men	  in	  the	  ninth	  decade	  of	  life	  have	  circulating	  
testosterone	  level	  below	  the	  normative	  range	  for	  young	  men	  (205).	  The	  
significance	  of	  the	  age-­‐‑related	  decline	  is	  widely	  debated.	  Testosterone	  has	  been	  
used	  as	  a	  biomarker	  for	  the	  expression	  of	  the	  male	  phenotype	  in	  men.	  For	  
younger	  men,	  low	  circulating	  testosterone	  level	  is	  commonly	  associated	  with	  
symptoms	  resulting	  in	  deficiency	  of	  this	  male	  phenotype,	  such	  as	  loss	  of	  muscle	  
mass	  and	  strength,	  reduction	  in	  bone	  density,	  and	  diminished	  libido	  and	  sexual	  
function	  (172).	  Clinical	  thresholds	  have	  been	  defined	  for	  diagnosing	  testosterone	  
deficiency,	  termed	  hypogonadism	  (172).	  Exogenous	  testosterone	  replacement	  
consistently	  results	  in	  ameliorating	  the	  symptoms,	  highlighting	  the	  dominant	  
role	  for	  testosterone	  in	  younger	  men	  to	  maintain	  the	  male	  phenotype	  (206,	  207).	  	  
	  
What	  is	  less	  clear	  is	  whether	  the	  maintenance	  of	  the	  sexual	  dimorphism	  in	  older	  
men	  is	  vital	  for	  a	  male’s	  longevity.	  There	  is	  emerging	  interest	  in	  the	  role	  of	  
circulating	  testosterone	  to	  aspects	  of	  physical	  function	  in	  the	  older	  male,	  ranging	  
from	  muscle	  strength	  and	  function,	  to	  cardiovascular	  disease	  and	  mortality.	  This	  
will	  be	  reviewed	  in	  Chapter	  7.1.2,	  but	  testosterone	  replacement	  has	  not	  been	  
universally	  successful	  in	  reversing	  any	  health	  decline	  associated	  with	  low	  
testosterone	  in	  the	  older	  male	  (208-­‐‑211).	  Consequently,	  having	  circulating	  
testosterone	  level	  that	  is	  below	  the	  range	  of	  younger	  men	  may	  confer	  survival	  
benefits,	  with	  this	  being	  putatively	  suggested	  in	  an	  observational	  study	  of	  
castrated	  men	  (212).	  
	  
There	  is	  an	  emerging	  concept	  of	  hypogonadism	  in	  the	  older	  men,	  called	  late	  
onset	  hypogonadism.	  There	  is	  a	  disconcordance	  between	  the	  high	  prevalence	  of	  




classical	  clinical	  features,	  being	  estimated	  conservatively	  at	  2%	  of	  older	  men	  
(213).	  	  
It	  is	  also	  unknown	  whether	  this	  age-­‐‑related	  decline	  in	  testosterone	  is	  specific	  to	  
the	  hormone,	  or	  the	  loss	  of	  the	  Leydig	  cell,	  with	  the	  latter	  being	  proposed	  as	  the	  
more	  likely	  mechanism	  (214-­‐‑217).	  INSL3	  has	  been	  proposed	  to	  be	  a	  more	  
precise	  biomarker	  for	  Leydig	  cell	  function	  (33,	  218)	  [Chapter	  1.4.1]	  than	  
testosterone.	  If	  the	  decline	  in	  testosterone	  level	  is	  predominantly	  due	  to	  a	  loss	  of	  
Leydig	  cell,	  then	  a	  strong	  association	  should	  exist	  between	  testosterone	  level	  and	  
INSL3	  level	  in	  blood,	  particularly	  in	  older	  men	  but	  not	  in	  younger	  men.	  There	  has	  
only	  been	  one	  cross-­‐‑sectional	  study	  of	  INSL3	  in	  an	  Australian	  cohort	  that	  showed	  
age-­‐‑related	  decline	  in	  men	  (134).	  However,	  this	  study	  has	  an	  age	  range	  spanning	  
from	  35	  to	  80	  years	  old	  in	  a	  single	  cohort,	  and	  is	  therefore	  not	  informative	  about	  
elderly	  men.	  	  
	  
Levels	  of	  INSL3	  have	  been	  associated	  with	  testicular	  pathology	  in	  an	  inconsistent	  
pattern.	  Men	  with	  low	  levels	  of	  gonadotropins	  leading	  low	  stimulation	  of	  
testicular	  function	  exhibit	  circulating	  INSL3	  levels	  that	  are	  below	  the	  normal	  
range	  for	  healthy	  men	  (29-­‐‑31).	  This	  is	  not	  consistently	  due	  to	  reduced	  Leydig	  cell	  
number,	  as	  there	  is	  a	  considerable	  overlap	  in	  ranges	  between	  men	  with	  very	  low	  
testicular	  volumes	  and	  those	  without	  (31).	  The	  findings	  are	  concordant	  with	  
studies	  of	  Klinefelter’s	  Syndrome	  where	  men	  have	  primary	  testicular	  pathology,	  
but	  a	  wide	  range	  of	  INSL3	  levels	  that	  overlap	  with	  levels	  of	  men	  deemed	  as	  
normal	  control	  (29,	  30,	  219).	  These	  men	  also	  have	  disconcordance	  with	  their	  
testosterone	  values.	  Not	  all	  testicular	  pathologies	  are	  associated	  with	  low	  INSL3	  
however;	  as	  men	  with	  infertility	  due	  to	  impaired	  spermatogenesis	  have	  levels	  of	  
INSL3	  that	  are	  similar	  to	  fertile	  men	  (29,	  30).	  This	  may	  indicate	  that	  INSL3	  
reflects	  different	  aspects	  of	  testicular	  function,	  and	  therefore	  the	  levels	  maybe	  
independent	  to	  the	  other	  three	  testicular	  hormones.	  	  
  




5.1.2  Objectives  of  study  
  
This	  Chapter	  will	  profile	  the	  circulating	  levels	  of	  four	  testicular	  hormones	  in	  a	  
cohort	  of	  young	  men,	  to	  assess	  for	  any	  interaction	  between	  the	  Sertoli	  and	  
Leydig	  hormones.	  An	  examination	  of	  the	  four	  testicular	  hormones	  in	  blood	  of	  
older	  men	  will	  then	  be	  conducted,	  and	  assess	  if	  the	  age-­‐‑related	  decline	  is	  linked	  
between	  the	  hormones.	  This	  will	  inform	  whether	  hypogonadism	  is	  invariantly	  
due	  to	  a	  loss	  of	  total	  testicular	  output,	  or	  if	  there	  are	  different	  forms	  of	  testicular	  
hormonal	  decline	  that	  can	  lead	  to	  better	  prediction	  of	  clinical	  hypogonadism	  in	  
the	  older	  male.	  








The	  cohort	  studied	  was	  derived	  from	  the	  Otago	  cohort,	  as	  described	  in	  Chapter	  
4A.2.1A.	  Younger	  men	  are	  defined	  as	  men	  younger	  than	  50	  years,	  whilst	  older	  
men	  are	  aged	  70	  years	  and	  older.	  
  
5.2.2  Hormonal  assays  
  
Four	  testicular	  hormones	  were	  assayed	  and	  examined	  as	  described	  in	  Chapters	  
2.1.4	  and	  2.1.5,	  and	  [Table	  2.1].	  
  
5.2.3  Statistical  analyses  
  
The	  hormonal	  profiles	  across	  the	  lifespan	  were	  represented	  by	  the	  geometric	  
mean	  and	  its	  confidence	  intervals,	  grouped	  by	  decades	  in	  younger	  men,	  and	  
every	  5	  years	  for	  older	  men.	  The	  ranges	  of	  hormonal	  values	  are	  different	  for	  each	  
decade,	  with	  this	  potentially	  being	  skewed	  if	  the	  data	  is	  represented	  by	  the	  
arithmetic	  mean.	  The	  geometric	  mean	  (nth	  root	  of	  the	  product	  of	  n	  values)	  was	  
chosen	  instead	  to	  provide	  a	  more	  accurate	  representation	  of	  the	  data.	  Statistical	  
differences	  between	  the	  groups	  were	  tested	  using	  one-­‐‑way	  ANOVA	  and	  Scheffe	  
test	  post-­‐‑hoc	  applied	  to	  examine	  for	  the	  differences	  between	  sub-­‐‑groups.	  
	  
Relationships	  between	  individual	  hormones	  were	  examined	  by	  Pearson’s	  linear	  
regression	  [Chapter	  2.2.].	  
	  
The	  Sertoli	  cell	  and	  Leydig	  cell	  each	  produce	  two	  hormones.	  The	  relative	  output	  
for	  each	  cell	  type	  was	  examined	  using	  the	  log	  of	  the	  ratio	  of	  the	  two	  hormones,	  
which	  were	  first	  normalised	  to	  the	  mean	  of	  younger	  men,	  aged	  under	  50	  years	  
[Chapter	  2.2.].	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Table  5.1  Characteristics  of  four  testicular  hormones  in  younger  and  older  men  of  the  Otago  cohort.  111  men  were  aged  
under  50  years  (mean  36.2  years),  whilst  98  men  were  aged  70  years  and  older  (mean  78.2  years).  Two  men  under  50  years  
and  one  man  over  70  years  lacked  samples  for  testosterone.  	  
	  








Age	  group	   <50	  years	   >70	  years	   <50	  years	   >70	  
years	  
	  
<50	  years	   >70	  
years	  
<50	  years	   >70	  years	  
Arithmetic	  Mean	  
(sd)	  
	  17.5	  	  
(8.7)	  






















































5.3.1  AMH  levels  post  field  notice  
  
The	  AMH	  levels	  in	  the	  Dunedin	  cohort	  were	  re-­‐‑measured	  post-­‐‑field	  notice	  
[Chapter	  2.1.5A].	  The	  pattern	  of	  age-­‐‑related	  changes	  in	  AMH	  levels	  [Fig.	  5.1]	  was	  
similar	  to	  that	  described	  in	  Chapter	  4.	  The	  relationship	  between	  AMH	  and	  InhB	  
was	  also	  preserved	  with	  the	  post-­‐‑field	  notice	  data,	  with	  there	  being	  no	  
statistically	  difference	  in	  the	  AMH	  versus	  InhB	  regression	  lines	  calculated	  from	  
the	  pre-­‐‑	  and	  post-­‐‑field	  AMH	  data	  [Fig.	  5.2].	  
  







Figure  5.1:  Levels  of  serum  AMH  post-­field  notice  in  Otago  cohort.  
  
A.	  Serum	  AMH	  was	  re-­‐‑assayed	  post-­‐‑field	  notice	  [Chapter	  2.1.5]	  with	  each	  green	  
triangle	  representing	  a	  man’s	  value.	  The	  distribution	  is	  similar	  to	  that	  seen	  pre-­‐‑
field	  notice	  [Fig.	  4.2A	  and	  B].	  B.	  illustrates	  the	  geometric	  mean	  and	  95%	  






Figure  5.2:  The  relationship  between  AMH  values  post-­field  notice  to  
InhB  is  maintained.  








Testosterone	  is	  the	  most	  extensively	  studied	  of	  the	  four	  testicular	  hormones	  in	  
the	  literature	  [Chapter	  5.1.1].	  The	  men	  in	  the	  cohort	  demonstrated	  variability	  in	  
their	  testosterone	  level	  [Fig.	  5.3A	  and	  B],	  with	  a	  distribution	  that	  was	  positively	  
skewed	  in	  men	  younger	  than	  50	  years	  (SK	  test	  1.1,	  p<0.0001)	  and	  men	  older	  
than	  70	  years	  (SK	  test	  0.50,	  p=0.044).	  Across	  the	  entire	  cohort,	  the	  average	  
testosterone	  level	  declined	  from	  the	  fourth	  decade	  of	  life	  (post-­‐‑hoc	  Scheffe	  test	  
p=0.0002),	  with	  this	  being	  statistically	  significant	  [Fig.	  5.3B,	  p<0.0001	  ANOVA].	  
This	  age-­‐‑related	  decline	  in	  testosterone	  occurred	  at	  an	  earlier	  age	  than	  AMH	  or	  




INSL3	  was	  similarly	  highly	  variable	  between	  men	  [Fig.	  5.3C],	  with	  a	  distribution	  
that	  was	  more	  positively	  skewed	  than	  testosterone	  in	  both	  younger	  and	  older	  
men	  (SK	  test	  1.2,	  p<0.0001	  and	  2.3,	  p<0.0001	  respectively).	  The	  geometric	  mean	  
for	  INSL3	  remained	  constant	  until	  after	  70	  years	  of	  age,	  when	  there	  was	  a	  
progressive	  decline	  in	  the	  average	  INSL3	  levels	  with	  advancing	  age	  [Fig.	  5.3D,	  
p<0.0001	  ANOVA,	  post-­‐‑hoc	  Scheffe	  test	  p=0.016],	  and	  concurrent	  increase	  in	  
variance	  of	  INSL3	  levels	  between	  men.	  These	  findings	  were	  in	  concordance	  with	  
the	  cross-­‐‑sectional	  patterns	  of	  the	  Sertoli	  hormones.	  
	  







Figure  5.3:  The  levels  of  serum  Leydig  hormones  in  233  community  
dwelling  men  (Otago  cohort)  from  the  cross-­sectional  study  are  
illustrated  across  the  lifespan  of  adult  men.    
A:	  each	  red	  circle	  represented	  an	  individual’s	  testosterone	  value.	  B:	  the	  
geometric	  mean	  and	  95%	  confidence	  interval	  for	  testosterone	  is	  indicated	  for	  
various	  age	  groups,	  with	  the	  number	  above	  the	  age	  group	  indicating	  sample	  size.	  
There	  is	  a	  progressive	  decline	  in	  the	  geometric	  mean	  of	  testosterone	  from	  30	  
years	  onwards	  compared	  to	  men	  in	  their	  20s,	  which	  was	  statistically	  significant	  
on	  ANOVA	  Scheffe	  post-­‐‑hoc	  test	  (*).	  C:	  each	  orange	  circle	  represented	  an	  
individual’s	  INSL3	  value.	  B:	  the	  geometric	  mean	  and	  95%	  confidence	  interval	  for	  
INSL3	  is	  indicated	  for	  various	  age	  groups,	  with	  the	  number	  above	  the	  age	  group	  
indicating	  sample	  size.	  The	  geometric	  mean	  level	  of	  INSL3	  in	  men	  over	  80	  years	  
is	  approximately	  45%	  of	  mean	  levels	  found	  in	  men	  under	  the	  age	  of	  30.	  	  




5.3.3  Testicular  endocrine  profiles  in  younger  men  
  
5.3.3A  Interactions  between  individual  hormones  
  
The	  variability	  in	  individual	  hormonal	  levels	  between	  younger	  men	  prompted	  
the	  need	  to	  examine	  whether	  the	  four	  testicular	  hormones	  are	  independent	  of	  
each	  other.	  AMH	  and	  InhB	  are	  largely	  independent	  to	  each	  other,	  with	  84%	  
dissociation,	  as	  shown	  in	  Chapter	  4	  [Fig.	  5.4A,	  R2=0.16,	  p<0.0001].	  Testosterone	  
and	  INSL3	  showed	  near	  complete	  dissociation	  to	  each	  other	  despite	  both	  
hormones	  originating	  from	  Leydig	  cells	  [Fig.	  5.4B,	  R2=0.00,	  p=0.63].	  This	  
phenomenon	  was	  also	  observed	  between	  testosterone	  and	  the	  Sertoli	  hormones	  
AMH	  and	  InhB	  individually	  [Fig.	  5.4C	  and	  D,	  R2=0.00,	  p=0.48	  to	  AMH,	  and	  
R2=0.00,	  p=0.50	  to	  InhB].	  There	  was	  a	  very	  weak	  positive	  trend	  for	  INSL3	  
correlating	  to	  AMH	  [Fig.	  5.4E,	  R2=0.06,	  p=0.010	  univariate	  linear	  regression]	  that	  
became	  statistically	  insignificant	  after	  correction	  for	  multiple	  testing	  (p=0.06,	  
Bonferroni	  correction).	  INSL3	  similarly	  had	  a	  non-­‐‑significant	  weak	  positive	  trend	  
to	  InhB	  [Fig.	  5.4F,	  R2=0.03,	  p=0.09].	  
  






Figure  5.4:  The  relationship  between  the  different  testicular  hormones  
AMH,  InhB,  testosterone  and  INSL3  are  examined  against  each  other  
using  Pearson  linear  regression,  in  the  younger  men’s  subgroup  of  the  
Otago  cohort  (19  –  49.9  years).    
Each	  circle	  represented	  a	  participant’s	  hormonal	  value.	  The	  hormones	  are	  
largely	  independent	  to	  each	  other.	  The	  minor	  association	  between	  AMH	  and	  
INSL3	  was	  not	  statistical	  significance	  following	  Bonferroni	  correction	  for	  




5.3.3B  Interaction  of  individual  hormones  to  the  relative  output  of  testicular  
cells  
	  
Both	  AMH	  and	  InhB	  are	  Sertoli	  cell	  products,	  and	  similarly	  testosterone	  and	  
INSL3	  are	  derived	  from	  Leydig	  cells.	  The	  relative	  output	  of	  each	  cell	  type	  can	  be	  
determined	  by	  the	  logarithm	  of	  their	  ratio,	  and	  tested	  against	  the	  individual	  
hormone	  of	  the	  other	  cell	  type	  to	  determine	  for	  any	  linkages	  between	  the	  two	  
cell	  types.	  The	  relative	  output	  of	  Leydig	  hormones	  was	  independent	  to	  the	  level	  
of	  the	  Sertoli	  hormone	  AMH	  (R2=0.03,	  p=0.09)	  and	  to	  InhB	  (R2=0.00,	  p=0.57),	  
with	  no	  discernable	  patterns	  amongst	  scatter	  plots	  graphs	  [Fig.	  5.5A	  and	  B].	  
Similarly,	  both	  INSL3	  and	  testosterone	  had	  no	  effect	  on	  the	  relative	  output	  of	  
Sertoli	  cells	  [Fig.	  5.5C,	  R2=0.00,	  p=0.72	  for	  testosterone,	  and	  Fig.	  5.5D,	  R2=0.02,	  
p=0.11	  for	  INSL3].	  
  







Figure  5.5:  Interaction  of  individual  hormones  to  relative  output  of  
testicular  cells  in  younger  men.    
The	  relative	  hormonal	  output	  of	  Leydig	  cells	  in	  younger	  men	  is	  depicted	  against	  
AMH	  in	  A.	  and	  InhB	  in	  B.	  Similarly,	  the	  relative	  hormonal	  output	  of	  Sertoli	  cells	  is	  
illustrated	  against	  testosterone	  in	  C.	  and	  INSL3	  in	  D.	  Each	  circle	  represented	  an	  




5.3.4  Testicular  endocrine  profiles  in  older  men  
  
5.3.4A  Interaction  between  individual  hormones  
  
The	  independence	  in	  the	  individual	  testicular	  hormones	  was	  then	  examined	  for	  
the	  cohort	  of	  men	  over	  70	  years,	  a	  group	  with	  variable	  health	  status	  and	  
function.	  
	  
AMH	  and	  InhB	  remained	  largely	  independent	  to	  each	  other	  [Fig.	  5.6A,	  R2=0.22,	  
p<0.0001].	  The	  weak	  partial	  linkage	  observed	  was	  not	  statistically	  different	  to	  
that	  found	  in	  younger	  men	  (p=0.21	  for	  differences	  in	  the	  linear	  regression	  lines).	  
	  
There	  was	  an	  emergence	  of	  a	  weak	  positive	  correlation	  between	  testosterone	  
and	  the	  other	  three	  hormones	  with	  diminishing	  order	  of	  association	  [Fig.	  5.6B,	  
R2=0.16,	  p=0.0003	  to	  INSL3;	  Fig.	  5.6C	  R2=0.10,	  p=0.010	  to	  InhB;	  and	  Fig.	  5.6D	  
R2=0.06,	  p=0.09	  after	  correction	  with	  Bonferroni	  for	  multiple	  testing].	  Given	  the	  
partial	  linkage	  between	  AMH	  and	  InhB,	  as	  well	  as	  between	  testosterone	  and	  the	  
individual	  Sertoli	  hormones,	  a	  multiple	  regression	  was	  tested	  with	  all	  three	  
hormonal	  variables.	  This	  showed	  that	  the	  weak	  relationship	  between	  
testosterone	  and	  InhB	  remained	  statistically	  significant	  after	  taking	  AMH	  into	  
account	  (multiple	  linear	  regression	  coefficient	  0.24,	  p=0.022).	  
	  
INSL3	  in	  older	  men	  displayed	  near	  total	  independence	  to	  the	  Sertoli	  hormones	  













Figure  5.6:  The  relationship  between  the  different  testicular  hormones  
AMH,  InhB,  testosterone  and  INSL3  are  examined  against  each  other  
using  Pearson  linear  regression,  in  the  older  men’s  subgroup  of  the  
Otago  cohort  (70  -­  90  years).    
Each	  circle	  represented	  a	  participant’s	  hormonal	  value.	  There	  is	  an	  emergence	  of	  
a	  minor	  association	  between	  testosterone	  and	  INSL3,	  InhB	  and	  AMH	  in	  
decreasing	  order,	  with	  the	  association	  to	  AMH	  being	  not	  significant	  after	  




5.3.4B  Interaction  of  individual  hormones  to  the  relative  output  of  testicular  
cells  
  
The	  relative	  output	  of	  both	  Sertoli	  and	  Leydig	  cells	  were	  again	  represented	  using	  
the	  logarithm	  of	  their	  hormonal	  ratio,	  normalised	  to	  their	  respective	  mean	  from	  
the	  younger	  men’s	  cohort.	  If	  both	  hormones	  were	  declining	  at	  a	  similar	  rate,	  
their	  logarithmic	  ratio	  would	  center	  on	  zero.	  The	  relative	  output	  of	  Leydig	  
hormones	  in	  older	  men	  however	  was	  below	  zero,	  indicating	  that	  there	  was	  
greater	  decline	  in	  INSL3	  than	  testosterone	  in	  older	  men	  [Fig.	  5.7A	  and	  B].	  Both	  
AMH	  and	  InhB	  remained	  independent	  to	  the	  relative	  output	  of	  the	  Leydig	  cells	  
(linear	  regression	  R2=0.00,	  p=0.94	  to	  AMH,	  and	  R2=0.00,	  p=0.55	  to	  InhB).	  
Similarly,	  both	  testosterone	  and	  INSL3	  had	  no	  effect	  on	  the	  relative	  output	  of	  
Sertoli	  hormones	  [Fig.	  5.7C,	  R2=0.0,	  p=0.52	  to	  testosterone,	  Fig.	  5.7D,	  R2=0.0,	  
p=0.50	  to	  INSL3].	  
  






Figure  5.7:  Interaction  of  individual  hormones  to  relative  output  of  
testicular  cells  in  older  men.  
The	  relative	  hormonal	  output	  of	  Leydig	  cells	  is	  depicted	  against	  AMH	  in	  A.	  and	  
InhB	  in	  B.	  Similarly,	  the	  relative	  hormonal	  output	  of	  Sertoli	  cells	  is	  illustrated	  
against	  testosterone	  in	  C.	  and	  INSL3	  in	  D.	  Each	  circle	  represented	  an	  individual	  
from	  the	  older	  men’s	  cohort.	  The	  individual	  hormones	  did	  not	  affect	  the	  relative	  
output	  of	  the	  cell,	  which	  varied	  between	  men.	  	  








5.3.5  Relative  output  of  the  testes  
  
The	  individual	  testicular	  hormonal	  profiles	  and	  its	  interactions	  to	  each	  other	  
were	  largely	  independent	  in	  older	  and	  younger	  men,	  but	  with	  heterogeneity.	  The	  
entire	  testicular	  output	  was	  then	  examined	  in	  older	  and	  younger	  men	  to	  
ascertain	  if	  patterns	  emerge	  across	  the	  entire	  testicular	  output.	  	  
	  
Older	  men	  had	  high	  variability	  in	  their	  total	  testicular	  output.	  However,	  a	  small	  
subgroup	  of	  older	  men	  had	  low	  levels	  of	  AMH,	  InhB	  and	  INSL3	  with	  variability	  in	  
their	  testosterone	  level	  [Fig.	  5.8A].	  A	  smaller	  minority	  of	  older	  men	  had	  
deficiencies	  in	  all	  four	  testicular	  hormones.	  This	  pattern	  was	  observed	  to	  a	  lesser	  
degree	  in	  younger	  men	  [Fig.	  5.8B].	  There	  was	  also	  a	  clear	  absence	  of	  men	  in	  both	  
















Figure  5.8:  The  relative  values  of  all  four  hormones  in  the  same  
individual  are  illustrated  for  younger  men  in  A.  and  older  men  in  B.    
Each	  circle	  represented	  an	  individual.	  The	  relative	  values	  are	  obtained	  by	  
normalising	  the	  individual	  hormonal	  value	  to	  the	  mean	  value	  for	  each	  respective	  
age	  group.	  The	  relative	  value	  for	  INSL3	  is	  shown	  by	  the	  diameter	  of	  the	  circle,	  
whilst	  the	  colour	  temperature	  of	  the	  circle	  depicts	  the	  relative	  value	  for	  InhB.	  
There	  is	  a	  wide	  diversity	  in	  hormonal	  profiles	  in	  both	  younger	  and	  older	  men,	  
with	  a	  minority	  in	  both	  groups	  having	  relatively	  low	  levels	  of	  all	  four	  hormones	  
(lower	  left	  of	  figures,	  small	  circles	  with	  a	  blue	  colour).	  	  






5.4.1  The  four  testicular  hormones  are  independent  to  each  other  
	  
This	  Chapter	  demonstrated	  that	  all	  four	  testicular	  hormones	  are	  independent	  
from	  each	  other,	  in	  both	  young	  and	  older	  men.	  This	  suggests	  that	  the	  regulation	  
and	  functions	  of	  the	  testicular	  hormones	  are	  largely	  distinct,	  and	  lack	  
commonality	  to	  either	  the	  cell	  type	  or	  to	  the	  testes	  as	  a	  gland.	  This	  is	  particularly	  
evident	  with	  INSL3	  that	  showed	  complete	  near	  dissociation	  to	  testosterone	  in	  
younger	  men.	  This	  is	  consistent	  with	  prior	  studies	  of	  Leydig	  hormones	  in	  both	  
healthy	  men	  and	  those	  with	  testicular	  pathologies	  [Chapter	  5.1.2].	  
	  
The	  examination	  of	  the	  testes	  therefore	  requires	  the	  examination	  of	  its	  total	  
output	  of	  all	  four	  hormones,	  as	  Leydig	  cell	  hormones	  and	  Sertoli	  cell	  hormones	  
appear	  to	  be	  distinct	  from	  each	  other.	  It	  is	  likely	  that	  all	  four	  hormones	  reflect	  
different	  aspects	  of	  their	  cellular	  function,	  and	  therefore	  incongruent	  with	  the	  
notion	  that	  any	  single	  hormone	  can	  adequately	  represent	  the	  state	  of	  the	  testes.	  
Consistent	  with	  this	  argument,	  there	  has	  been	  an	  approach	  to	  measure	  all	  four	  
hormones	  for	  pathological	  conditions	  (55,	  219),	  and	  this	  Chapter	  adds	  normality	  
data	  for	  the	  interpretation	  of	  abnormal	  states	  particularly	  in	  the	  older	  male.	  
	  
There	  is	  an	  absence	  of	  correlation	  between	  Leydig	  hormones	  and	  Sertoli	  
hormones,	  as	  well	  as	  the	  effect	  of	  individual	  Leydig	  hormones	  on	  relative	  output	  
of	  Sertoli	  cells,	  and	  vice	  versa.	  This	  challenges	  the	  notion	  that	  testosterone	  
regulates	  Sertoli	  cell	  function	  in	  the	  adult	  [Chapter	  5.1.2]	  which	  would	  require	  a	  
relationship	  between	  hormones	  from	  the	  two	  cell	  types.	  This	  however	  does	  not	  
discount	  the	  possibility	  that	  testosterone	  may	  regulate	  aspects	  of	  Sertoli	  cell	  








5.4.2  Age-­related  association  between  hormones  are  minor  
  
The	  Sertoli	  hormones	  were	  not	  completely	  independent	  to	  each	  other,	  in	  both	  
younger	  and	  older	  men,	  with	  16%	  common	  variance	  between	  the	  two	  hormones,	  
with	  the	  strength	  of	  this	  relationship	  being	  statistically	  unchanged	  in	  older	  men.	  
This	  suggests	  a	  common	  factor	  linking	  between	  the	  two	  hormones	  that	  is	  
invariant	  to	  the	  effect	  of	  ageing,	  with	  Sertoli	  cell	  number	  being	  a	  putative	  
common	  influence.	  
	  
In	  contrast	  to	  Sertoli	  hormones,	  the	  Leydig	  hormones	  showed	  age-­‐‑related	  
coupling	  evident	  by	  a	  small	  association	  in	  older	  men	  but	  not	  in	  younger	  men.	  The	  
association	  appeared	  to	  be	  the	  strongest	  when	  both	  Leydig	  hormones	  are	  low.	  
This	  maybe	  indicative	  of	  a	  critical	  loss	  of	  Leydig	  cells	  which	  crossed	  the	  
threshold	  of	  the	  testes’	  ability	  to	  maintain	  differential	  hormonal	  levels.	  This	  
observation	  requires	  further	  validation	  studies,	  as	  this	  is	  the	  first	  to	  examine	  
total	  Leydig	  cell	  output	  in	  men	  over	  80	  years.	  
  
5.4.3  Total  testicular  output  profiles  are  diverse  between  men  
  
The	  profiles	  of	  the	  total	  testicular	  hormones	  vary	  markedly	  between	  men	  across	  
the	  age	  spectrum.	  This	  is	  the	  first	  study	  to	  examine	  all	  four	  hormones	  in	  healthy	  
adult	  men,	  and	  indicates	  that	  diversity	  exists	  within	  the	  population	  of	  normal	  
men,	  akin	  to	  a	  biometric	  of	  the	  testes.	  A	  minority	  of	  older	  but	  not	  younger	  men	  
exhibited	  deficiencies	  in	  all	  4	  hormones,	  and	  therefore	  have	  a	  global	  dysfunction	  
of	  the	  entire	  endocrine	  testes.	  This	  is	  similar	  to	  all	  women	  following	  menopause	  
who	  have	  near	  cessation	  of	  all	  their	  ovarian	  hormones	  (220).	  
	  
The	  clinical	  features	  of	  men	  with	  pan-­‐‑hypotesticular	  state	  are	  currently	  
unknown.	  However,	  these	  men	  were	  heterogeneous	  in	  their	  health	  status	  and	  
function	  with	  no	  unifying	  symptoms.	  The	  hypogonadal	  state	  of	  all	  
postmenopausal	  women	  may	  shed	  light	  into	  possible	  clinical	  manifestations	  in	  




with	  the	  ageing	  phenotype.	  The	  correlation	  of	  testicular	  hormonal	  profiles	  and	  
aspects	  of	  phenotype	  in	  ageing	  will	  be	  examined	  in	  Chapter	  7.	  
	  
Interestingly,	  there	  was	  a	  clear	  absence	  of	  men	  both	  young	  and	  old	  with	  high	  
levels	  of	  all	  four	  hormones,	  despite	  some	  men	  having	  high	  levels	  of	  single	  
hormones.	  The	  significance	  of	  this	  is	  unclear,	  but	  may	  indicate	  that	  possession	  of	  
a	  pan-­‐‑hypertesticular	  state	  is	  not	  conducive	  to	  evolutionary	  fitness.	  
  
5.4.4  Testosterone  is  preserved  in  some  older  men  
  
There	  was	  a	  subgroup	  of	  older	  men	  with	  low	  levels	  of	  AMH,	  InhB	  and	  INSL3	  that	  
more	  consistently	  associated	  with	  each	  other.	  The	  testosterone	  levels	  in	  these	  
men	  were	  variable.	  One	  possibility	  is	  that	  with	  ageing	  or	  in	  hypogonadism,	  
changes	  in	  the	  protein	  hormones	  are	  occurring	  prior	  to	  changes	  in	  the	  steroid	  
hormones.	  This	  is	  observed	  in	  women	  undergoing	  the	  menopausal	  transition,	  
where	  the	  loss	  of	  AMH	  and	  inhibins	  preceded	  the	  decline	  in	  oestrogen	  by	  a	  
number	  of	  years	  (74,	  221).	  It	  is	  further	  postulated	  that	  gonadal	  steroidal	  
hormones	  can	  be	  dysregulated	  when	  the	  endocrine	  function	  of	  the	  gonad	  is	  
impaired,	  as	  seen	  in	  menopausal	  women	  who	  exhibits	  fluctuations	  in	  their	  
oestrogen	  levels	  (222),	  and	  suggested	  in	  the	  testosterone	  data	  presented	  in	  this	  
Chapter.	  The	  hormonal	  state	  of	  the	  testes	  has	  historically	  been	  defined	  by	  the	  
level	  of	  testosterone.	  The	  data	  is	  incongruent	  with	  this	  premise,	  as	  low	  levels	  of	  
other	  three	  testicular	  hormones	  are	  not	  consistently	  associated	  with	  low	  
testosterone	  level,	  and	  low	  testosterone	  not	  consistently	  linked	  with	  low	  levels	  
of	  other	  hormones,	  thereby	  limiting	  the	  predictive	  value	  of	  low	  testosterone	  as	  a	  
strong	  biomarker	  for	  global	  hypogonadism.	    
  
5.4.5  Age-­related  decline  in  Leydig  hormones  
  
INSL3	  exhibited	  age	  related	  decline	  with	  high	  variability	  between	  men.	  This	  was	  
consistent	  with	  the	  only	  other	  study	  on	  adult	  lifespan	  of	  INSL3	  (134),	  and	  




environmental	  influences.	  The	  wide	  spread	  of	  INSL3	  values	  in	  the	  Otago	  cohort	  is	  
also	  observed	  in	  the	  Australian	  cohort	  by	  Anend-­‐‑Ivell	  et	  al.	  This	  Chapter	  
extended	  the	  finding	  from	  Anend-­‐‑Ivell	  et	  al	  (134)	  from	  men	  younger	  than	  30,	  
and	  those	  over	  80	  years.	  Testosterone	  on	  average	  declined	  at	  an	  earlier	  age	  than	  
the	  other	  three	  hormones,	  with	  this	  being	  seen	  in	  some	  epidemiological	  studies	  
[Chapter	  5.1.1].	  	  
  
5.4.6  Limitations  of  study  
  
This	  study	  is	  a	  cross-­‐‑sectional	  study,	  and	  therefore	  could	  not	  exclude	  secular	  
changes	  as	  discussed	  in	  Chapter	  4.4.4.	  The	  sample	  size	  was	  sufficiency	  to	  detect	  
statistically	  significant	  differences	  between	  younger	  and	  older	  men,	  with	  subtle	  
age-­‐‑related	  effects	  requiring	  a	  much	  larger	  sample	  size	  typical	  of	  epidemiological	  
studies	  of	  testosterone.	  Furthermore,	  the	  intention	  of	  this	  study	  was	  to	  examine	  
for	  any	  differences	  between	  older	  and	  younger	  men,	  and	  showed	  a	  clear	  
difference	  between	  the	  two	  groups.	  This	  study	  did	  not	  endeavour	  to	  profile	  the	  
entire	  age	  range,	  and	  therefore	  lacked	  a	  robust	  enough	  sample	  size	  in	  the	  
middle-­‐‑aged	  group.	  
	  
Gonadotropins	  were	  not	  measured	  in	  this	  study,	  as	  the	  cross-­‐‑sectional	  design	  
was	  unable	  to	  account	  for	  the	  ultradian	  fluctuations	  of	  gonadotropin	  levels.	  
Consequently,	  there	  is	  lack	  of	  consistent	  statistical	  correlation	  between	  
gonadotropins	  and	  testicular	  hormones	  in	  epidemiological	  studies	  of	  similar	  
nature	  (134,	  177,	  178,	  223).	  	  
	  
It	  was	  observed	  that	  for	  three	  out	  of	  four	  hormones,	  the	  distribution	  of	  the	  
hormones	  was	  positively	  skewed	  rather	  than	  normally	  distributed,	  in	  both	  
younger	  and	  older	  men.	  This	  requires	  caution	  in	  the	  utility	  of	  a	  normative	  
reference	  range,	  which	  is	  usually	  generated	  by	  taking	  the	  middle	  95th	  centile	  
values	  from	  a	  reference	  population	  group.	  






The	  four	  testicular	  hormones	  AMH,	  InhB,	  testosterone	  and	  INSL3	  have	  
independent	  circulating	  profiles	  in	  men,	  both	  in	  the	  young	  and	  in	  the	  elderly.	  
This	  results	  in	  a	  total	  testicular	  output	  that	  is	  highly	  variable	  between	  men,	  and	  
suggest	  that	  the	  testes	  are	  a	  complex	  endocrine	  organ	  with	  multiple	  hormones	  
that	  is	  independently	  regulated	  and	  serves	  different	  functions.	  This	  is	  analogous	  
to	  the	  anterior	  pituitary	  gland	  that	  likewise	  has	  independent	  hormonal	  output.	  
	  
Older	  men	  have	  on	  average	  lower	  levels	  of	  all	  four	  testicular	  hormones,	  with	  this	  
being	  highly	  variable	  amongst	  older	  men.	  The	  independence	  of	  all	  four	  
hormones,	  and	  lack	  of	  strong	  association	  particularly	  at	  low	  levels	  suggest	  that	  
hypogonadism	  can	  be	  classified	  into	  subclasses	  with	  deficiencies	  in	  different	  
hormones	  reflecting	  different	  pathologies.	  Only	  a	  minority	  of	  older	  men	  exhibit	  a	  
globally	  low	  testicular	  output	  state,	  analogous	  to	  a	  pan-­‐‑hypopituitarism	  and	  to	  
all	  postmenopausal	  women.	  The	  significance	  of	  low	  levels	  of	  each	  hormone	  and	  
their	  combinations	  will	  be	  explored	  in	  Chapter	  7.	  












Chapter  6:    




The	  circulating	  level	  of	  AMH	  has	  been	  described	  in	  Chapter	  4,	  and	  varies	  
between	  men.	  The	  absolute	  difference	  in	  variation	  however	  is	  relatively	  small	  in	  
comparison	  to	  the	  decrease	  in	  AMH	  levels	  typically	  found	  in	  boys	  prior	  to	  
puberty	  (41).	  The	  assumption	  is	  that	  the	  AMH	  being	  reported	  is	  a	  single	  entity.	  
Recently,	  proAMH	  has	  been	  detected	  in	  blood	  (90),	  and	  the	  current	  leading	  
commercial	  ELISA	  for	  AMH	  reports	  a	  composite	  of	  both	  proAMH	  and	  the	  cleaved	  
form,	  AMHN,C,	  which	  is	  defined	  as	  total	  AMH	  by	  my	  research	  group	  (224)1.	  
Consequently,	  total	  AMH	  lacks	  the	  ability	  to	  discriminate	  between	  proAMH	  and	  
the	  receptor-­‐‑competent	  cleaved	  form.	  There	  has	  been	  emerging	  interest	  that	  
prohormones,	  and	  its	  cleavage	  extent,	  may	  exhibit	  functional	  significance	  or	  act	  
as	  biomarkers	  [Chapter	  1.6.1].	  Recently,	  my	  laboratory	  group	  has	  developed	  an	  
ELISA	  which	  allows	  the	  ability	  to	  quantify	  the	  amount	  of	  proAMH	  in	  blood,	  and	  
by	  deduction	  from	  total	  AMH,	  the	  cleaved	  AMHN,C	  can	  be	  calculated	  (129).	  A	  
calculated	  ratio	  of	  cleavage	  extent	  has	  also	  been	  introduced	  as	  the	  API	  (AMH	  
prohormone	  index),	  which	  describes	  the	  proportion	  of	  proAMH	  to	  total	  AMH	  
(224).	  This	  Chapter	  will	  profile	  the	  circulating	  levels	  of	  proAMH,	  AMHN,C	  and	  the	  
API	  in	  males,	  with	  a	  focus	  on	  the	  comparison	  between	  boys	  and	  men.	  
  
     
                                                                                                
1  This	  paper	  contains	  data	  from	  this	  Chapter.	  	  The	  citation	  relates	  to	  information	  




6.1.1  Cleavage  of  proAMH  occurs  in  testes  
	  
Like	  all	  members	  of	  the	  TGFβ	  superfamily,	  AMH	  is	  initially	  synthesised	  as	  
preproAMH.	  The	  signal	  peptide	  is	  cleaved	  intracellularly,	  resulting	  in	  the	  
formation	  of	  proAMH	  (225).	  Cleavage	  of	  proAMH	  yields	  a	  C-­‐‑terminal	  component,	  
and	  a	  N-­‐‑terminal	  component,	  which	  remains	  non-­‐‑covalently	  bounded	  (89).	  
Cleavage	  of	  proAMH	  is	  thought	  to	  occur	  within	  the	  testes,	  based	  on	  a	  series	  of	  
experiments	  from	  my	  laboratory	  group	  (Pankhurst	  and	  McLennan,	  personal	  
communication).	  First,	  recombinant	  human	  proAMH	  protein	  is	  not	  cleaved	  when	  
incubated	  in	  serum.	  Secondly,	  intravenous	  injection	  of	  recombinant	  human	  
proAMH	  into	  mice	  do	  not	  result	  in	  an	  accumulation	  of	  human	  recombinant	  
AMHN,C.	  The	  transgenic	  mice	  that	  do	  express	  recombinant	  human	  AMH	  
endogenously	  are	  able	  to	  cleave	  proAMH	  to	  AMHN,C.	  As	  AMHN,C	  is	  AMHR2-­‐‑
competent	  form	  of	  AMH,	  this	  raises	  the	  possibility	  that	  the	  bioactivity	  of	  AMH	  in	  
blood	  is	  regulated	  by	  a	  testicular	  hormone,	  and	  the	  need	  to	  correlate	  the	  extent	  
of	  cleavage	  of	  proAMH	  to	  the	  testicular	  hormones,	  including	  AMH	  itself.	  
  
6.1.2  Putative  cleavage  enzymes  of  proAMH  
	  
Several	  putative	  members	  of	  proconvertase	  enzymes	  are	  candidates	  to	  elicit	  
cleavage	  of	  proAMH.	  This	  includes	  the	  proprotein	  convertases	  of	  
subtilisin/kexin-­‐‑type	  (PCSK),	  notably	  furin	  (PCSK3),	  PCSK5	  and	  PCSK6	  (226).	  
Plasmin	  is	  also	  able	  to	  cleave	  proAMH	  resulting	  in	  a	  bioactive	  form	  (227).	  The	  
actions	  of	  the	  PCSKs	  are	  broad,	  as	  they	  cleave	  multiple	  proproteins	  (228,	  229).	  
The	  expression	  and	  the	  activation	  of	  plasmin	  and	  the	  PCSKs	  are	  subject	  to	  
complex	  regulation	  (229,	  230),	  and	  therefore	  the	  extent	  of	  AMH	  cleavage	  (API)	  
may	  act	  as	  a	  biomarker	  to	  inform	  about	  certain	  states	  of	  the	  body.	  PCSK4	  is	  
expressed	  by	  germ	  cells,	  and	  mice	  with	  loss	  of	  function	  mutation	  of	  PCSK4	  are	  
infertile	  (231).	  Furin	  is	  an	  important	  PCSK	  responsible	  for	  the	  cleavage	  of	  
multiple	  members	  of	  the	  TGFβ	  superfamily	  (228).	  Furin	  can	  cleave	  proTGFβ,	  and	  
the	  active	  TGFβ	  itself	  can	  up-­‐‑regulate	  furin	  activity	  resulting	  in	  a	  positive	  
feedback	  loop	  (232).	  This	  has	  been	  advocated	  to	  contribute	  to	  the	  pathogenesis	  




potential	  therapeutic	  target	  (234).	  Another	  PCSK	  enzyme,	  PCSK9	  is	  now	  the	  most	  
topical	  therapeutic	  marker	  in	  the	  clinical	  management	  of	  lipid	  disorders	  in	  
clinical	  endocrinology	  (235),	  highlighting	  the	  emerging	  importance	  of	  
consideration	  of	  cleavage	  activities	  of	  proproteins.	  
  
6.1.3  Objectives  of  study  
  
The	  aims	  of	  this	  Chapter	  is	  to	  describe	  the	  profiles	  of	  circulating	  proAMH,	  its	  
cleaved	  form	  (AMHN,C)	  and	  the	  extent	  of	  AMH	  cleavage	  (API)	  in	  males.	  The	  
determination	  of	  these	  AMH	  species	  and	  API	  between	  boys,	  young	  men,	  and	  
older	  men	  may	  reflect	  differences	  in	  the	  physiology	  of	  these	  three	  cohorts.	  The	  
API	  will	  also	  be	  correlated	  to	  the	  four	  testicular	  hormones,	  including	  circulating	  
AMH	  level	  itself,	  to	  determine	  if	  testicular	  hormones	  regulate	  cleavage	  of	  
proAMH.	  	  
  






The	  data	  from	  this	  Chapter	  were	  derived	  from	  the	  analyses	  of	  hormonal	  assays	  
obtained	  from	  the	  participants	  in	  the	  Otago	  cohort	  [Chapter	  4A.2].	  The	  proAMH	  
assay	  is	  described	  in	  Chapter	  2.	  A	  total	  of	  201	  men’s	  serum	  was	  available	  to	  be	  
assayed	  for	  their	  proAMH,	  leaving	  33	  men	  without	  data	  for	  proAMH.	  32	  out	  of	  
the	  33	  men	  from	  this	  cohort	  were	  of	  the	  younger	  men’s	  subset,	  with	  the	  
remaining	  individual	  being	  older	  then	  70.	  All	  of	  the	  men	  with	  their	  proAMH	  not	  
assayed	  had	  detectable	  total	  AMH	  levels.	  
	  
API	  was	  calculated	  for	  men	  with	  detectable	  levels	  of	  both	  total	  and	  proAMH.	  Men	  
with	  total	  AMH	  levels	  less	  than	  1.2	  pM,	  and	  proAMH	  values	  less	  than	  1	  pM	  were	  
excluded	  from	  the	  analyses	  of	  API,	  as	  the	  variance	  in	  their	  low	  levels	  would	  
result	  in	  loss	  of	  accuracy	  for	  the	  calculation	  of	  API.	  










6.3.1  Description  of  the  precursor  and  active  AMH  forms,  cleavage  activity  
across  lifespan  
  
6.3.1A  Younger  men  
  
The	  level	  of	  proAMH	  was	  highly	  variable	  in	  men	  younger	  than	  50	  years	  [Fig.	  6.1B	  
and	  Table	  6.1],	  with	  a	  distribution	  that	  was	  positively	  skewed	  (SK	  test	  2.6,	  
p<0.0001).	  All	  younger	  men	  had	  detectable	  levels	  of	  proAMH,	  with	  the	  lowest	  
recorded	  level	  being	  2.1	  pM.	  The	  profiles	  for	  AMHN,C	  appeared	  similar	  to	  
proAMH,	  and	  both	  mirrored	  the	  distribution	  for	  total	  AMH	  [Fig.	  6.1A-­‐‑C].	  The	  
marker	  of	  cleavage	  activity	  API	  was	  distributed	  across	  a	  narrow	  range	  (11-­‐‑25%),	  
and	  lacked	  any	  correlation	  to	  age	  in	  younger	  men	  [Fig.	  6.1D,	  R2=0.01,	  p=0.50	  
Pearson	  linear	  regression].	  
  







Figure  6.1:  The  levels  of  circulating  AMH  species  and  API  in  the  Otago  
cross-­sectional  cohort  from  19  –  90  years.  	  
Each	  circle	  represents	  an	  individual’s	  value	  for	  A.	  AMH,	  B.	  proAMH,	  C.	  AMHN,C	  
and	  D.	  API.	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Table  6.1  Characteristics  of  circulating  AMH  species  and  the  API  in  the  Otago  cohort  of  men  from  19  –  90  years.  79  men  
were  aged  under  50  years  (mean  age  40.2  years),  whilst  98  men  were  aged  at  least  70  years  (mean  age  78.2  years).    
	   Total	  AMH	  (pM)	   proAMH	  (pM)	   AMHN,C	  (pM)	   API	  (%)	  
Age	  group	   <50	  years	   >70	  years	   <50	  years	   >70	  years	  
	  
<50	  years	   >70	  
years	  



































Young	  vs	  older	  men	  















6.3.1B  Older  men  
  
Men	  aged	  70	  years	  and	  older	  had	  significantly	  lower	  average	  values	  of	  proAMH	  
compared	  to	  younger	  men	  [Fig.	  6.1B	  and	  Table	  6.1,	  4.5	  pM	  compared	  to	  7.7	  pM,	  
p<0.0001	  Student’s	  t-­‐‑	  test).	  In	  contrast	  to	  younger	  men,	  in	  this	  older	  men	  cohort	  
there	  were	  10%	  of	  men	  with	  undetectable	  levels	  of	  proAMH	  (1	  pM).	  Older	  men	  
who	  lacked	  proAMH	  had	  lower	  levels	  of	  total	  AMH	  and	  AMHN,C	  when	  compared	  
to	  those	  with	  detectable	  levels	  of	  AMH	  (p<0.0001	  for	  both	  with	  Mann-­‐‑Whitney	  U	  
test).	  However,	  there	  was	  no	  difference	  with	  regards	  to	  age	  between	  the	  two	  
groups	  (p=0.21	  Mann-­‐‑Whitney	  U	  test).	  Only	  half	  of	  the	  men	  with	  undetectable	  
proAMH	  level	  had	  concurrent	  undetectable	  total	  AMH,	  with	  the	  remainder	  being	  
low	  (range	  1.3	  -­‐‑	  5.6	  pM).	  The	  mean	  levels	  of	  AMHN,C	  were	  also	  significantly	  lower	  
in	  older	  men	  than	  younger	  men	  (p<0.0001).	  The	  API	  in	  older	  men	  varied	  within	  a	  
narrow	  range,	  and	  on	  average	  was	  no	  different	  to	  those	  of	  younger	  men	  [Table	  
6.1,	  p=0.64	  student’s	  t	  test].	  However,	  in	  a	  minority	  of	  men	  (5%),	  the	  API	  is	  
significantly	  higher.	  These	  elevated	  API	  were	  associated	  with	  low	  total	  AMH	  
levels	  [Fig.	  6.4A,	  average	  total	  AMH	  level	  5.2	  pM).	  
  




6.3.2  Relationship  between  proAMH  and  AMHN,C  
  
ProAMH	  was	  strongly	  associated	  to	  total	  AMH	  levels	  (R2	  =0.92,	  p<0.0001	  
Pearson	  linear	  regression)	  across	  the	  spectrum	  of	  total	  AMH	  levels	  in	  the	  entire	  
cohort	  [Fig.	  6.2A].	  The	  relationship	  between	  proAMH	  and	  AMHN,C	  was	  strong	  but	  
not	  complete	  (R2=0.88,	  p<0.0001),	  indicating	  12%	  variation	  between	  the	  two	  
AMH	  species	  in	  circulation.	  
  









Figure  6.2:  The  relationship  between  the  circulating  AMH  species  are  
shown  for  men  in  the  Otago  cohort  from  19  –  90  years.    
Each	  circle	  represents	  an	  individual’s	  value.	  ProAMH	  is	  correlated	  to	  both	  total	  A.	  
AMH	  and	  B.	  AMHN,C	  with	  statistical	  significance.	  	  




6.3.3  Relationship  between  AMHN,C  and  testicular  hormones  
	  
The	  level	  of	  AMHN,C	  was	  highly	  correlated	  to	  total	  AMH	  across	  a	  wide	  range	  of	  
AMH	  values,	  indicating	  that	  total	  AMH	  is	  representative	  of	  AMHN,C	  values	  [Fig.	  
6.3A].	  AMHN,C	  levels	  partially	  correlated	  with	  InhB	  levels	  [Fig.	  6.3B,	  R2=0.25,	  
p<0.0001],	  as	  expected	  with	  the	  partial	  relationship	  already	  known	  between	  
total	  AMH	  and	  InhB	  [Chapter	  4].	  There	  was	  near	  complete	  dissociation	  between	  
AMHN,C	  and	  the	  individual	  Leydig	  hormones	  [Fig.	  6.3C	  and	  D].	  	  
  








Figure  6.3:  The  relationship  between  circulating  AMHN,C  and  individual  
testicular  hormones  are  depicted  for  men  in  the  Otago  cohort  from  19  –  
90  years.    
Each	  circle	  represents	  an	  individual’s	  value.	  AMHN,C	  correlated	  to	  A.	  total	  AMH	  





6.3.4  Relationship  between  API  and  testicular  hormones  
  
The	  extent	  of	  cleavage	  of	  AMH	  was	  independent	  to	  the	  total	  AMH	  concentration,	  
in	  younger	  men	  [Fig.	  6.4A,	  R2=0.01,	  p=0.32].	  The	  API	  was	  also	  independent	  to	  the	  
levels	  of	  the	  other	  three	  testicular	  hormones	  [Fig.	  6.4B-­‐‑D].	  	  
	  
The	  API	  was	  largely	  invariant	  to	  the	  four	  testicular	  hormones	  in	  older	  men,	  
similar	  to	  that	  found	  in	  younger	  men,	  but	  with	  some	  important	  differences.	  
There	  was	  an	  emergence	  of	  a	  weak	  negative	  relationship	  between	  API	  and	  total	  
AMH	  level	  in	  older	  men	  [Fig.	  6.5A,	  R2=13%,	  p=0.0003],	  which	  was	  not	  observed	  
in	  younger	  men.	  Secondly,	  there	  was	  a	  minority	  of	  men	  with	  elevated	  values	  of	  
API,	  all	  occurring	  at	  low	  values	  of	  total	  AMH.	  API	  remained	  independent	  to	  the	  
levels	  of	  the	  other	  three	  testicular	  hormones	  in	  older	  men	  [Fig.	  6.5B-­‐‑D],	  
mirroring	  the	  finding	  in	  younger	  men.	  	  
  







Figure  6.4:	  The  relationship  between  API  and  individual  circulating  
testicular  hormones  are  depicted  for  the  younger  men  in  the  Otago  
cohort  from  19  –  50  years.    
Each	  circle	  represents	  an	  individual’s	  value.	  The	  API	  was	  independent	  to	  all	  four	  
testicular	  hormones	  in	  blood	  of	  younger	  men.	  	  







Figure  6.5:  The  relationship  between  API  and  individual  circulating  
testicular  hormones  in  older  men  70  years  and  older  in  the  Otago  
cohort.    
Each	  circle	  represents	  an	  individual’s	  value.	  There	  was	  a	  weak	  relationship	  to	  
total	  AMH,	  but	  API	  is	  independent	  to	  InhB,	  testosterone	  and	  INSL3.	  	  








6.3.5  API  is  distinct  between  boys  and  men  
  
The	  level	  of	  total	  AMH	  is	  known	  to	  be	  an	  order	  of	  magnitude	  higher	  in	  
prepubescent	  boys	  compared	  to	  men	  [Chapter	  1.5.2	  and	  Fig.	  6.6A].	  Circulating	  
proAMH	  levels	  showed	  similar	  difference	  between	  boys	  and	  men	  [Fig.	  6.6B].	  The	  
cleavage	  activity	  of	  AMH	  for	  men	  described	  above	  is	  therefore	  compared	  to	  the	  
data	  of	  API	  of	  boys	  that	  were	  collected	  by	  my	  laboratory	  group	  (with	  permission	  
to	  reproduce	  data	  here).	  The	  mean	  API	  for	  boys	  was	  nearly	  double	  that	  of	  
younger	  men	  (33.0	  compared	  to	  18.2,	  p<0.0001)	  and	  to	  older	  men	  (33	  compared	  
to	  17.9,	  p<0.0001).	  There	  was	  no	  overlap	  in	  the	  ranges	  of	  the	  API	  between	  boys	  
and	  younger	  men,	  as	  well	  as	  the	  majority	  of	  older	  men	  [Fig.	  6.6C].	  The	  minority	  


























Figure  6.6:  Circulating  total  AMH,  proAMH  and  API  are  compared  
between  a  cohort  of  prepubertal  boys  and  adult  males  from  the  Otago  
cohort.    
Men	  have	  approximately	  10%	  of	  values	  of	  total	  AMH	  and	  proAMH	  compared	  to	  
boys.	  The	  API	  values	  for	  men	  are	  distinct	  to	  those	  in	  boys.	  	  






6.4.1  First  description  of  normative  range  for  AMH  
  
This	  is	  the	  first	  quantitative	  description	  of	  the	  cleavage	  of	  circulating	  AMH	  in	  
men.	  	  It	  defines	  the	  physiological	  range	  for	  both	  proAMH	  and	  AMHN,C	  in	  the	  
serum	  and	  provides	  insight	  into	  the	  regulation	  of	  AMH	  physiology.	  The	  
normative	  data	  provides	  a	  reference	  range	  for	  both	  proAMH	  and	  AMHN,C,	  in	  
order	  to	  guide	  observational	  studies	  correlating	  AMH	  levels	  and	  clinical	  
conditions.	  This	  can	  form	  the	  first	  basis	  for	  possible	  utility	  of	  AMH	  as	  a	  
biomarker	  for	  clinical	  diagnosis.	  Similarly,	  the	  state	  of	  the	  cleavage	  may	  be	  
informative	  about	  the	  nature	  of	  pathology.	  Some	  older	  men	  with	  low	  AMH	  levels	  
have	  higher	  API	  values,	  approaching	  that	  typically	  found	  in	  boys.	  This	  suggests	  
that	  for	  these	  men	  with	  variable	  health	  status,	  the	  emergence	  of	  pathology	  may	  
lead	  to	  less	  efficient	  cleavage	  of	  proAMH.	  The	  clinical	  significance	  of	  disorders	  of	  
protease	  activities	  such	  as	  furin	  and	  corin	  in	  their	  cleavage	  of	  pro-­‐‑BNP	  and	  pro-­‐‑
ANP	  levels	  have	  led	  to	  formation	  of	  diseases	  such	  as	  salt	  retaining	  hypertension	  
and	  heart	  failure	  (236-­‐‑238).	  This	  gives	  rise	  to	  the	  need	  to	  examine	  API	  level	  as	  a	  
marker	  of	  cleavage	  activities	  in	  pathological	  states	  and	  correlating	  with	  
functional	  traits.	  	  
  
6.4.2  Regulation  of  cleavage  of  AMH  
  
The	  source	  of	  circulating	  AMHN,C	  is	  putatively	  derived	  from	  intratesticular	  
cleavage	  of	  proAMH	  [Chapter	  6.1.1].	  This	  raises	  the	  possibility	  that	  the	  cleavage	  
of	  proAMH	  in	  the	  testes	  is	  influenced	  by	  one	  of	  the	  classical	  regulators	  of	  the	  
testes	  (LH,	  FSH)	  or	  by	  one	  the	  testicular	  hormones.	  	  If	  so,	  then	  the	  API	  index	  
should	  associate	  with	  the	  circulating	  levels	  of	  one	  or	  more	  of	  the	  testicular	  
hormones.	  	  Consequently,	  the	  absence	  of	  any	  association	  between	  the	  API	  and	  
circulating	  hormone	  levels	  in	  health	  men	  suggests	  that	  the	  post-­‐‑translational	  
regulation	  of	  AMH	  is	  via	  some	  other	  regulatory	  influence.	  	  This	  argument	  




accurate	  biomarker	  for	  the	  level	  of	  the	  hormone	  adjacent	  to	  Sertoli	  cells.	  	  The	  
levels	  of	  hormones	  within	  the	  testes	  are	  higher	  than	  in	  the	  circulation	  (32,	  147),	  
with	  their	  intratesticular	  influence	  modulated	  by	  factors	  such	  as	  binding	  
proteins	  (239).	  	  These	  factors	  may	  degrade	  the	  relationship	  between	  the	  
testicular	  hormones	  and	  the	  API,	  but	  would	  not	  be	  expect	  to	  entirely	  extinguish	  
it,	  if	  the	  testicular	  hormone(s)	  were	  a	  major	  regulator.	  	  The	  role	  of	  testicular	  
hormones	  needs	  to	  be	  examined	  by	  other	  experiments,	  but	  the	  current	  data	  
indicates	  that	  other	  avenues	  of	  enquiry	  should	  be	  a	  higher	  priority.	  
	  
Clues	  regarding	  regulation	  of	  cleavage	  of	  AMH	  maybe	  derived	  from	  the	  
consideration	  of	  the	  fundamental	  differences	  between	  boys	  and	  men,	  as	  men	  
have	  more	  effective	  cleavage	  of	  their	  AMH	  than	  boys,	  with	  no	  overlap	  between	  
the	  two	  life	  stages.	  Men	  but	  not	  boys	  undergo	  spermatogenesis,	  and	  one	  
possibility	  is	  that	  the	  cleavage	  of	  AMH	  may	  reflect	  the	  state	  of	  spermatogenesis	  
in	  a	  male.	  This	  points	  to	  the	  need	  to	  examine	  conditions	  in	  men	  with	  impaired	  
spermatogenesis,	  such	  as	  Sertoli	  cell	  only	  syndrome	  and	  non-­‐‑obstructive	  
azoospermia.	  The	  testicular	  hormonal	  profiles	  in	  boys	  are	  also	  distinct	  to	  that	  in	  
men,	  typically	  with	  high	  total	  AMH,	  near	  undetectable	  testosterone,	  low	  INSL3	  
and	  diminished	  InhB	  level.	  This	  raises	  the	  possibility	  that	  the	  intratesticular	  
environment	  may	  regulate	  the	  cleavage	  of	  AMH	  as	  evident	  by	  the	  large	  scale	  of	  
difference	  between	  boys	  and	  men,	  which	  is	  not	  evident	  when	  examining	  smaller	  
magnitude	  of	  difference	  between	  individuals.	  	  
  
6.4.3  Technical  issue  
  
The	  API	  is	  a	  ratio	  of	  values	  derived	  from	  two	  hormonal	  assays.	  Some	  of	  the	  
variation	  between	  individuals	  might	  arise	  from	  the	  assay	  variations	  inherent	  in	  
ELISAs.	  However,	  this	  is	  not	  large	  enough	  to	  account	  for	  the	  significant	  variation	  
of	  API	  between	  boys	  and	  men,	  suggesting	  real	  biological	  association.	  The	  
coefficient	  of	  variation	  in	  API	  is	  of	  similar	  magnitude	  to	  that	  found	  when	  
examining	  ratio	  of	  the	  two	  Sertoli	  hormones	  or	  two	  Leydig	  hormones,	  further	  






Normative	  data	  for	  proAMH,	  AMHN,C	  and	  its	  cleavage	  activity	  has	  been	  defined	  
for	  a	  group	  of	  healthy	  men,	  and	  provides	  the	  basis	  for	  the	  next	  Chapter	  to	  
examine	  physical	  traits	  in	  older	  men	  with	  varying	  clinical	  conditions,	  in	  order	  to	  
elucidate	  any	  functional	  role	  for	  AMH.	  The	  regulation	  of	  cleavage	  is	  not	  
significantly	  determined	  by	  the	  circulating	  testicular	  hormonal	  levels	  but	  
showed	  distinct	  differences	  between	  boys	  and	  men	  that	  suggest	  the	  possibility	  of	  
API	  reflecting	  the	  state	  of	  maturation	  of	  the	  testes.	  This	  will	  be	  of	  relevance	  in	  
the	  next	  Chapter	  to	  examine	  whether	  de-­‐‑differentiation	  of	  the	  testes	  is	  a	  













AMH  and  frailty  in  the  older  





The	  objective	  of	  this	  thesis	  is	  to	  advance	  the	  premise	  that	  circulating	  AMH	  has	  
functional	  significance	  in	  men.	  At	  the	  commencement	  of	  the	  PhD,	  there	  were	  no	  
substantial	  indication	  as	  to	  where	  AMH	  might	  have	  function	  in	  adults,	  or	  
whether	  AMH	  is	  detectable	  or	  even	  varies	  between	  men.	  AMH	  may	  putatively	  act	  
like	  a	  BMP	  ligand,	  and	  therefore	  AMH	  might	  have	  broad	  functions	  [Chapter	  
1.6.2].	  Furthermore,	  the	  common	  intracellular	  signalling	  cascade	  that	  AMH	  
shares	  with	  the	  BMP	  subgroup	  indicates	  that	  AMH	  function	  may	  be	  cryptic,	  and	  
only	  observed	  in	  conditions	  where	  there	  are	  multiple	  dysfunctions	  in	  the	  
regulation	  of	  similar	  functions	  [Chapter	  1.4].	  This	  is	  most	  likely	  to	  occur	  in	  an	  
ageing	  male,	  particularly	  in	  those	  with	  frailty.	  Consequently,	  this	  PhD	  has	  
embarked	  on	  a	  pilot	  study	  to	  determine	  the	  feasibility	  of	  screening	  for	  
correlation	  between	  circulating	  AMH	  levels	  in	  a	  cohort	  of	  older	  men	  with	  
heterogenous	  functions.	  Despite	  the	  sequential	  nature	  of	  the	  thesis,	  the	  study	  
performed	  in	  this	  Chapter	  was	  conducted	  concurrently	  to	  the	  determination	  of	  
AMH	  and	  other	  testicular	  hormones	  in	  blood.	  Hence	  there	  is	  no	  a	  priori	  
hypothesis	  as	  to	  the	  relationship	  between	  AMH	  and	  functional	  traits	  in	  the	  older	  




determined,	  as	  the	  coefficient	  of	  variation	  for	  AMH	  in	  the	  older	  male	  was	  
unknown.	  	  
  
7.1.1  The  endocrine  system  in  ageing  
  
Many	  endocrine	  systems	  in	  the	  older	  person	  exhibit	  age-­‐‑related	  changes.	  Only	  
one	  system	  showed	  an	  universal	  cessation	  of	  function	  –	  that	  of	  the	  female	  
reproductive	  system	  with	  menopause.	  This	  has	  been	  associated	  with	  pathology	  
not	  otherwise	  seen	  in	  the	  younger	  women,	  and	  provides	  clues	  as	  to	  the	  
functional	  significance	  of	  ovarian	  hormones,	  including	  gamete	  production,	  the	  
maintenance	  of	  the	  female	  phenotype,	  bone	  metabolism,	  and	  cardiovascular	  
disease	  (240-­‐‑244).	  This	  PhD	  study	  on	  circulating	  AMH	  have	  shown	  that	  this	  
cessation	  of	  ovarian	  AMH	  production	  is	  permanent	  in	  women	  [Chapter	  4B.3],	  
and	  that	  some	  older	  men	  also	  exhibit	  complete	  loss	  of	  testicular	  hormonal	  
output	  [Chapter	  5.3.5].	  
	  
In	  most	  other	  systems,	  hormone	  levels	  on	  average	  are	  lower	  in	  the	  older	  person	  
than	  amongst	  younger	  people.	  The	  true	  significance	  of	  this	  is	  debated.	  Not	  all	  
older	  people	  manifest	  symptoms	  or	  pathology	  commonly	  attributed	  to	  the	  
deficiency	  of	  a	  particular	  hormone,	  which	  would	  be	  more	  frequently	  seen	  in	  the	  
younger	  person.	  The	  growth	  hormone	  axis	  is	  a	  classical	  example	  of	  this.	  Growth	  
hormone	  deficiency	  can	  result	  in	  short	  stature	  in	  children	  (245),	  and	  in	  younger	  
adults	  is	  associated	  with	  osteopenia,	  poor	  quality	  of	  life	  and	  changes	  to	  body	  
composition	  (246-­‐‑248).	  Absolute	  circulating	  growth	  hormone	  level	  and	  its	  
surrogate	  marker	  insulin-­‐‑like	  growth	  factor-­‐‑1	  (IGF-­‐‑1)	  are	  lower	  on	  average	  in	  
the	  older	  person	  than	  in	  the	  young.	  There	  is	  inconsistent	  association	  to	  
symptoms	  in	  the	  older	  group	  (249,	  250).	  This	  age-­‐‑related	  change	  may	  be	  an	  
adaptive	  response	  for	  survival,	  as	  normalisation	  of	  growth	  hormone	  level	  to	  a	  
younger	  person’s	  range	  increases	  the	  risk	  of	  diseases	  such	  as	  tumour	  growth	  and	  
development	  of	  diabetes	  mellitus	  (251,	  252).	  Consequently,	  the	  normative	  range	  
for	  growth	  hormone	  level	  is	  age-­‐‑adjusted	  in	  clinical	  practice	  (253).	  	  
  




7.1.2  Late  onset  hypogonadism  
  
Circulating	  testosterone	  level	  on	  average	  declines	  with	  ageing	  [Chapter	  5.1.1	  and	  
5.3.2A].	  Low	  levels	  of	  testosterone	  in	  younger	  men	  results	  in	  overt	  pathology	  of	  
hypogonadism	  related	  to	  the	  loss	  of	  maintenance	  of	  the	  male	  phenotype.	  In	  older	  
men,	  the	  association	  is	  less	  clear.	  This	  is	  akin	  to	  the	  situation	  to	  growth	  hormone	  
with	  ageing.	  Low	  testosterone	  level	  in	  the	  older	  person	  have	  been	  associated	  to	  a	  
number	  of	  different	  conditions,	  ranging	  from	  sarcopenia,	  frailty,	  cardiovascular	  
disease,	  to	  cognitive	  impairment	  and	  mortality	  (254-­‐‑261).	  Replenishment	  with	  
exogenous	  testosterone	  therapy	  have	  resulted	  in	  short	  term	  improvement	  such	  
as	  muscle	  strength	  and	  general	  vitality.	  However	  there	  are	  no	  results	  of	  long-­‐‑
term	  survival	  benefit,	  and	  some	  evidence	  of	  harm	  (262)	  including	  cardiovascular	  
disease	  (210)	  	  and	  prostate	  cancer	  (263).	  This	  indicates	  that	  low	  testosterone	  
level	  may	  at	  best	  be	  a	  biomarker	  for	  the	  general	  loss	  of	  homeostasis	  in	  the	  ageing	  
body.	  The	  concept	  is	  late-­‐‑onset	  hypogonadism	  is	  being	  refined,	  and	  more	  
strongly	  associated	  with	  sexual	  function	  in	  the	  older	  male.	  Consequently	  the	  
prevalence	  of	  late	  onset	  hypogonadism	  is	  low	  at	  5%	  in	  older	  men	  (264).	  This	  
thesis	  has	  expanded	  on	  the	  hypogonadism	  definition	  to	  include	  the	  assessment	  
of	  the	  other	  three	  testicular	  hormones	  AMH,	  InhB	  and	  INSL3.	  This	  thesis	  has	  
found	  that	  only	  a	  minority	  of	  men	  exhibit	  deficiency	  in	  all	  of	  their	  testicular	  
hormones,	  with	  each	  hormone	  having	  independent	  profiles	  in	  both	  older	  and	  
younger	  men.	  This	  implies	  that	  each	  testicular	  hormone	  may	  serve	  different	  
functions	  in	  men,	  and	  some	  or	  all	  of	  the	  other	  testicular	  hormones	  may	  be	  a	  
better	  biomarker	  to	  inform	  about	  the	  state	  of	  the	  ageing	  male	  compared	  to	  
testosterone.	  This	  has	  not	  been	  studied	  for	  AMH,	  InhB	  and	  INSL3	  at	  the	  start	  of	  
this	  thesis.	  	  	  
  
7.1.3  The  frailty  phenotype    
  
The	  function	  of	  circulating	  AMH	  may	  be	  cryptic	  in	  men,	  unlike	  the	  overt	  
phenotype	  generated	  by	  testosterone.	  Furthermore,	  the	  stable	  levels	  of	  
circulating	  AMH	  throughout	  the	  day	  is	  suggestive	  that	  AMH	  may	  inform	  about	  
the	  state	  of	  Sertoli	  cell	  rather	  than	  its	  acute	  regulation.	  This	  is	  similar	  to	  the	  posit	  




pertubation	  in	  AMH	  function	  may	  only	  be	  seen	  following	  chronic	  changes,	  such	  
as	  in	  the	  older	  male.	  The	  characteristic	  of	  AMH	  signalling	  as	  a	  TGFβ	  superfamily	  
member	  means	  that	  it	  is	  possible	  that	  AMH	  may	  function	  as	  part	  of	  a	  complex	  
network	  with	  redundancy	  and	  interactions	  [Chapter	  1.6.2].	  Hence	  its	  action	  may	  
not	  be	  immediately	  obvious	  unless	  there	  is	  significant	  dysregulations	  to	  this	  
network.	  A	  useful	  working	  model	  to	  assess	  this	  is	  in	  the	  frail	  person.	  
	  
Frailty	  is	  best	  conceptualised	  as	  a	  reduction	  in	  physiological	  reserve,	  leading	  to	  
clinical	  symptoms	  due	  to	  failure	  of	  multiple	  physiological	  systems	  (265).	  The	  
manifestations	  of	  frailty	  varies	  according	  to	  definition,	  but	  common	  criteria	  
includes	  pertubations	  in	  physical	  function,	  gait	  speed,	  and	  cognition	  (266,	  267).	  
Weight	  loss	  is	  also	  commonly	  associated	  with	  frailty	  (267,	  268).	  	  Low	  
testosterone	  level	  has	  been	  associated	  with	  frailty	  (259,	  269).	  Testosterone	  
replacement	  do	  not	  result	  in	  long	  term	  amelioration	  of	  the	  frailty	  phenotype	  
(270).	  This	  suggests	  that	  testosterone	  may	  be	  a	  biomarker	  to	  other	  independent	  
factors	  of	  frailty,	  with	  the	  presence	  of	  other	  testicular	  hormones	  currently	  being	  
unknown.	  
	  
The	  mechanism	  of	  frailty	  or	  its	  components	  are	  not	  fully	  understood.	  Members	  of	  
the	  TGFβ	  superfamily	  may	  play	  a	  role	  in	  its	  pathogenesis,	  with	  the	  best	  
documented	  being	  myostatin,	  a	  member	  of	  the	  BMP	  subfamily.	  Myostatin	  is	  a	  
known	  muscle	  growth	  regulator	  (271),	  and	  inhibition	  of	  myostatin	  in	  aged	  mice	  
resulting	  in	  muscular	  growth	  (272).	  However,	  association	  studies	  between	  
muscle	  strength	  and	  circulating	  myostatin	  level	  has	  been	  inconsistent	  (273-­‐‑275).	  
This	  does	  not	  necessarily	  prove	  that	  myostatin	  is	  not	  a	  determinant	  of	  frailty,	  as	  
myostatin	  is	  subject	  to	  complex	  regulation	  including	  cleavage	  and	  binding	  
proteins	  which	  may	  impact	  upon	  its	  function	  in	  sarcopenia	  (276).    
  




7.1.4  Objectives  of  study  
  
The	  objectives	  of	  this	  Chapter	  is	  to	  explore	  for	  any	  putative	  association	  between	  
circulating	  AMH	  levels,	  and	  its	  API,	  to	  aspects	  of	  functional	  traits.	  This	  is	  a	  pilot	  
study	  on	  a	  heterogenous	  group	  of	  older	  men,	  with	  some	  participants	  displaying	  
features	  of	  frailty.	  The	  study	  will	  be	  performed	  in	  the	  context	  of	  other	  testicular	  
hormones,	  to	  determine	  if	  any	  associations	  between	  AMH	  and	  functional	  traits	  
are	  linked	  to	  changes	  in	  other	  testicular	  hormones.	  Findings	  from	  this	  study	  will	  
guide	  more	  specific	  observational	  studies	  and	  potential	  causality	  studies.	  	  
  








The	  participants	  were	  derived	  from	  the	  subgroup	  of	  Otago	  cohort	  comprising	  of	  
men	  aged	  70	  years	  and	  older,	  as	  described	  in	  Chapter	  4.2.1A.	  	  
	  
7.2.2  Hormonal  assays  
	  
The	  circulating	  hormones	  assayed	  were	  those	  described	  in	  Chapter	  5	  and	  6,	  
including	  total	  AMH,	  proAMH,	  AMHN,C,	  Inhibin	  B,	  testosterone	  and	  INSL3.	  The	  
API	  was	  calculated	  from	  proAMH	  and	  total	  AMH	  as	  per	  Chapter	  6.	  	  
	  
7.2.3  Clinical  measurements  
	  
All	  tests	  were	  conducted	  in	  a	  single	  session,	  during	  the	  daytime	  hours	  between	  
8am	  to	  3pm.	  This	  was	  performed	  in	  an	  indoor	  gymnasium	  facility	  of	  the	  local	  
hospital,	  which	  is	  usually	  utilised	  for	  outpatient	  physiotherapy	  rehabilitation.	  	  
	  
7.2.3A  Anthropometric  measurements  
	  
Each	  participant	  was	  examined	  for	  the	  following:	  height	  (Seca	  213	  stadiometer),	  
weight	  (Seca	  813	  scale),	  and	  waist	  circumference,	  defined	  as	  the	  transverse	  
circumference	  midline	  between	  the	  iliac	  crests	  and	  the	  lowest	  palpable	  ribs	  
(277).	  BMI	  (Body	  mass	  index)	  was	  calculated	  using	  the	  following	  formula:	  
weight	  (kg)	  /	  height	  (m)2.	  Waist	  circumference	  correlated	  to	  weight	  and	  BMI	  
with	  statistical	  significance	  (R=0.87,	  p<0.0001	  for	  weight,	  and	  R=0.85,	  p<0.0001	  
for	  BMI)	  and	  to	  a	  lesser	  degree	  to	  height	  (R=0.38,	  p<0.0001)	  [Table	  7.1A].	  	  
	  




7.2.3B  Physical  functional  capacity  
	  
The	  physical	  functional	  capacity	  for	  each	  participant	  was	  examined	  by	  the	  
Timed-­‐‑Up	  and	  Go	  test	  (278),	  the	  Short	  Physical	  Performance	  Battery	  Test	  (279),	  
and	  the	  6	  minute	  walk	  test	  (280).	  All	  three	  tests	  have	  been	  validated	  as	  measures	  
for	  physical	  capacity	  and	  frailty	  (278-­‐‑280).	  There	  was	  partial	  correlation	  
between	  all	  three	  measures	  of	  physical	  function	  in	  this	  cohort,	  to	  high	  statistical	  
significance	  [Table	  7.1B].	  
	  
The	  Timed-­‐‑Up	  and	  Go	  Test	  (TUG)	  measures	  the	  time	  taken	  to	  stand	  from	  a	  sitting	  
position,	  walk	  to	  a	  marker	  3	  metres	  away,	  turn	  and	  return	  to	  sitting	  position	  at	  
origin,	  all	  conducted	  at	  usual	  walking	  speed.	  The	  TUG	  informs	  about	  the	  mobility	  
and	  balance,	  and	  exhibit	  high	  interclass	  correlation	  (ICC	  >	  0.95)	  (278).	  
	  
The	  Short	  Physical	  Performance	  Battery	  Test	  (SPPB)	  is	  a	  composite	  of	  three	  
tests,	  each	  scored	  out	  of	  4	  to	  compile	  a	  total	  score	  of	  12.	  The	  first	  test	  measures	  
the	  time	  required	  to	  repeatedly	  stand	  and	  sit	  from	  a	  chair,	  without	  utilising	  the	  
arms.	  This	  test	  examines	  for	  lower	  limbs	  strength	  and	  balance.	  The	  second	  test	  
examines	  for	  standing	  balance,	  ranging	  from	  full	  tandem	  (one	  foot	  directly	  in	  
front	  of	  the	  other)	  to	  a	  loss	  of	  standing	  balance	  without	  aid.	  The	  final	  test	  records	  
the	  time	  required	  to	  walk	  8	  feet	  (2.44m),	  which	  establish	  the	  gait	  speed.	  Lower	  
SPPB	  score	  predicts	  short	  term	  mortality	  and	  admission	  to	  residential	  care	  
(279).	  	  
	  
The	  third	  test	  of	  physical	  function	  is	  the	  6	  minute	  walk	  test	  (6MWT)	  that	  
measures	  the	  distance	  walked	  lengthwise	  throughout	  the	  gymnasium,	  at	  usual	  
walking	  speed.	  The	  6	  minute	  walk	  tests	  predicts	  frailty	  and	  mortality	  risk,	  
particularly	  in	  patients	  with	  cardiopulmonary	  diseases	  (280).	  	  
	  




7.2.3C  Cognitive  Test  
	  
Similar	  to	  the	  physical	  testing,	  a	  number	  of	  cognitive	  tests	  were	  utilised	  to	  
comprehensively	  measure	  cognitive	  function.	  The	  most	  commonly	  utilised	  tool	  
for	  assessment	  of	  cognitive	  function	  both	  clinically	  and	  in	  research	  is	  the	  Mini	  
Mental	  State	  Examination	  (MMSE),	  a	  30	  points	  test	  that	  examines	  a	  wide	  range	  of	  
different	  components	  of	  cognition	  including	  orientation,	  memory	  recall,	  
attention,	  calculation,	  language	  and	  visuospatial	  skills.	  A	  diagnostic	  cut	  off	  value	  
of	  24	  or	  less	  predicts	  dementia,	  with	  a	  specificity	  of	  99%,	  whilst	  using	  a	  cut	  off	  
value	  of	  27	  or	  less	  discriminates	  between	  normal	  cognition	  and	  mild	  cognitive	  
impairment/dementia	  with	  specificity	  of	  91%	  (281).	  	  
	  
The	  Modified	  Mini	  Mental	  State	  Examination	  (3MS)	  is	  a	  100	  points	  test	  that	  
extends	  the	  MMSE,	  and	  correlated	  highly	  with	  the	  MMSE	  both	  in	  this	  cohort	  
(Table	  7.1C,	  R=	  0.84,	  p<0.0001)	  and	  in	  the	  literature	  (282).	  In	  some	  clinical	  
centres,	  3MS	  is	  used	  in	  lieu	  of	  the	  MMSE.	  	  
	  
Both	  Trail	  Making	  Test	  A	  (TMT	  A)	  and	  Trail	  Making	  Test	  B	  (TMT	  B)	  tests	  for	  
visual	  scanning,	  task	  switching	  and	  executive	  function	  tests.	  It	  involves	  recording	  
the	  time	  required	  to	  connect	  25	  circles	  placed	  in	  a	  random	  order	  on	  the	  page,	  
with	  TMT	  A	  examining	  consecutive	  numbering,	  whilst	  TMT	  B	  requires	  
alternating	  between	  a	  number	  and	  a	  letter.	  Since	  depression,	  particularly	  in	  the	  
older	  adult,	  share	  similar	  clinical	  features	  with	  cognitive	  impairment,	  a	  screening	  
validated	  tool	  for	  depression	  is	  used	  in	  this	  study.	  There	  was	  partial	  
relationships	  between	  Geriatric	  Depression	  Scale	  (GDS)	  and	  other	  tests	  of	  
cognition	  [Table	  7.1C].	  The	  GDS	  is	  a	  15	  point	  questionnaire	  that	  ask	  15	  yes/no	  
questions	  to	  a	  range	  of	  depressive	  symptoms,	  with	  higher	  scores	  indicating	  
greater	  risk	  of	  depression.	  	  
	  




7.2.4  Statistical  analyses  
	  
All	  univariate	  analyses	  between	  two	  variables	  were	  conducted	  using	  Pearson’s	  
correlation.	  Partial	  correlation	  was	  performed	  when	  examining	  for	  the	  effect	  of	  
multiple	  variables	  on	  the	  relationship	  between	  two	  variables.	  




Table  7.1:  Linear  correlation  between  different  tests  within  same  
domain,  with  A.  showing  anthropometric  measurements,  B.  physical  
function,  and  C.  cognitive  function.  Relationships  that  are  statistically  
significant  are  presented  in  blue.    






Height	   Weight	   Waist	  
circumference	  
BMI	  






Weight	   R=0.61	  	  
p<0.0001	  










-­‐‑	   R=0.85	  
p<0.0001	  










TUG	   SPPB	   6MWT	  




SPPB	   R=-­‐‑0.60	  
p<0.0001	  
-­‐‑	   R=0.73	  
p<0.0001	  








MMSE	   3MS	   TMT	  A	   TMT	  B	   GDS	  








3MS	   R=0.84	  
p<0.0001	  




















-­‐‑	   R=0.13	  
p=0.2	  















7.3.1  Cohort  characteristics  
  
The	  characteristics	  of	  the	  participants	  are	  shown	  in	  Table	  7.1.	  The	  average	  age	  
for	  the	  cohort	  was	  78	  years	  old,	  with	  a	  mean	  weight	  of	  80	  kg,	  an	  overweight	  BMI	  
of	  27	  kg/m2,	  	  but	  normal	  mean	  waist	  circumference	  of	  98	  cm.	  The	  physical	  
performance	  measures	  were	  variable	  in	  the	  description	  of	  the	  cohort,	  with	  the	  
TUG	  being	  and	  SPPB	  being	  of	  normal	  range	  for	  the	  age	  group,	  whilst	  the	  mean	  
6MWT	  was	  lower	  than	  reported	  average	  in	  literature,	  but	  with	  high	  variance	  	  
(283,	  284).	  The	  average	  cognitive	  scores	  were	  also	  in	  the	  normal	  range	  for	  the	  
age.	  	  
  




Table  7.2:  Characteristics  of  99  men  aged  70  years  and  older  in  the  
Otago  cohort  
  
Features	   Mean	  (sd)	   Median	  (range)	  
Age	  (years)	   78.1	  (5.1)	   77.4	  (66.5-­‐‑89.7)	  
Height	  (m)	   1.71	  (0.06)	   1.71	  (1.53-­‐‑1.86)	  
Weight	  (kg)	   79.9	  (12.6)	   77.8	  (55.0-­‐‑123.2)	  
Waist	  circumference	  
(cm)	  
97.8	  (9.5)	   98	  (80-­‐‑124)	  
BMI	  (kg/m2)	   27.3	  (3.4)	   27.0	  (19.3-­‐‑37.2)	  
Time	  Up	  and	  Go	  Test	  
(seconds)	  
10.7	  (7.6)	   9	  (5-­‐‑78)	  
Short	  Performance	  
Battery	  Test	  (0-­‐‑12)	  
10.1	  (2.4)	   11	  (0-­‐‑12)	  
6	  minute	  walk	  test	  (m)	   293.7	  (76.7)	   303	  (0-­‐‑422)	  
15	  point	  Geriatric	  
Depression	  Scale	  (0-­‐‑15)	  
1.2	  (1.7)	   1	  (0-­‐‑10)	  
Modified	  Mini-­‐‑Mental	  
State	  Examination	  	  
(0-­‐‑100)	  
93	  (8)	   96	  (44-­‐‑100)	  
Mini	  Mental	  State	  
Examination	  (0-­‐‑30)	  
28	  (2)	   28	  (17-­‐‑30)	  
Trail	  Making	  Test	  A	  
(seconds)	  
46.3	  (20.0)	   41	  (19-­‐‑127)	  
Trail	  Making	  Test	  B	  
(seconds)	  
134.3	  (151)	   90	  (27-­‐‑960)	  




7.3.2  AMH  correlation  to  features  
  
7.3.2A  Anthropometric  markers  
  
The	  API	  was	  inversely	  associated	  to	  a	  person’s	  weight	  and	  BMI	  [Table	  7.3A,	  R=-­‐‑
0.24,	  p=0.02	  for	  weight,	  and	  R=-­‐‑0.23,	  p=0.02	  for	  BMI].	  This	  relationship	  was	  
maintained	  after	  correction	  for	  age	  and	  waist	  circumference,	  as	  age	  and	  waist	  
circumference	  are	  independently	  associated	  to	  weight	  and	  BMI	  [Table	  7.3B].	  
Obesity	  was	  associated	  with	  more	  efficient	  cleavage	  of	  AMH	  [Fig.	  7.2A	  and	  B],	  
whilst	  men	  with	  normal	  or	  low	  BMI	  exhibited	  a	  wide	  range	  of	  API.	  	  
	  
The	  circulating	  levels	  of	  total	  AMH,	  proAMH,	  and	  AMHN,C	  however	  showed	  no	  
relationship	  to	  weight	  or	  BMI.	  Elevated	  waist	  circumference	  is	  a	  marker	  of	  
truncal	  obesity,	  and	  none	  of	  the	  AMH	  hormones	  or	  the	  API	  displayed	  any	  
association	  to	  waist	  circumference.	  Similarly,	  there	  was	  no	  relationship	  to	  height.  
  




Table  7.3A:  The  linear  univariate  correlation  R  and  its  statistical  
significance  is  described  between  AMH  and  anthropometric  
measurements  in  99  men  70  years  and  older.  Bonferroni  correction  for  
multiple  testing  is  shown  in  parentheses.  Relationships  that  are  
statistically  significant  are  presented  in  blue.    
  
	   Height	   Weight	   Waist	  
circumference	  
BMI	  


















































Table  7.3B:  Partial  correlation  of  API  to  weight  and  BMI,  after  correction  
for  age.  
	   Weight	   BMI	  
API	   R=-­‐‑0.22,	  p=0.03	   R=-­‐‑0.22,	  p=0.03	  
Age	   R=-­‐‑0.33,	  p=0.001	   R=-­‐‑0.20,	  p=0.05	  







Figure  7.1:  Relationship  between  API  and  characteristics  of  men  aged  70  
years  and  older  in  the  Otago  cohort.  	  
Each	  dot	  represents	  an	  individual.	  The	  API	  was	  inversely	  associated	  to	  both	  A.	  
weight	  and	  B.	  BMI,	  and	  as	  well	  as	  to	  the	  C.	  6	  minute	  walk	  test.	  	  




7.3.2B  Physical  frailty  
  
Advanced	  age	  was	  associated	  with	  physical	  frailty	  with	  high	  statistical	  
significance	  (R=-­‐‑0.31,	  p=0.002	  for	  SPPB,	  and	  R=-­‐‑0.32,	  p=0.002	  for	  6MWT).	  There	  
is	  greater	  cleavage	  of	  AMH	  in	  participants	  that	  are	  more	  frail,	  after	  correcting	  for	  
the	  effect	  of	  age	  [Table	  7.4,	  partial	  correlation	  6MWT	  to	  API,	  R=0.23,	  p=0.03].	  At	  
higher	  API,	  there	  is	  a	  absence	  of	  men	  with	  poor	  physical	  function	  from	  the	  
6MWT	  [Fig.	  7.2C].	  Circulating	  levels	  of	  AMH	  hormones	  were	  not	  associated	  with	  
frailty	  in	  both	  univariate	  analyses	  and	  after	  correcting	  for	  the	  effect	  of	  age.	  
  
  
Table  7.4:  The  linear  univariate  correlation  R  and  its  statistical  
significance  is  described  between  AMH  and  physical  measurements  in  
99  men  70  years  and  older.  Bonferroni  correction  for  multiple  testing  is  
shown  in  parentheses.  Relationships  that  are  statistically  significant  are  
presented  in  blue.  
	   TUG	   SPPB	   6MWT	  




































7.3.2C  Cognitive  domains  
  
MMSE	  is	  a	  broad	  measure	  of	  cognition,	  and	  widely	  utilised	  to	  assist	  in	  diagnosing	  
and	  monitoring	  cognitive	  impairment.	  MMSE	  negatively	  associated	  with	  
circulating	  levels	  of	  total	  AMH	  (R=-­‐‑0.23),	  proAMH	  (R=-­‐‑0.24)	  and	  AMHN,C	  (R=-­‐‑
0.23)	  [Table	  7.5A,	  Fig.	  7.2].	  Cognitive	  decline	  is	  associated	  to	  depressive	  
symptoms,	  to	  a	  high	  level	  of	  significance,	  with	  both	  markers	  being	  linked	  to	  age.	  
A	  partial	  correlation	  was	  therefore	  performed	  between	  circulating	  AMH	  
hormones	  and	  cognitive	  function	  as	  measured	  by	  MMSE,	  correcting	  for	  the	  effect	  
of	  age	  and	  the	  GDS	  score.	  The	  partial	  correlation	  was	  strengthened	  slightly	  
between	  circulating	  AMH	  hormones	  and	  MMSE	  [Table	  7.5B].	  ProAMH	  similarly	  
improved	  its	  strength	  of	  relationship	  to	  3MS,	  another	  marker	  of	  cognitive	  
function,	  after	  correcting	  for	  the	  effect	  of	  depressive	  symptoms	  [Table	  7.5B].	  
Conversely,	  there	  was	  no	  relationship	  between	  circulating	  AMH	  hormones	  and	  
depressive	  symptoms	  in	  both	  univariate	  and	  partial	  correlation	  after	  correcting	  
for	  cognitive	  function	  and	  age.	  API	  was	  independent	  to	  all	  tests	  of	  cognitive	  
function	  and	  depression.	  
  




Table  7.5A:  The  linear  univariate  correlation  R  and  its  statistical  
significance  is  described  between  AMH  and  cognitive  measurements  in  
99  men  70  years  and  older.  Bonferroni  correction  for  multiple  testing  is  
shown  in  parentheses.  Relationships  that  are  statistically  significant  are  
presented  in  blue.  
	   MMSE	   3MS	   TMT	  A	   TMT	  B	   GDS	  

























































Table  7.5B:  Partial  correlation  of  MMSE  and  3MS  to  AMH  markers,  
corrected  for  effect  of  age  and  GDS  score.  Relationships  that  are  
statistically  significant  are  presented  in  blue.  
	   MMSE	   3MS	  
Total	  AMH	   	  R=-­‐‑0.25	  
(p=0.02)	  
	  	  




AMHN,C	   	  R=-­‐‑0.25	  
(p=0.02)	  
	  	  










Figure  7.2:  Relationship  between  the  various  circulating  AMH  
measurements  and  the  mini  mental  state  exam  (MMSE)  in  men	  aged  70  
years  and  older  in  the  Otago  cohort.    
Each	  dot	  represents	  an	  individual.	  AMH	  showed	  negative	  correlation	  to	  MMSE	  
score	  with	  statistical	  significance.	  A	  MMSE	  of	  27	  or	  higher	  (dark	  purple	  dashed	  
line)	  is	  associated	  with	  normal	  cognition.	  MMSE	  score	  less	  than	  24	  (light	  purple	  
dashed	  line)	  is	  associated	  with	  cognitive	  impairment.	  	  




7.3.3  Context  of  other  testicular  hormones  
  
Relationships	  were	  observed	  between	  circulating	  AMH	  hormones	  or	  the	  API,	  to	  
physical	  and	  cognitive	  traits	  in	  older	  men.	  Post-­‐‑hoc	  analyses	  were	  then	  
performed	  to	  determine	  if	  these	  associations	  were	  distinct	  to	  AMH,	  or	  similar	  in	  
the	  context	  of	  other	  testicular	  hormones.	  
  
7.3.3A  Anthropometric  measurements  
  
No	  relationship	  was	  observed	  between	  weight	  and	  BMI	  and	  the	  circulating	  levels	  
of	  InhB,	  testosterone	  and	  INSL3.	  Circulating	  INSL3,	  in	  contrast	  to	  circulating	  
AMH,	  associated	  to	  a	  man’s	  height	  with	  statistical	  significance,	  after	  correcting	  
for	  the	  common	  effect	  of	  age	  [Fig.	  7.3A	  and	  Table	  7.6,	  partial	  correlation	  R=0.25,	  
p=0.03].	  This	  appeared	  to	  be	  specific	  to	  circulating	  levels	  of	  INSL3,	  as	  neither	  the	  
circulating	  levels	  of	  testosterone	  nor	  InhB	  showed	  any	  association,	  in	  both	  
univariate	  and	  multivariate	  analyses.	  	  
  
7.3.3B  Physical  frailty  
  
Lower	  circulating	  levels	  of	  InhB	  was	  associated	  with	  increasing	  frailty	  with	  
statistical	  significance	  (linear	  regression	  to	  TUG,	  R=-­‐‑0.20,	  p=0.046,	  Fig.	  7.3B),	  
with	  the	  relationship	  preserved	  after	  partial	  correlation	  to	  age	  [Table	  7.7].	  This	  
observation	  was	  unique	  to	  InhB	  only,	  and	  not	  seen	  with	  AMH,	  testosterone	  or	  
INSL3.	  However,	  the	  statistical	  effect	  appeared	  to	  be	  influenced	  by	  a	  single	  
individual	  with	  poor	  function	  of	  TUG	  and	  low	  InhB,	  with	  the	  strength	  of	  
statistical	  significance	  being	  lost	  when	  the	  data	  was	  re-­‐‑analysed	  after	  exclusion	  
of	  this	  individual	  (linear	  regression	  p=0.17).	  	  
  
7.3.3C  Cognitive  function  
  
There	  were	  no	  relationship	  between	  circulating	  levels	  of	  InhB,	  testosterone	  and	  
INSL3	  to	  measures	  of	  cognition	  and	  depression,	  in	  both	  univariate	  and	  partial	  
correlation	  studies	  correcting	  for	  age	  and	  depression	  [Table	  7.8].	  This	  was	  in	  
contrast	  to	  the	  statistical	  significant	  associations	  observed	  between	  circulating	  




Table  7.6:  Univariate  linear  regression  between  circulating  levels  of  
InhB,  testosterone  and  INSL3  to  anthropometric  measures  in  99  men  70  
years  and  older.  Relationships  that  are  statistically  significant  are  
presented  in  blue.  
	   Height	   Weight	   Waist	  
circumference	  
BMI	  




























Table  7.7:  Univariate  linear  regression  between  circulating  levels  of  
InhB,  testosterone  and  INSL3  to  physical  function  in  99  men  70  years  
and  older.  Relationships  that  are  statistically  significant  are  presented  in  
blue.  
	   TUG	   SPPB	   6MWT	  



























Table  7.8:  Univariate  linear  regression  between  circulating  levels  of  
InhB,  testosterone  and  INSL3  to  cognitive  function  in  99  men  70  years  
and  older.  Relationships  that  are  statistically  significant  are  presented  in  
blue.  
	   MMSE	   3MS	   TMT	  A	   TMT	  B	   GDS	  






































Figure  7.3:  Relationship  between  selected  testicular  hormones  and  traits  
in  men  aged  70  years  and  older  in  the  Otago  cohort.  	  
Each	  dot	  represents	  an	  individual.	  A.	  Higher	  levels	  of	  circulating	  INSL3	  are	  
associated	  to	  taller	  height.	  B.	  Individuals	  with	  longer	  time	  on	  Time-­‐‑Up	  and	  Go	  







To	  date	  there	  is	  an	  absence	  of	  knowledge	  regarding	  functions	  of	  circulating	  AMH	  
in	  man.	  This	  Chapter	  described	  the	  world’s	  first	  exploration	  of	  circulating	  levels	  
of	  AMH	  and	  its	  cleavage	  extent	  in	  a	  cohort	  of	  older	  men	  with	  diverse	  functional	  
capacity.	  This	  pilot	  study	  has	  identified	  the	  feasibility	  of	  conducting	  further	  
research	  to	  define	  functions	  of	  circulating	  AMH	  in	  specific	  domains.	  	  
	  
7.4.1  Circulating  AMH  level  and  cognition  
  
Circulating	  AMH	  level	  inversely	  correlated	  to	  cognitive	  function	  in	  older	  men.	  
This	  points	  towards	  a	  possible	  area	  for	  investigation	  of	  function	  of	  AMH.	  Any	  
functional	  significance	  for	  AMH	  in	  the	  brain	  is	  likely	  to	  be	  broad,	  as	  the	  
association	  is	  the	  strongest	  to	  MMSE	  and	  3MS,	  which	  are	  broad	  measures	  of	  
cognition.	  Interestingly,	  the	  relationship	  is	  lesser	  to	  a	  more	  specific	  cognitive	  
test,	  such	  as	  the	  Trail	  Making	  Tests,	  which	  assess	  cognitive	  speed	  and	  executive	  
functions	  (285,	  286).	  
	  
Circulating	  AMH	  level	  have	  been	  associated	  to	  aspects	  of	  development	  in	  boys.	  
AMH	  levels	  are	  negatively	  associated	  with	  measurements	  of	  autism	  scores	  in	  
boys	  (66).	  AMH	  also	  putatively	  slows	  the	  speed	  of	  maturation	  of	  boys	  (62),	  and	  
together	  may	  influence	  neuronal	  development.	  This	  is	  underscored	  by	  animal	  
studies	  that	  showed	  male	  phenotypic	  behaviour	  is	  associated	  with	  the	  presence	  
of	  AMH	  in	  the	  prepubescent	  state	  (67),	  which	  is	  induced	  by	  AMH	  regulation	  of	  
specific	  areas	  of	  brain	  development	  (287,	  288).	  If	  AMH	  does	  have	  function	  in	  the	  
brain,	  it	  might	  putatively	  regulate	  neuronal	  development	  during	  childhood	  that	  
contributes	  to	  the	  magnitude	  of	  cognitive	  reserve.	  The	  cognitive	  ability	  of	  
younger	  humans	  is	  predictive	  of	  the	  risk	  of	  cognitive	  decline	  in	  older	  years	  (289,	  
290).	  
	  
Alternatively,	  AMH	  may	  be	  an	  indirect	  marker	  for	  cognitive	  decline.	  AMH	  is	  
putatively	  associated	  with	  cardiovascular	  function	  (193,	  291),	  and	  higher	  levels	  




[Chapter	  4A.3.2].	  Cardiovascular	  disease	  is	  implicated	  in	  the	  development	  of	  
cognitive	  impairment,	  including	  vascular	  dementia	  and	  Alzheimer’s	  Disease	  
(292,	  293).	  Circulating	  AMH	  level	  may	  be	  a	  putative	  biomarker	  for	  cognitive	  
impairment	  associated	  with	  vascular	  pathologies,	  with	  this	  requiring	  further	  
examination.	  
	  
AMH	  may	  function	  as	  a	  hormone	  and	  directly	  influence	  brain	  function.	  This	  is	  
similar	  to	  the	  effect	  of	  testicular	  testosterone	  on	  cognitive	  function	  (294,	  295).	  
The	  ability	  for	  AMH	  to	  cross	  the	  blood	  brain	  barrier	  is	  unknown,	  and	  warrants	  
specific	  animal	  studies.	  AMH	  itself	  may	  act	  as	  a	  paracrine	  factor,	  with	  local	  
production	  of	  AMH	  in	  the	  brain	  being	  documented	  (296)	  and	  animal	  studies	  
showing	  AMH	  being	  a	  neuroprotective	  factor	  (127).	  	  
  
7.4.2  Cleavage  of  AMH  as  biomarker  for  weight  change  and  frailty  
  
The	  extent	  of	  proAMH	  cleavage	  showed	  distinct	  correlation	  to	  physical	  function	  
and	  weight.	  The	  cleavage	  extent	  of	  a	  hormone	  may	  function	  as	  a	  biomarker	  
[Chapter	  1.6.1].	  Multiple	  enzymes	  cleave	  proAMH	  in	  vitro,	  but	  there	  is	  currently	  
no	  information	  about	  which	  of	  the	  enzyme(s)	  is	  physiologically	  relevant.	  	  This	  
limits	  the	  ability	  to	  draw	  specific	  conclusions	  regrading	  the	  mechanism	  
underlying	  the	  association	  between	  the	  API	  and	  traits.	  
  




7.4.3  Testicular  hormones  exhibit  varying  association  to  aspects  of  ageing  
  
All	  four	  testicular	  hormones	  decline	  with	  ageing,	  as	  shown	  in	  Chapter	  5.	  
However,	  in	  this	  cohort	  of	  older	  men,	  each	  testicular	  hormone	  exhibit	  distinct	  
correlation	  to	  different	  traits.	  Circulating	  AMH	  level	  has	  statistical	  significant	  
relationship	  to	  cognitive	  function	  [Chapter	  7.4.1].	  Circulating	  levels	  of	  INSL3	  is	  
associated	  to	  an	  older’s	  height,	  which	  is	  independent	  to	  a	  person’s	  age.	  Height	  
typically	  diminish	  with	  ageing	  as	  a	  consequence	  of	  reduced	  vertebral	  height	  from	  
osteoporosis	  (297),	  and	  INSL3	  is	  a	  regulator	  of	  bone	  (11,	  219,	  298).	  This	  
provides	  a	  direction	  to	  investigate	  for	  the	  role	  of	  INSL3	  in	  osteoporosis	  in	  men,	  
either	  as	  a	  biomarker	  or	  a	  therapeutic	  target.	  Circulating	  level	  of	  InhB	  correlated	  
to	  the	  Time-­‐‑Up-­‐‑and-­‐‑Go	  test,	  another	  measure	  of	  physical	  function	  with	  relevance	  
to	  balance,	  lower	  limbs	  muscle	  strength	  and	  coordination.	  The	  significance	  of	  
this	  correlation	  is	  unknown	  as	  there	  are	  multiple	  determinants	  of	  the	  TUG	  test.	  
However	  when	  considered	  in	  the	  entirety,	  the	  differential	  profiles	  of	  four	  
testicular	  hormones	  to	  different	  phenotypic	  traits	  indicate	  the	  need	  to	  examine	  
all	  four	  testicular	  hormones	  in	  blood,	  when	  correlating	  to	  biological	  traits.	  This	  
pilot	  study	  therefore	  has	  shown	  that	  it	  is	  possible	  to	  examine	  all	  four	  circulating	  
testicular	  hormones	  to	  a	  heterogenous	  group	  of	  older	  men,	  with	  the	  specific	  
interaction	  between	  the	  four	  of	  them	  to	  a	  trait	  requiring	  further	  specific	  studies.	  
  




7.4.4  Technical  considerations  
  
The	  use	  of	  multiple	  testings	  within	  a	  domain	  usually	  require	  correction	  with	  a	  
statistical	  technique	  such	  as	  Bonferroni.	  However,	  multiple	  measures	  within	  the	  
domains	  exhibited	  relationships	  to	  each	  other,	  thereby	  significantly	  reducing	  the	  
statistical	  power	  when	  applying	  a	  correction	  test	  such	  as	  Bonferroni	  which	  
applies	  a	  priori	  assumption	  that	  each	  variable	  being	  tested	  are	  independent.	  For	  
instance,	  the	  anthropometric	  domain	  includes	  weight,	  height	  and	  BMI,	  but	  BMI	  
being	  a	  ratio	  of	  weight	  and	  height.	  Partial	  correlation	  was	  therefore	  applied	  to	  
correct	  for	  known	  or	  assumed	  covariates	  such	  as	  age	  to	  circulating	  hormonal	  
levels	  and	  variables	  within	  a	  domain.	  
	  
This	  pilot	  study	  employed	  multiple	  tests	  for	  the	  same	  domain,	  using	  a	  mixture	  of	  
continuous	  testing	  such	  as	  the	  TUG,	  and	  more	  discrete	  testing	  such	  as	  the	  SPPB.	  
Whilst	  clinical	  diagnosis	  require	  the	  use	  of	  cut-­‐‑off	  criterias,	  greater	  strength	  of	  
association	  may	  be	  observed	  with	  the	  use	  of	  continuous	  testing	  to	  circulating	  
hormonal	  values.	  This	  pilot	  study	  have	  shown	  that	  it	  is	  feasible	  to	  use	  both	  forms	  
of	  testing	  to	  generate	  further	  hypotheses	  for	  more	  targeted	  research.	  
	  
Depression	  is	  associated	  with	  cognitive	  decline,	  and	  demonstrated	  in	  this	  pilot	  
study.	  The	  results	  from	  this	  Chapter	  has	  shown	  the	  need	  to	  include	  
measurements	  of	  depression	  when	  correlating	  hormonal	  levels	  to	  cognitive	  
states	  due	  to	  potential	  confounding	  effect	  of	  depression.	  	  
	  
This	  study	  is	  of	  cross-­‐‑sectional	  nature,	  which	  is	  appropriate	  as	  a	  feasibility	  study	  
to	  guide	  avenues	  for	  further	  research,	  particularly	  of	  a	  longitudinal	  design.	  The	  
associations	  between	  circulating	  testicular	  hormones	  to	  different	  traits	  may	  be	  
acquired	  with	  ageing,	  or	  reflect	  baseline	  level	  through	  secular	  changes.	  
  






This	  pilot	  study	  has	  shown	  that	  it	  is	  feasible	  to	  correlate	  circulating	  AMH	  levels,	  
and	  its	  API,	  to	  aspects	  of	  age-­‐‑related	  function.	  This	  generates	  directions	  for	  
research	  to	  explore	  for	  putative	  functions	  of	  AMH,	  particularly	  in	  the	  area	  of	  
cognition	  and	  physical	  frailty.	  The	  relationship	  appeared	  to	  be	  distinct	  to	  the	  
other	  testicular	  hormones.	  This	  highlight	  the	  need	  to	  examine	  all	  four	  testicular	  
hormones	  when	  examining	  for	  any	  relationship	  to	  traits.	  

















AMH	  is	  a	  testicular	  hormone	  in	  men.	  Despite	  its	  label	  as	  a	  hormone,	  it	  is	  
unknown	  if	  AMH	  has	  any	  functional	  significance	  in	  the	  adult	  male.	  This	  thesis	  
began	  with	  the	  premise	  that	  circulating	  AMH	  level	  may	  have	  functions,	  and	  that	  
the	  functions	  may	  not	  be	  overt	  in	  men.	  The	  main	  objective	  for	  this	  thesis	  is	  to	  
advance	  this	  argument	  by	  setting	  up	  the	  foundations	  for	  further	  research	  of	  AMH	  
in	  men.	  This	  thesis	  has	  met	  its	  objective	  by	  documenting	  basic	  physiological	  
parameters	  of	  circulating	  AMH.	  Along	  the	  way,	  the	  PhD	  has	  expanded	  upon	  the	  
definition	  of	  a	  hormone,	  and	  the	  concept	  of	  testicular	  endocrine	  function.	  The	  
following	  description	  is	  a	  narrative	  of	  this	  research	  with	  its	  implication	  to	  the	  
wider	  scientific	  and	  clinical	  community.	  
	  
8.2  Is  AMH  a  hormone?  
	  
The	  understanding	  of	  a	  hormone	  has	  expanded	  vastly	  in	  recent	  years,	  with	  the	  
awareness	  that	  a	  hormone	  may	  exhibit	  pleiotropic	  roles.	  Insulin-­‐‑like	  growth	  
factor	  is	  one	  example,	  which	  has	  dual	  role	  as	  both	  a	  hormone	  (299)	  and	  a	  
paracrine	  factor	  (300).	  InhB	  is	  well	  recognised	  as	  a	  testicular	  hormone,	  but	  also	  a	  
member	  of	  the	  TGFβ	  superfamily,	  and	  subject	  to	  its	  complex	  regulations	  and	  
interactions	  with	  other	  signalling	  molecules	  [Chapter	  1.6.2].	  AMH	  is	  unlikely	  to	  
be	  a	  classical	  hormone	  with	  overt	  functions,	  but	  it	  may	  have	  cryptic	  endocrine	  
functions,	  which	  are	  biologically	  and	  clinically	  important.	  Several	  lines	  of	  
evidence	  advances	  this	  argument.	  AMH	  is	  secreted	  into	  blood	  from	  the	  testes,	  




significantly	  between	  men,	  and	  exhibit	  correlation	  to	  functional	  traits	  in	  men.	  
These	  observations	  are	  correlative	  and	  are	  insufficient	  alone	  to	  prove	  function.	  	  
Nonetheless	  this	  thesis	  provides	  compelling	  reason	  why	  AMH	  should	  be	  
examined	  in	  men,	  as	  a	  hormone.	  	  
	  
If	  AMH	  does	  have	  functional	  significance,	  it	  is	  likely	  to	  be	  a	  biomarker	  of	  the	  state	  
of	  the	  testes.	  AMH	  is	  stable	  in	  blood	  throughout	  the	  day,	  and	  is	  independent	  to	  
the	  other	  testicular	  hormones,	  including	  InhB.	  AMH	  may	  putatively	  reflect	  the	  
state	  of	  spermatogenesis,	  similar	  to	  how	  circulating	  AMH	  is	  utilised	  as	  a	  
biomarker	  for	  ovarian	  reserve	  in	  women	  of	  reproductive	  age.	  Whether	  total	  
AMH,	  proAMH	  or	  its	  cleaved	  form	  AMHN,C	  are	  more	  accurate	  reporters	  of	  AMH	  
function,	  or	  whether	  they	  reflect	  different	  aspects	  of	  AMH	  function	  is	  yet	  to	  be	  
determined.	  	  
	  
8.3  Establishment  of  normative  range  for  AMH  in  men  
	  
This	  thesis	  has	  provided	  the	  first	  description	  of	  circulating	  AMH	  level	  in	  older	  
men.	  The	  data	  enables	  the	  generation	  of	  a	  normative	  range	  for	  AMH.	  This	  can	  be	  
utilised	  to	  identify	  individuals	  outside	  of	  the	  normative	  range	  for	  further	  study	  
into	  AMH	  function.	  All	  clinical	  endocrine	  practice	  requires	  the	  establishment	  of	  
normal	  values,	  and	  the	  findings	  here	  may	  be	  of	  value	  for	  future	  clinical	  practice.	  
The	  use	  of	  AMH	  as	  a	  diagnostic	  marker	  in	  the	  paediatric	  patient	  with	  ambiguous	  
genitalia	  has	  been	  described	  (301,	  302),	  but	  this	  uses	  a	  dichotomy	  of	  whether	  
AMH	  is	  present	  or	  absent	  in	  blood.	  The	  normative	  values	  allows	  a	  more	  refined	  
approach	  for	  diagnostic	  purposes.	  Furthermore,	  knowledge	  of	  normal	  
physiological	  parameters	  can	  guide	  experimental	  studies	  on	  AMH,	  which	  to	  date	  
has	  used	  non-­‐‑physiological	  range	  of	  AMH	  dosing,	  and	  AMH	  preparations	  with	  
undefined	  proportions	  of	  proAMH	  and	  AMHN,C.	  
	  




8.4  API  is  distinct  to  circulating  AMH  level  and  may  be  a  
biomarker  
	  
The	  discovery	  that	  API	  is	  distinct	  between	  boys	  and	  men,	  and	  independent	  to	  the	  
circulating	  level	  of	  AMH	  suggest	  that	  API	  may	  have	  significance.	  This	  is	  
supported	  by	  correlation	  to	  functional	  traits	  in	  men.	  Cleavage	  activity	  of	  a	  
prohormone	  has	  been	  advanced	  in	  some	  studies	  as	  putative	  biomarkers,	  and	  this	  
study	  has	  certainly	  advanced	  that	  concept.	  Processing	  of	  a	  hormone	  following	  
synthesis	  adds	  another	  layer	  of	  complexity	  to	  the	  regulation	  of	  a	  hormonal	  
function,	  and	  highlights	  that	  a	  simplistic	  understanding	  of	  hormonal	  function	  
may	  not	  be	  sufficient	  in	  today’s	  scientific	  environment.	  	  
	  
8.5  The  testes  is  a  complex  endocrine  organ  
	  
The	  classic	  understanding	  of	  the	  endocrine	  testes	  has	  primarily	  been	  based	  upon	  
testosterone,	  including	  the	  definition	  of	  testicular	  function.	  The	  testes	  is	  likely	  to	  
be	  a	  complex	  organ,	  with	  multiple	  hormones	  each	  working	  independently	  and	  in	  
some	  instances	  in	  concert	  to	  maintain	  the	  male	  phenotype.	  Testosterone	  has	  a	  
prime	  role	  in	  generating	  sexual	  dimorphism,	  as	  does	  AMH,	  although	  the	  other	  
testicular	  hormones	  may	  contribute	  in	  subtlier	  manners.	  The	  stability	  of	  AMH	  
and	  INSL3	  suggest	  that	  they	  reflect	  a	  more	  basal	  state	  of	  the	  testes,	  and	  less	  
likely	  to	  be	  influenced	  by	  sporadic	  factors.	  This	  also	  challenges	  the	  concept	  that	  
the	  male	  phenotype	  is	  solely	  generated	  by	  testosterone	  only.	  This	  is	  particularly	  
pertinent	  in	  the	  understanding	  of	  hypogonadism.	  This	  thesis	  has	  shown	  that	  
whilst	  testicular	  hormones	  exhibit	  age-­‐‑related	  decline,	  the	  phenomenon	  is	  
occuring	  independently.	  Thus	  there	  is	  a	  spectrum	  of	  variability	  in	  low	  levels	  of	  
testicular	  hormones,	  and	  may	  reflect	  different	  aspects	  of	  testicular	  ageing.	  
Whether	  one	  form	  has	  more	  clinical	  significance	  than	  others	  requires	  further	  
examination.	  The	  thesis	  therefore	  sets	  up	  the	  premise	  that	  gonadal	  endocrine	  
function	  requires	  the	  examination	  of	  all	  four	  testicular	  hormones,	  and	  may	  in	  





8.6  Future  directions  
	  
This	  thesis	  has	  generated	  several	  lines	  of	  enquiries	  for	  future	  research.	  The	  
determinants	  of	  variability	  in	  circulating	  AMH	  between	  men	  is	  unknown.	  A	  long-­‐‑
term	  longitudinal	  study	  of	  AMH	  would	  determine	  whether	  levels	  of	  AMH	  
established	  at	  birth	  or	  in	  childhood	  is	  a	  major	  determinant	  to	  their	  adult	  level,	  or	  
if	  environmental	  influences	  during	  adulthood	  plays	  a	  bigger	  role.	  The	  association	  
of	  AMH	  with	  functional	  traits	  requires	  more	  examination	  in	  targeted	  groups	  with	  
pathologies,	  such	  as	  those	  with	  dementia,	  sarcopenia,	  or	  cardiovascular	  disease.	  
The	  endogenous	  half-­‐‑life	  of	  AMH	  in	  men	  is	  unknown,	  and	  its	  knowledge	  would	  
guide	  further	  studies	  looking	  into	  replacement	  of	  AMH	  in	  animals	  and	  humans	  to	  




This	  PhD	  journey	  has	  demonstrated	  to	  the	  author	  that	  science	  is	  never	  black	  and	  
white,	  but	  rich	  in	  its	  many	  hues	  of	  discoveries.	  The	  exploration	  of	  novel	  research	  
is	  exciting	  and	  equally	  frustrating,	  in	  attempting	  to	  change	  people’s	  perception	  of	  
a	  flat	  earth.	  The	  first	  step	  of	  hopefully	  many	  more	  have	  been	  cast,	  	  to	  convince	  
the	  world	  that	  men	  are	  complex	  creatures.	  This	  thesis	  adds	  to	  the	  conversation	  
that	  sometimes,	  the	  function	  of	  man	  is	  influenced	  by	  his	  testes.	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